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Abstract 
Specialized Pro-Resolution Mediators (SPM’s) in Paediatric Cystic Fibrosis 
(CF) Lung Disease 
 
CF is caused by a mutation in the Cystic Fibrosis Transmembrane conductance 
Regulator (CFTR) and results in airway surface liquid (ASL) dehydration, impaired 
muco-ciliary clearance, chronic pulmonary infection and inflammation leading to 
progressive lung destruction.  Specialized Pro-Resolution Mediators (SPM’s) such 
as Lipoxins and Resolvins are SPM’s involved in the active resolution of 
inflammation. Previous work showed that Lipoxin A4 restores airway surface liquid 
height in CF bronchial epithelium.  Our aim was to investigate the role of SPMs, 
including Lipoxin A4 and Resolvin D1 in CF airway disease. 
 
We studied the physiological effects of RvD1 in CF using primary CF alveolar 
macrophages and polarized, differentiated Primary CF and NuLi-1, and CuFi-1 cell 
lines as a bronchial epithelial model.  We collected bronchoalveolar lavage (BAL) 
samples from young children with CF and controls at clinical baseline (SHIELD 
CF) and sputum from school aged children during CF Pulmonary Exacerbation 
(CFPE) (PRINCE Study).  
 
We report that Resolvin D1 restored ASL height in Primary CF bronchial epithelia 
and CuFi-1 cells.  Resolvin D1 attenuated TNFα induced IL8 secretion in CuFi-1 
cells.  Furthermore Resolvin D1 improved phagocytic capacity and bacterial killing 
of Pseudomonas aeruginosa in primary CF alveolar macrophages.  We 
demonstrate an imbalance in Lipoxin A4 (LXA4) versus Leukotriene B4 (LTB4) 
production in CF airways, despite the absence of infection, related to a deficiency 
of the LXA4 synthetic enzyme 15 Lipoxygenase-2 in CF macrophages. We have 
demonstrated that the levels of Resolvin D2 and 15-d-Prostaglandin J2 correlate 
strongly with the extent of recovery of premorbid FEV1 during CF pulmonary 
exacerbation.  
 
We have elucidated important beneficial physiological effects of SPMs in CF 
airway cells, shown defective class switching in children with CF compared to 
controls, and demonstrated a link between sputum SPM levels and lung function 
recovery during acute infection in CF. Our findings shed some light on the failure 
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to resolve inflammation in CF airways and suggest strong therapeutic potential for 
SPMs in CF. 
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wound around the foundation stones of everything I have worked to build in the 
last ten years.   
 
“May God bless and keep you always, May your wishes all come true… May your 
heart always be joyful, And may your song always be sung.” (Bob Dylan) 
 
My beautiful children, Johan and Beatrice.  You bring delight and happiness to my 
heart.  You make it very easy for me to get out of bed every morning, and to bust a 
gut to get my days’ work done, so as to be able to rush home in the evening just to 
be around you.  You are both courageous, good natured little characters who have 
embraced life with both hands.  I am literally in awe of you and will always love you 
to pieces.  
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Jannah & Wolfgang, my German family know how to live!  You have shared your 
home, your table, your wine, gemutlich, philosophy, swimming pools, mountains 
and sea.  Jannah in particular played a big part in making this work possible by 
helping me and the kids when Henning needed to travel.  Jannah you were good 
company, held the home-front together and shared in many of the little milestones 
along the way.    
 
My family Stephen, Ellen, Aimee, Eoghan, Ethy, Oonagh and Bernard.  You are 
my home and having floated around in the world for a while I’ve never found 
anyone to beat the lot of ye.  Thanks for everything that you are.  
 
A few friends in particular have supported me over the lifetime of this project and 
have been there to remind me what life is really all about.  Barry and Sheila 
Boland, Andrea Miklasova, Maeve Nunez, Mariya Kryvyak, Vicky Mars, Steve 
Koh, Fergus Simpson, Josie and Tom Usher, Karsten Barrs and the Knorr twins. 
 
“I see a brighter star tonight as I look at the sky, 
It glistens in a teardrop as it drifts upon a sigh (1).” 
 
“Like the stars, our ideals are hard to reach, but they serve for navigation in the 
night.” (Oxford Handbook of Clinical Medicine) 
 
Oisin Boland was an electric child.  He is one of a few kids whose memory echoes 
around in my head and drives me on to try harder.  And so we work on in the 
memory of those kids that we couldn’t help enough. 
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CHAPTER 1 
INTRODUCTION 
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1 Introduction 
1.1 Cystic Fibrosis (CF) 
CF is the most common life-limiting inherited disease in Caucasians, with 
approximately 1 in 19 people carrying one mutation in the gene encoding the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and 1 in 1,461 
people in Ireland being affected by CF (2).  CF affects many organ systems, 
however, lung destruction is the main cause of mortality in CF.   
 
The most common mutation of the CFTR gene (Phe508del) results in defective 
chloride secretion in the lung, which reduces airway surface liquid hydration.  
Sodium hyperabsorption is also a feature of CF airways which further exacerbates 
the airway liquid dehydration.  Airway surface liquid dehydration impairs muco-
ciliary clearance and disrupts innate immune defence mechanisms favouring 
chronic bacterial colonization.  Chronic bacterial bronchitis and the associated 
neutrophil predominant inflammatory response cause progressive bronchiectasis, 
lung destruction, respiratory failure and premature mortality. 
 
1.1.1 Dorothy Andersen and the Recognition of Cystic Fibrosis 
Prior to 1938, the “coeliac syndrome” was a recognised clinical entity, linked to 
features of pancreatic steatorrhoea.  This “syndrome” encompassed a mixture of 
cases that today we would recognise as coeliac disease and cystic fibrosis. In 
1938, Dorothy Andersen (niece of Hans Christian Andersen) was the first to 
extensively describe “Cystic Fibrosis of the pancreas” whilst working at Babies’ 
Hospital, in New York (3).  She described the clinical findings of a group of 
children who all had cystic fibrosis of the pancreas at post mortem.  A neonatal 
cohort (many of whom had meconium ileus), and a second group of children dying 
between 1 and 6 months were examined.  The characteristic features which these 
children had in common were described; failure to gain weight with an adequate 
diet beginning in the neonatal period, a large abdomen at birth, hunger, absence 
of vomiting or diarrhoea, large stools, sometimes recognised as fatty, intolerance 
to fat in the diet, and chronic infection of the respiratory tract.  A third group died 
between 6 months and 14.5 years and had additional features including; 
osteoporosis, exophthalmia, bronchiectasis, otitis media and sinus infection.  The 
cause of death in all children surviving the first week of life was bronchitis, 
bronchiectasis or bronchopneumonia (3). 
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In an early report, Lloyd Dickey, writing about the pulmonary aspects of the 
disease, suggests that the condition may have existed in cases previously 
diagnosed as “chronic, or unresolved pneumonias” (4).  He describes the 
treatments of the day including; pancreatic enzymes, large amounts of Vitamin A, 
banana powder and sulfathiazole (4). 
 
1.1.2 Presentation & Diagnosis 
CF can come to the attention of the physician; prenatally, via new-born screening, 
via detection in a close relative, or via symptomatic presentation in children or 
adults.  The CF Foundation Consensus Report (1996) recommends that the 
diagnosis of CF should be based on the presence of one or more characteristic 
clinical features (described in Table 1-1), a history of CF in a sibling, or a positive 
new-born screening test, plus laboratory evidence of an abnormality in the CFTR 
gene or protein (i.e. abnormal sweat chloride or nasal potential difference OR 
identification of a disease-causing mutation in each copy (trans) of the CFTR 
gene) (5).  The primary test for confirming the diagnosis of CF is the sweat 
chloride test.  A sweat chloride (performed according to the correct procedure in 
an accredited lab) of ≥60mmol/L is abnormal and indicative of CF, whilst a sweat 
chloride ≤39mmol/L (≤29mmol/L in infants under 6 months of age) is considered 
normal and makes a diagnosis of CF unlikely (5).  Where the sweat chloride falls 
in the intermediate range, the diagnosis of CF becomes more complicated and 
consensus guidelines have been established to assist the physician in managing 
such cases (5).     
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Table 1-1 Phenotypic features consistent with a diagnosis of CF  
Classic Symptoms and Signs of CF (5) 
Chronic sino-pulmonary disease: 
Persistent colonisation/infection with typical CF pathogens 
Chronic cough and sputum production 
Persistent chest radiograph abnormalities (e.g. bronchiectasis, atelectasis, 
infiltrates, hyperinflation) 
Airway obstruction, manifested by wheezing and air trapping 
Nasal polyps 
Digital clubbing 
Gastrointestinal and nutritional abnormalities: 
Meconium ileus, distal intestinal obstruction syndrome, rectal prolapse 
Pancreatic insufficiency, recurrent acute pancreatitis, chronic pancreatitis 
Prolonged neonatal jaundice, chronic hepatic disease with evidence of focal biliary 
cirrhosis or multilobular cirrhosis 
Failure to thrive, hypoproteinemia and oedema, fat soluble vitamin deficiencies 
Salt loss syndromes, acute salt depletion, chronic metabolic alkalosis 
Genital abnormalities in males, obstructive azoospermia 
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1.1.3 Extra-Pulmonary Manifestations 
CFTR expression is highest among epithelial sites in the body and as such, 
epithelial sites are particularly affected by CF disease.  CF affects the 
gastrointestinal tract, causing; fat malabsorption, meconium ileus, rectal prolapse, 
and distal intestinal obstruction syndrome.  In the 1950’s, improvements in the 
surgical management of meconium ileus led to significant advances in the life 
expectancy of children with CF (6).  In the liver, CF gives rise to extra-hepatic 
manifestations including; cholelithiasis and sclerosing cholangitis, as well as, intra-
hepatic manifestations, such as; neonatal cholestasis, steatosis, focal biliary 
cirrhosis, and multi-lobular cirrhosis.  CF affects the pancreas causing pancreatic 
insufficiency, pancreatitis, and diabetes mellitus.  In the 1980’s, the development 
of acid resistant microspheres (Pancrease & Creon) significantly improved the 
management of pancreatic insufficiency in CF (7).  Nutritional effects include 
malnutrition, micronutrient deficiencies, and osteopaenia.  In the reproductive tract, 
CF causes obstructive azoospermia in men, and impaired fertility in women. 
 
1.1.4 Prognosis 
The life expectancy for individuals with CF has increased dramatically since the 
first description of the disease by Dorothy Andersen in 1938.  In a recent CF 
Foundation report, more than half of 18-29 year olds with CF (52.8%) had normal 
– mildly impaired lung function (FEV1 ≥70%) and the predicted median survival 
was 41.1 years of age (8).  68.5% of adults with CF has at least some college 
education, 39.8% were married or living with a partner and 69% were either 
studying or in employment (8).  The relationship between genotype and pulmonary 
disease severity is weak and therefore prognostic predictions on the basis of 
genotype analysis are to be avoided in individual patients with CF (5). 
 
In order to continue to achieve gains in life expectancy and quality of life for people 
with CF, therapeutic innovations are called for to develop new treatments to; 
restore CFTR function, rehydrate the airway surface, improve muco-ciliary 
clearance, prevent, supress and eradicate or treat bacterial infection, disrupt 
biofilm formation, deal with the emergence of multi-drug resistance and antibiotic 
side effects, improve innate immune defence and promote repair. 
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1.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
In 1989, three back to back papers were published in Science identifying the 
CFTR gene and its protein product as the underlying causative gene defect in CF 
opening the door to the understanding the disease at its most basic level (9-11). 
 
1.2.1 CFTR Structure 
The CFTR is a protein comprising 1,480 amino acids which functions as a chloride 
channel in the apical membrane of exocrine epithelial cells (9-11).  It is a member 
of the ATP-binding cassette (ABC) transporter family, which conducts anions, 
principally chloride and bicarbonate (Figure 1-1). 
 
 
 
Figure 1-1  Structure of the cystic fibrosis transmembrane conductance 
regulator (CFTR) channel  
Structurally, the CFTR comprises five domains; two transmembrane membrane 
spanning domains (TMD1 and TMD2), each composed of six transmembrane 
segments (TM 1-12) that form the channel; two nucleotide binding domains (NBD1 
& NBD2) capable of ATP hydrolysis; and a regulatory domain (R) which has 
phosphorylation sites.  Phosphorylation of the R domain by Protein Kinase A 
(PKA), regulated by cAMP and hydrolysis of ATP by the NBDs activate the 
chloride channel (10, 12, 13) (reproduced from (12)).   
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1.2.2 CFTR Ion Channel Function 
Long before the CFTR gene and its protein product were ever identified, Darling 
and Di Sant’Agnese recognised that sweat chloride was elevated in CF (14).  
Andersen had reported heat prostration in a group of children with CF admitted 
during a severely hot spell during August 1948 (15).  In 1953, Darling and Di 
Sant’Agnese performed “sweat tests” by subjecting participants to thermal stress, 
and found abnormally high sweat sodium and chloride in children with CF (14).   
They concluded that this elevated sweat salt content was due to a disturbance of 
the sweat glands themselves (14).  In 1983, experiments performed on isolated 
sweat ducts identified chloride as the principal affected electrolyte in CF and 
revealed the physiological basis for high sweat chloride values (16).  
 
The membrane spanning domains of CFTR form an anion selective pore through 
which anions flow, driven by the transmembrane electrochemical gradient (17).  
Cycles of ATP binding and hydrolysis control channel gating and phosphorylation 
of the R domain by Protein Kinase A regulates channel activity (12, 13, 17, 18).  In 
airway epithelium, CFTR functions as an apical chloride channel where it 
selectively transports chloride and bicarbonate between the cytoplasm and the 
airway lumen. Trans-epithelial chloride secretion also involves basolateral chloride 
entry into the cell via Na/K/2Cl co-transporters.  Trans-epithelial chloride secretion 
plays a major role in the hydration of the airway surface liquid.  In sweat duct 
epithelia, CFTR drives the reabsorption of salt (13, 16, 19).   
 
1.2.3 CFTR Regulatory Function 
CFTR affects the function of other ion channels and transporters.  Whilst the link 
between dysfunctional CFTR and alterations in the function of other ion channels 
in airway epithelia remains an active area of debate, a number of authors have 
proposed mechanistic links.  CFTR is reported to have a C terminal cognate 
binding motif which can facilitate interaction with PDZ domain containing proteins 
(20).  Chloride conductance through CFTR contributes to the transmembrane 
electrochemical potential, and therefore affects the transport of other charged 
species (13, 21).  Particularly relevant to airway surface liquid hydration, CFTR 
regulates sodium transport and other chloride transporters in airway epithelia. 
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Sodium absorption in the airways is mediated by the amiloride-sensitive epithelial 
Na+ Channel (ENaC) which plays a major role in regulating the hydration of the 
airway surface liquid (22, 23).  Amiloride-sensitive sodium absorption is elevated 
by 2- to 3- fold in CF (24).  Both direct (25-28) and indirect (21, 29) coupling 
between CFTR and ENaC activity (30-33), expression (34-36) and sodium 
absorption (37) have been reported. 
 
CFTR also regulates the activity of other Chloride secretory pathways (38). 
Calcium-activated chloride conductance is reported to be amplified in CF cells, 
implying that CFTR normally inhibits calcium sensitive chloride conductance (39). 
CFTR interacts with intracellular signalling networks, including via intracellular 
calcium and cAMP in confined functional compartments which could regulate the 
activity of other chloride ion channels (40).  CFTR was further reported to regulate 
intracellular calcium by mediating nucleotide release and activating cell surface 
purinoreceptors in airway epithelia (41).  Ousingsawat et al. recently demonstrated 
that CFTR and the calcium activated chloride channel TMEM16 show both 
functional and molecular interaction (42, 43). 
 
1.2.4 CFTR Mutations and CFTR Directed Therapeutic Approaches 
Despite CF being recognised as an inherited condition (autosomal recessive) as 
early as 1944 (44), the gene encoding the CFTR was finally identified in 1989 (9-
11).  It is located on the long arm of chromosome 7 (7q31.2) and comprises a 
promoter region and 27 coding exons.  Two major international collaborative 
projects catalogue data relating to mutations in the CFTR gene; CFTR1 (initiated 
by the Cystic Fibrosis Genetic Analysis Consortium in 1989 and maintained by the 
CF centre at Sick Kid’s in Toronto ), and; CFTR2 (2010, supported by the US CF 
Foundation (45)).   
 
The CFTR2 project reports that more than 1800 variations in the CFTR gene have 
been discovered (45).  Twenty three mutations have been identified by the 
American College of Medical Genetics as clearly CF-causing.  Among the 
remaining 1700 plus mutations, some cause full blown CF, some cause CF some 
of the time, some cause a milder form of CF, and other mutations likely have no 
association with CF (45).  Some CFTR polymorphisms modify disease severity. 
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CFTR mutations have been classified into 6 classes according to their effect on 
CFTR function (illustrated in Figure 1-2). 
 
Class I: Defective Protein Synthesis 
Class I mutations (e.g. W1282X) include nonsense and frame-shift mutations 
which lead to premature termination codons (PTC’s) and disruption of CFTR 
protein synthesis.  They are associated with a severe form of disease (46).  
Aminoglycosides can alter ribosomal RNA conformation and reduce the accuracy 
of codon – anti-codon pairing and lead to read-through of PTC’s (47, 48).  Ataluren 
(PTC124) was tested as a drug designed to “read-through” PTC’s, however a 
phase III trial demonstrated no significant benefit of treatment over placebo (49). 
 
 
 
Figure 1-2  Classification of CFTR mutations  
Class I: Defective Protein Synthesis; Class II: Defective Protein Processing; Class 
III: Defective Protein Regulation; Class IV: Impaired Conductance; Class V: 
Reduced CFTR Level; Class VI: Decreased CFTR stability (Reproduced from 
(50)).   
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Class II: Defective Protein Processing 
The CFTR mutations which affect the majority of Caucasian patients are class II 
mutations including Phe508del.  Phe508del is a 3 base pair deletion causing a 
loss of phenylalanine at position 508.  After translation, CFTR is normally 
glycosylated and folded in the endoplasmic reticulum / Golgi apparatus in such a 
way that allows the protein to be trafficked to the apical membrane.  In class II 
mutations this processing is impaired and the abnormally processed protein is 
degraded (50).   
 
CFTR “Correctors” 
The aim of “corrector” drugs is to address the processing and trafficking defect of 
the F508del-CFTR protein to enable it to reach the cell surface.  The corrector 
Lumacaftor (VX-809) alone was trialled among people homozygous for the 
Phe508del CFTR mutation in a Phase IIa study (51).  Lumacaftor gave a small 
reduction in sweat chloride but didn’t significantly affect any other clinical outcome.   
The results of Phase III studies (called TRAFFIC and TRANSPORT) of the drug 
combination Ivacaftor (CFTR Potentiator discussed below) plus Lumacaftor for 
people homozygous for the Phe508del CFTR mutation have recently been 
publicised in a press release from Vertex pharmaceuticals (52).  The preliminary 
results reported by Vertex Pharmaceuticals included a mean absolute 
improvement in FEV1 of 2.6 to 4.0% and a reduction in the rate of pulmonary 
exacerbation.  VX-661 is also in Phase II trials in combination with Ivacaftor (53). 
 
Class III: Defective Protein Regulation 
Class III mutations (e.g. G551D) lead to the production of CFTR proteins which 
reach the apical membrane but their regulation is defective and the channel 
cannot be activated by ATP or cAMP.   
 
CFTR Potentiators 
The potentiator Kalydeco (also known as Ivacaftor VX-770) is now licenced for 
people with CF who are 6 years and above with the G551D mutation in the CFTR 
gene (54, 55).  It is believed to work by increasing the open probability of the 
chloride channel and thus improving the activity of cell surface located mutant 
CFTR (54, 56, 57).  Clinically important improvements reported by the phase III 
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trials included; increases in FEV1, weight gain, reduced sweat chloride, reduced 
exacerbation rate and improved scores on the CFQ-R (54, 55).   
 
Class IV: Impaired Conductance 
Class IV mutations (e.g. R117H) are associated with altered conductance and a 
reduced rate of chloride transport. 
 
Class V: Reduced CFTR Level 
Class V mutations (e.g. 3849 + 10kb C→T) lead to the production of a normal 
CFTR protein but at a reduced level.  Examples include promoter mutations, 
amino acid substitutions and splicing mutations.  Higher levels of correctly spliced 
transcripts are associated with milder disease (58).  Histone deacetylase inhibitors 
and splicing modulators have been proposed as therapies for this class of 
mutations (59). 
 
Class VI: Decreased CFTR Stability 
Class VI mutations including premature termination and frame-shift mutations 
cause C-terminal truncations and lead to a CFTR protein with a shortened half-life 
(60).  
 
Gene Therapy 
In vitro experiments have been successful in achieving restoration of ion transport 
(Nasal Potential Difference) using either modified viral vectors or synthetic gene 
transfer to deliver a CFTR transgene (53).  Hurdles in clinical application have 
included; variable expression, short duration / need for repeated dosing and 
immune responses to the viral vectors (53).  A large, phase IIb, repeated dose, 
randomised, placebo controlled trial of cationic liposome mediated CFTR gene 
therapy is currently ongoing (61). 
 
Whilst successes have been achieved in CFTR directed therapy, there remain 
both; CFTR classes for which no specific treatments exist; and residual burdens of 
established airway disease, for which non-CFTR therapeutic strategies might 
derive benefit.  
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1.3 Pathophysiology of CF Lung Disease 
Histopathological findings in the airways of people with CF 
The most prominent histopathological features of CF lung disease are 
bronchiectasis and air trapping that can be detected from early infancy (3, 62).  CF 
lung disease primarily affects the airways sparing the alveoli until late in the 
disease (3).  Additional macro-pathologic findings include bronchitis, mucopurulent 
plugging of bronchi, and bronchopneumonia (63).  At a tissue level, glandular 
hypertrophy, predominance of mucous acini within glands, and goblet cell 
hyperplasia of the bronchial mucosa have been reported (63).  Hallmarks of the 
disease are chronic bacterial infection and acute inflammation characterised by 
large numbers of neutrophils persisting within the airway lumen (64). There is 
lymphocytic infiltration of the submucosa (64).  Infection and inflammation have 
been reported from early infancy (65) and bronchiectasis has been associated with 
elevated Neutrophil Elastase activity in bronchoalveolar lavage fluid in early 
childhood (66). 
 
1.3.1 Pathogenesis Sequence 
The links between ion transport defects and ASL dehydration caused by CFTR 
mutation and the consequent pathogenesis sequence (illustrated in Figure 1-3) of 
infection and inflammation in the pathogenesis of CF lung disease remain the 
subject of intensive investigation and controversy.  We will explore each link in this 
sequence in greater depth and explore treatment strategies designed to address 
each step in the cascade.  
 
 
 
43 
 
   
Figure 1-3  Illustration of the key steps in the pathogenesis of CF lung 
disease   
Defective CFTR is the earliest insult in the pathogenesis of lung disease.  It gives 
rise to an abnormal airway surface environment which is prone to infection.  A 
vicious cycle of inflammation and infection contribute to lung damage manifested 
as bronchiectasis. 
 
1.4 Airway Surface Liquid Dehydration in CF  
1.4.1 Structure and Function of the ASL 
Mucociliary clearance propels inhaled particles, micro-organisms and allergens 
from the lung towards the pharynx where they are subsequently either 
expectorated or swallowed.  Mucus clearance requires adequate hydration of the 
Airway Surface Liquid (ASL); a two phase liquid system that interfaces with 
beating cilia comprising a mucus phase and the periciliary liquid layer (PCL) (67, 
68).  Studies of normal airway epithelial cell cultures under steady-state conditions 
suggest that the optimal depth of the PCL is approximately 7µm, corresponding to 
the height of the outstretched cilia and facilitating efficient ciliary beating (67-70).  
 
The hydration of the Airway Surface Liquid (ASL) depends on balanced sodium 
absorption and chloride secretion (67).  Sodium absorption and chloride secretion 
Defective / 
Deficient CFTR 
Abnormal Airway 
Surface 
Environment 
Infection Inflammation 
Bronchiectasis 
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are active transcellular ion transport processes which create the osmotic force for 
water movement via aquaporins and the paracellular route (71, 72). 
 
In CF, mutation of the CFTR results in the loss of chloride efflux and sodium 
hyper-absorption and gives rise to airway surface dehydration and impaired muco-
ciliary clearance (73-75) (illustrated in Figure 1-4).  The disruption of this innate 
immune defence mechanism allows the development of bacterial infection and the 
associated neutrophil mediated inflammatory response. 
 
 
 
Figure 1-4  Electron Microscopy images of the ASL on well-differentiated 
non-CF and CF human airway cultures  
Well-differentiated non-CF (left) human airway cultures demonstrate optimally 
extended cilia supporting a thin mucus layer.  Well differentiated CF (right) human 
airway cultures demonstrate a depleted periciliary layer with bent over cilia and a 
concentrated adherent mucus layer (reproduced from Boucher (73)). 
 
1.4.2 Ion transport in ASL regulation 
The optimal hydration of the ASL is achieved via balanced trans-epithelial sodium 
absorption and chloride secretion (73-75).  Trans-epithelial sodium absorption is 
mediated by the Epithelial Sodium Channel (ENaC) in the apical membrane and 
the Na/K ATPase localised in the basolateral membrane.  Trans-epithelial chloride 
secretion is mediated by CFTR and Calcium activated Chloride channels (CaCC) 
in the apical membrane and the Na/K/2Cl co-transporter in the basolateral 
membrane (43, 76-78).   
 
1.4.3 Chloride transport in ASL regulation  
Trans-epithelial chloride secretion is mediated by CFTR and Calcium activated 
Chloride channels (CaCC) in the apical membrane (43, 76-78).  Chloride enters 
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the cell at the basolateral membrane via Na/K/2Cl co-transporters.  The electro-
chemical driving force for the trans-epithelial movement of chloride is generated by 
the recycling of potassium through potassium-selective ion channels in the 
basolateral membrane (79).  We reviewed the function of CFTR as an apical 
chloride ion channel in section 1.2.2. 
 
Calcium-activated chloride conductance (CaCC) is recognised in airway epithelia 
and influences airway surface hydration via chloride secretion into the ASL (80-
85).  Two chloride channels have been reported to contribute to CaCC in the 
airways (86); TMEM16A (also known as Anoctamin 1) has been identified as the 
predominant component of CaCC in the luminal airway epithelial membrane (87, 
88); whilst, Bestrophin 1 (Best-1) shows endoplasmic reticulum (ER) localization 
and facilitates receptor-mediated calcium signalling and probably serves as a 
chloride counter ion channel in the ER (87, 89).   
 
1.4.4 Sodium transport in ASL regulation  
Sodium absorption in the airways is mediated by the amiloride-sensitive epithelial 
Na+ Channel (ENaC) a hetero-trimer comprising α, β, and γ subunits (22).  The 
importance of ENaC mediated sodium absorption in regulating ASL hydration was 
emphasised by transgenic mouse studies in which over-expression of the β-ENaC 
subunit gave rise to a CF-like lung pathology phenotype (90).  ENaC expression 
and activity are tightly regulated (91).  ENaC is inhibited by intracellular second 
messengers such as cAMP, calcium and PIP2 (77).  Furthermore, proteolytic 
cleavage of ENaC by intracellular or extracellular proteases activates sodium 
conductance (77). Interestingly, SPLUNC1 is a secreted innate defence protein 
present in the ASL which acts as a soluble volume sensor and regulator of ENaC 
activity by protecting ENaC from proteolytic cleavage (92).  
 
1.4.5 The Purinergic signalling system regulating ASL Volume 
Trans-epithelial ion transport and ASL hydration are regulated by the neuro-
humoral environment (e.g. nucleotides (39, 93), steroid hormones (94, 95), Nitric 
oxide (96), Acetylcholine (97)).   
 
A purinergic signalling system is particularly important in the physiological 
regulation of ASL height allowing the system to be sensitive to dynamic stretch, 
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viral infection and inflammation (76, 98, 99) (illustrated in Figure 1-5).  The 
dynamic volume of the ASL is sensed by the surface liquid concentration of 
purines such as ATP and Adenosine (76, 100).  The ASL concentration of 
nucleotides dynamically regulates ion transport processes, balancing sodium 
absorption and chloride secretion to maintain a functional ASL height (76, 98, 99).  
For example, under static conditions, airway epithelia gradually release ATP onto 
the airway surface where it is converted to adenosine by cell surface exo-
enzymes. Adenosine signals through the A2b purinoreceptor, regulating 
intracellular cAMP and affecting CFTR mediated chloride secretion and ENaC 
activity (101). Moreover, phasic stresses stimulate relatively large increases in 
ATP release onto the airway surface where a high concentration of ATP activates 
purinoreceptors resulting in the inhibition of sodium absorption and activation of 
chloride secretion via CFTR and the CaCC (67, 100).   
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Figure 1-5  Normal regulation of Airway Surface Liquid (ASL) height   
ASL volume is regulated by the surface liquid concentration of ATP and 
Adenosine. Under static conditions, airway epithelia release ATP onto the airway 
surface where it is converted to adenosine by cell surface exo-enzymes. 
Adenosine activates the A2b purinoreceptor resulting in increased intracellular 
cAMP concentration and activation of CFTR regulation of Epithelial Sodium 
channel (ENaC) and Chloride secretion. Phasic stress stimulates ATP release 
onto the airway surface where high concentration ATP activates P2Y2 
purinoreceptor resulting in ENaC inhibition and activation of chloride secretion via 
CFTR and the Calcium Activated Chloride channels (CaCC)(reproduced from 
(102)). 
 
1.4.6 ASL Regulation in Cystic Fibrosis 
In CF, the dynamic regulation of ASL hydration is dramatically affected by the loss 
of CFTR channel function and regulatory activity.  Not only does CFTR normally 
transport chloride and bicarbonate into the ASL, it exerts regulatory effects on both 
ENaC and CaCC (13, 20-43).  In the absence of CFTR mediated inhibition, ENaC 
mediated sodium absorption is elevated by 2- to 3- fold (24) and CaCC mediated 
chloride secretion is amplified in CF cells (39).  Furthermore, significant cross-talk 
links chloride secretion and sodium absorption in airway epithelia, via intracellular 
calcium and cAMP cascades and extracellular purines, with consequences for the 
regulation of ASL hydration (24, 38-41, 77, 103-107).   
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The overall consequence of CFTR mutation in airway epithelia is the inability to 
inhibit sodium absorption and drive chloride secretion.  Consequently in CF, the 
ASL is more rapidly absorbed from airway surfaces and the airway epithelial layer 
is unable to maintain a functional ASL height/volume under basal conditions. This 
results in; ASL dehydration, inefficient ciliary beating, mucus dehydration and the 
adhesion of mucus plaques to the airway surface (73-75, 102). Evidence from 
animal experiments suggests that airway surface hydration is the most important 
variable in determining the efficiency of mucus clearance (73).  
 
Airway cells can compensate for the absence of CFTR activity, especially during 
the motion phase, in part by increasing the release of ATP onto the airway 
surface, activating purinoreceptors, inhibiting sodium absorption via ENaC and 
activating Chloride secretion via CaCC (67). However, this means that in CF, the 
airway is relatively dependent on ATP as its signalling mechanism, rendering the 
CF airway particularly vulnerable when viral infection results in the induction of 
ecto-ATP-ases, upon which, the ASL volume can be seen to collapse (illustrated in 
Figure 1-6) (67, 102).  
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Figure 1-6  Airway Surface Liquid (ASL) height is reduced in CF   
In CF, loss of CFTR results in reduced ability to inhibit sodium absorption and 
secrete chloride. Fluid is more rapidly absorbed from airway surfaces and the 
epithelium is unable to maintain a functional ASL height. The residual ASL height 
is relatively dependent on ATP signalling in CF, rendering the CF airway 
particularly vulnerable when viral infection results in the induction of ecto-ATP-
ases (reproduced from (102)). 
 
1.4.7 Pharmacological strategies to improve ASL hydration and muco-ciliary 
clearance in CF 
Pulmozyme, also known as Dornase alfa, is a recombinant deoxyribonuclease 
(DNase) that cleaves extracellular DNA in the airway and improves the 
rheodynamics of mucus (108).  Pulmozyme was tested in children and found to 
improve the Lung Clearance Index (LCI) significantly (108, 109). 
 
Hypertonic saline inhalation has been demonstrated to reduce the rate of 
pulmonary exacerbation in older children and improve infant lung function 
parameters in an infant population (110, 111).  It is proposed to mediate its 
beneficial effects on muco-ciliary clearance via rehydration of the ASL (112-114).   
 
Mannitol is an osmotic agent administered as a dry powder by inhalation to 
rehydrate the ASL.  In Phase III studies it was found to significantly improve FEV1, 
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however, was associated with adverse effects including cough, pharyngolaryngeal 
pain and haemoptysis (115).  
 
Several compounds are in development which aim to restore muco-ciliary function 
via ASL rehydration including; hyperosmolar agents designed to draw water into 
the dehydrated ASL; and ion transport modulators targeting the activation of 
alternative chloride transport pathways and/or the inhibition of ENaC mediated 
sodium hyperabsorption (116-123). 
 
1.5 CF Airway Infection 
1.5.1 Pathogenesis of CF Airway Infection 
The CF airway is predisposed to bacterial infection, and airway infection is 
independently associated with the evolution of lung function impairment (124).  
Mechanistic links between CFTR mutation and the susceptibility to bacterial 
infection characteristic of CF have been attributed to; the chemical composition of 
the ASL, including pH; the characteristics of the airway epithelial surface; the 
mechanical function of the muco-ciliary apparatus; and impaired phagocytosis and 
bacterial killing by phagocytes (125-127).  
 
The ASL is not an inert lubricating liquid.  It has a rapid bactericidal effect on 
incident bacteria via the function of anti-microbial peptides and proteins such as 
human beta-defensins, lysozyme, lactoferrin, palate lung and nasal epithelial clone 
(PLUNC), Secretory leucocyte protease inhibitor and surfactant protein SP-A (128-
131).  The function of anti-microbial peptides is salt and pH-sensitive (128, 129).  
CFTR facilitates HCO3- transport into the ASL, and in the absence of functional 
CFTR, the ASL pH is reported to be significantly more acidic (128).  Impaired 
bactericidal capacity of the ASL has been reported in CF (128, 132, 133).  
Furthermore, excessive binding of Staphylococcus aureus and Pseudomonas 
aeruginosa to the apical membrane of CF bronchial epithelia has been reported, 
related to an increased concentration of asialoganglioside 1 expression (134, 135).   
 
Mucus clearance performs a mechanical innate defence function in the lung by 
trapping bacteria and micro-particles allowing them to be swept out of the lungs 
into the oropharynx.  Muco-ciliary transport depends on optimal hydration of the 
ASL (a depth of ~7µm) to allow the cilia to be fully outstretched, beat efficiently 
51 
 
and allow efficient mucus clearance (69, 84).  In CF, altered ion transport results in 
ASL dehydration, collapse of the cilia and dysfunctional mucus transport (69, 84).  
Thickened and hypoxic mucus plaques adhere to CF epithelia and produce a 
nidus for bacterial colonisation (136, 137).  Furthermore, Pseudomonas 
aeruginosa product pyocyanin has been reported to disrupt ciliary function (138) 
 
Finally, both epithelia and alveolar macrophages play a role in airway defence by 
bacterial internalisation and killing.  A failure of CF epithelial cells to internalise and 
kill bacteria (139), and impaired intracellular killing of Pseudomonas aeruginosa by 
human and mouse CF macrophages have been reported (125-127).   
 
1.5.2 Bacterial pathogens affecting the airways in CF  
Early in the course of CF lung disease Staphylococcus aureus and Haemophilus 
influenza are most prevalent.  Pseudomonas aeruginosa colonisation becomes 
more prevalent through early childhood into adulthood. Methicillin Resistant 
Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, Burkholderia 
cepacia complex and Multidrug resistant Pseudomonas aeruginosa affect a 
smaller percentage of patients with CF across the age range (8).    
 
1.5.3 Conventional antibiotic management strategies  
Conventional antibiotics have been used in the management of CF airway 
infection since the 1940’s.  Paul Di Sant'Agnese and Andersen used 
“chemotherapy (…and in particular…) penicillin and drugs of the sulphonamide 
group, with special reference to penicillin aerosol (140)”.  Current strategies to 
retard the onset and evolution of chronic endoluminal bacterial infection have 
focused on; Staphylococcus aureus prophylaxis; Pseudomonas aeruginosa 
eradication and chronic suppression; and treatment of acute exacerbation.  The 
development of specific protocols to guide the appropriate antibiotic management 
of the CF airway has driven the evolution of “best practice” and incremental 
improvements in lung health across the board (141).   
 
Staphylococcus aureus (S. aureus) 
S. aureus is a common early pathogen in CF (142). Colonization itself may or may 
not cause clinically significant pulmonary inflammation or deterioration (143, 144), 
but may predispose to Pseudomonas aeruginosa infection in a variety of ways 
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(145).  Its pathogenicity depends on the combined action of more than 40 different 
extracellular toxins, enzymes, quorum sensors and cell surface proteins controlled 
by global regulatory elements (146-148).  Small colony variants are slow growing 
antibiotic resistant sub-populations of S. aureus, which are more likely to persist in 
the airway and are associated with worse lung disease in children (142, 149). 
MRSA is characterised by resistance to penicillin (performed by β-lactamase), and 
penicillinase-resistant compounds like methicillin and flucloxacillin (altered 
penicillin-binding protein PBP2a).  MRSA chronic colonisation has been linked to 
bronchiectasis and a greater rate of FEV1 decline (150).   
 
Anti-staphylococcal prophylaxis with Flucloxacillin to reduce S. aureus carriage 
rate is common practice, though debated as a strategy (141, 151).  The objective 
is to prevent S. aureus carriage and indirectly to prevent the acquisition of P. 
aeruginosa.  Controversy has surrounded the practice since Ratjen et al. reported 
that patients receiving prophylaxis had significantly fewer S. aureus sputum 
isolates, but a significantly higher rate of P. aeruginosa acquisition (152).  
Interpretation of these findings was complicated by differences in the antibiotic 
selection employed since many of the study population received a broad-spectrum 
cephalosporin antibiotic, which has subsequently been more specifically 
associated with the isolation of P. aeruginosa (143).  Eradication strategies for 
MRSA are the subject of on-going clinical trial evaluation (153).  For example, 
AeroVanc is an inhaled dry powder version of the antibiotic vancomycin which is 
being evaluated for the treatment of MRSA airway infection (154).   
 
Pseudomonas aeruginosa (P. aeruginosa) 
Persistent lower airways P. aeruginosa infection causes significant morbidity and 
mortality in CF (155).  Genotypically identical P. aeruginosa isolates can express 
different phenotypic characteristics (156).  Early infections are usually with non-
mucoid environmental strains which are relatively antibiotic sensitive and more 
amenable to eradication (157).  Later in the course of disease a mucoid, antibiotic-
resistant P. aeruginosa phenotype emerges and accompanies an accelerated 
decline in pulmonary function (158, 159).  P. aeruginosa possesses several 
virulence factors which allow it to bind, grow in biofilm and evade the host 
response; type IV pili mediate attachment to host cells interacting with the 
glycolipid receptor asialoGM1 (135); fimbrial adhesins are involved in adhesion 
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and biofilm formation (160); P. aeruginosa binds to mucin (161).  P. aeruginosa 
have quorum sensing systems (162).   P. aeruginosa can grow in anaerobic 
conditions and under hypoxic stress or oxygen free radical attack P. aeruginosa 
forms a biofilm (137, 163).  In biofilm P. aeruginosa can produce lipoproteins that 
induce an inflammatory response by the host cell (164).  Hyper-mutation has also 
been reported in P. aeruginosa isolates from CF patients (165).  Patient to patient 
cross-infection can occur and transmissible epidemic strains (probably acquired by 
droplet transmission) have been reported (156). 
 
The optimal management of P. aeruginosa includes prevention, including cohort 
segregation (166), early detection (167), aggressive attempted eradication (168), 
chronic antibiotic suppression and the treatment of acute exacerbation (141, 169).  
Several antibiotic formulations for the treatment or chronic suppression of P. 
aeruginosa airway infection are either in use, or in the “pipeline”, including; 
tobramycin, used as a nebulised solution or as a dry powder; inhaled aztreonam 
(CaystonTM) and an inhaled liposomal formulation of amikacin called ArikaceTM.   
 
1.5.4 Intrinsically drug resistant CF pathogens 
Burkholderia cepacia complex (Bcc) is a group of gram negative bacteria including 
B. cepacia, B. multivorans and B. cenocepacia.  Bcc can cause cepacia 
syndrome; a fulminating pneumonia with a very high mortality rate presenting with 
high fever, severe progressive respiratory failure, leucocytosis, and elevated 
erythrocyte sedimentation rate (170).  Bcc are often multi-drug resistant and 
sometimes pan-resistant (they produce an inducible β-lactamase, can use 
penicillin as a carbon source and are even resistant to defensins) and 
transmissible via social or nosocomial contact (13, 171).   
 
Nontuberculous Mycobacterial infection can complicate CF lung disease.  It is 
often difficult to diagnose in patients with CF in view of its indolent progression and 
the overlap between clinical features of CF and disease caused by NTM.  
Furthermore, the clinical course of NTM infection in CF can be unpredictable with 
some patients experiencing a very indolent course and others demonstrating NTM 
related progressive clinical decline (13).   
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1.5.5 Other Bacteria relevant to CF lung disease 
Since Haemophilus influenzae often colonises the upper airways of healthy 
children (172) there is controversy as to whether colonisation alone plays any role 
in CF.  There is broader agreement that it plays a role in acute exacerbation of CF 
and as such should be treated (173).  Debate surrounds whether 
Stenotrophomonas maltophilia causes clinically significant pulmonary deterioration 
(174, 175), however, it may play an indirect role by secreting β-lactamases and 
inhibiting antibiotic therapy, encouraging the growth of more virulent CF pathogens 
(176).  The clinical significance of Achromobacter xylosoxidans in CF lung disease 
is not clear; it can give rise to transient or chronic lung infection, and tends to 
affect people with advanced CF lung disease (173). 
 
Developments in the field of environmental microbiology have led to the realisation 
that many more species of bacteria are present in both CF airways and in disease 
control airways than are captured by culture based methods (177).  The 
relationships within these “polymicrobial communities” of aerobes, facultative 
anaerobes and obligate anaerobes and their role in CF lung disease are subjects 
of hot debate.  Positive relationships between high pulmonary microbial diversity 
and pulmonary health are reported (178).  
 
1.5.6 Infection invites a host inflammatory response 
Following initial bacterial colonisation, the micro-environment becomes 
increasingly complicated.  The inflammatory response fails to eradicate infection 
and chronic endoluminal bacterial infection persists alongside a prolonged, 
frustrated, ineffective inflammatory response.   
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1.6 CF Airway Inflammation 
1.6.1 Pathogenesis of airway inflammation in CF 
Disrupted innate defence leaves the airway in CF prone to infection and the 
resultant host response to infection is exaggerated, maladaptive and ineffective.  
Characteristics of the inflammatory response include abnormal cytokine secretion 
and neutrophil infiltration in the lung (179, 180).  Inflammation in CF fails to 
eradicate the infectious insult and persists in a self-propagating cycle of neutrophil 
mediated acute inflammation and chronic bacterial infection, leading to tissue 
damage, bronchiectasis and declining lung function (3, 62-64).  There is debate 
around the hierarchical relationship between infection and inflammation in the 
pathogenic sequence of airway disease in CF.  Young culture negative infants with 
CF have been reported to have elevated IL8 concentrations in their airways (65, 
181), however investigators studying young infants with CF detected by new-born 
screening have also provided evidence that increased inflammatory marker 
detection in the airway follows the development of infection in CF (182, 183). 
 
In order to identify the cell types mechanistically responsible for exaggerated 
immune responses to infection in the airway in CF, Bruscia et al. studied the 
inflammatory response to LPS challenge in wild type and CFTR knockout mice, 
and mouse bone marrow chimeras transplanted with either CFTR deficient or wild 
type bone marrow (179).  They demonstrated that enhanced pro-inflammatory 
cytokine secretion in this mouse model was attributable to CFTR deficiency in 
recruited immune cells, whereas enhanced neutrophil migration was attributable to 
both epithelial and recruited immune cells (179).  We will consider the underlying 
pathogenic mechanisms operant in epithelia, neutrophils, and macrophages in CF 
and then go on to consider the interplay between cells types via inflammatory 
cytokine networks.  Furthermore, we will consider anti-inflammatory strategies to 
ameliorate inflammation in CF. 
 
1.6.2 Normal pro-inflammatory signalling and exaggerated signalling in CF airway 
epithelia 
The immune system senses pathogens via conserved molecular patterns that 
interact with Pattern Recognition Receptors such as the Toll-like receptor family 
(184).  These receptors are coupled to signal transduction cascades that control 
inducible immune response genes, most importantly, the NFĸB family of 
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transcription factors.  NFĸB transcription factors are powerful regulators of 
inducible gene expression that co-ordinates innate and adaptive responses to 
antigenic stimuli, resulting in cytokine production to achieve pathogen clearance 
(illustrated in Figure 1-7) (185). 
 
Figure 1-7 Schematic of the canonical NFĸB signalling pathway 
NFĸB dimers are normally sequestered in the cytoplasm associated with IĸB 
proteins.  Pro-inflammatory signals stimulate receptors belonging to the tumour 
necrosis factor receptor (TNFR) or Toll-like receptor (TLR) families, which activate 
the IĸB kinase (IKK) complex. Activation of the IKK complex (comprising IKKα, 
IKKβ and NEMO subunits) results IĸB phosphorylation, ubiquitylation and 
proteasome-dependent degradation. This allows NFĸB dimers to translocate to the 
nucleus, bind to NFĸB sites on the promoters of target genes and activate the 
transcription of genes with pro-inflammatory functions (Reproduced from 
Pasparakis (185)). 
 
Pseudomonas aeruginosa flagellum for example, triggers an inflammatory 
response by binding to TLR5 in co-operation with either TLR2, or the asialo-GM1 
receptor (186).  These receptors transduce a MyD88-dependent signalling 
cascade that activates protein kinases and a calcium-sensitive signalling pathway 
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(186), resulting in IL8 induction via phosphorylation of MAPK’s p38, ERK and JNK 
and activation of NFĸB (186, 187).  IL8 is a potent neutrophil chemo-attractant.   
 
In CF epithelia, excessive NFĸB activation has been observed (65, 188, 189) 
attended by increased IL8 concentration (190) and excessive neutrophil 
recruitment (64).  A number of explanations for this excessive NFĸB activation 
have been advanced.  Amplified NFĸB activation in response to persistent 
bacterial infection and pro-inflammatory cytokine stimulation (191, 192) represents 
a cell extrinsic explanation for this finding.  However, cell intrinsic explanations 
have also been advanced associated with; ER stress due to the accumulation of 
misfolded CFTR protein; and, ER calcium store expansion and amplification of the 
calcium-dependent inflammatory response (192, 193). 
 
1.6.3 NFĸB activation via the Unfolded Protein Response 
In a study comparing the effect of G551D versus Phe508del mutant CFTR 
expression on NFĸB activation, a sevenfold excess in NFĸB activation was 
attributed to ER retention of the misfolded Phe508del CFTR (194).  ER retention of 
misfolded Phe508del CFTR leads to ER stress and activation of the unfolded 
protein response (UPR) (189). UPR activation leads to a reduction of protein 
synthesis via phosphorylation and inactivation of the translation initiation factor 
e1F-2α, as an adaptive mechanism to cope with ER stress (195, 196).  However, 
in addition to switching off protein synthesis, ER stress also signals for activation 
of NFĸB via the ER-overload response, thus, contributing to an inflammatory 
response (196, 197).  Conversely, ER stress in the context of increased protein 
synthesis during an acute inflammatory response, may also affect CFTR 
expression itself via the UPR (195).  
 
1.6.4 Normal calcium regulation in airway epithelia and amplification of the 
calcium dependent inflammatory response in CF 
The intracellular calcium concentration under normal circumstances is maintained 
relatively low (100 nM) compared to the extracellular concentration (about 2 mM). 
Extracellular stimuli communicate with airway epithelial cells via G-Protein 
Coupled Receptors (GPCR) that generate an influx of calcium into the cell. GPCR 
stimulation activates Phospholipase C (198), to cleave Phosphatidylinositol 4,5-
bisphosphate into Diacylglycerol (DAG) and Inositol triphosphate (IP3).  IP3 
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activates its specific receptor (IP3R) and stimulates calcium release from the ER. 
Depletion of calcium from the ER activates extracellular calcium influx. Removal of 
calcium from the cytoplasm depends on the activation of the SERCA2 pump (199) 
to replenish the ER and also upon the plasma membrane calcium ATPase to 
extrude calcium towards the extracellular space (200). 
 
Intracellular calcium affects almost all major cellular processes, including those 
involved in ASL dynamics, ciliary beat frequency (201-203), secretion of mucus 
and ion transport (204, 205).  Enzymes and proteins participating in pro-
inflammatory signalling cascades including NFĸB pathway (kinases, 
phosphatases, transcription factors, calcineurin and calmodulin) are also calcium-
sensitive.  
 
Several aspects of intracellular calcium homeostasis are disturbed in CF airway 
epithelial cells.  GPCR induced calcium release from intracellular stores and entry 
through the plasma membrane are amplified in CF airway epithelial cells (192).  
IP3Rs-dependent calcium release from the ER is increased as a consequence of 
misfolded mutant CFTR trapped in the ER (193, 206).  ER calcium stores are 
expanded in CF epithelia, associated with ER concentration and condensation 
around the nucleus and IP3R clustering at the ER membrane, resulting in 
facilitated activation (192, 193).  Depletion of calcium from the ER normally 
activates Stromal Interaction Molecule 1 (STIM1) which, in turn activates Calcium 
release-activated calcium channel protein 1 (Orai1) and transient receptor 
potential 6 channel (TRPC6) to activate extracellular calcium influx (207, 208).  
CFTR normally supresses extracellular calcium influx via a regulatory effect on 
TRPC6 and this suppression is lost in CF cells (209).  Enhanced Orai1/STIM1 
complex formation during store depletion in CF cells is also reported to contribute 
to increased calcium signalling (210).  Furthermore, the correction of mutant CFTR 
folding and trafficking to the membrane using miglustat is associated with the 
normalisation of calcium homeostasis (193).  Lastly, chronic infection itself may 
lead to the amplification of intracellular calcium stores, since non-CF airway 
epithelial cells were also reported to respond to chronic bacterial stimulation with 
increased ER size and calcium storage (192).   Taken together, several paths lead 
to abnormal calcium homeostasis in CF airway epithelia, which plays a role in 
excessive NFĸB activation via the amplification of calcium dependent inflammatory 
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response signalling pathways (192, 193).  Over-exuberant NFĸB activation and IL8 
secretion by airway epithelial cells drive excessive neutrophil recruitment in the CF 
airway (65, 179). 
 
1.6.5 Neutrophils in CF Airway Inflammation 
The inflammatory response in the airway in CF is neutrophil dominated and 
associated with an excessively high neutrophil burden (180).  Moreover, neutrophil 
effector functions including bacterial phagocytosis and killing are impaired in CF 
(211-213) and Neutrophil Elastase release by neutrophils causes lung damage 
(66).   
 
A number of factors contribute to the excessive neutrophil population in the airway. 
Airway concentrations of neutrophil chemo-attractants such as IL8 (65) and 
Leukotriene B4  (LTB4) (214) are elevated.  LTB4 and IL8 in particular negatively 
correlate with pulmonary function in CF (190, 214).  Selectins, involved in tethering 
neutrophils to the endothelium in the earliest step of neutrophil transmigration into 
the lungs are increased in the circulations of people with CF (215, 216).  Soluble 
ICAM-1, involved in the strong adhesion of neutrophils to endothelium is reported 
to be elevated in serum in people with CF (215).  In co-cultures of CF neutrophils 
and bronchial epithelial cells, neutrophil adherence to the epithelium is increased 
resulting in increased IL8 secretion (217).  The efferocytic removal of neutrophils 
from the airway is also reported to be impaired, due to Neutrophil Elastase 
mediated calreticulin cleavage, and resulting in the inhibition of phosphatidylserine 
mediated ingestion of apoptotic neutrophils (218-220). 
 
Unfortunately, the robust neutrophil response in CF does not achieve the aim of 
containing and eradicating the bacterial insult.  On the contrary, neutrophils get 
trapped in biofilms where they can self-injure (221).  They have reduced 
phagocytic capacity (211).  Defective intra-phagolysosomal hypochlorous acid 
production in CF neutrophils is reported to result in impaired chlorination of 
bacterial proteins (212).  Neutrophil Elastase cleaves the chemokine receptor 
CXCR1 on neutrophils, disabling IL8’s ability to enhance their bactericidal capacity 
(213). 
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Whilst proteases such as matrix metalloproteinases and Elastase, released by 
neutrophils, play an important role in phagocytosis and bacterial killing, they can 
also degrade the extracellular matrix and cause lung damage.  The clinico-
pathologic importance of Neutrophil Elastase (NE) in CF lung disease was recently 
emphasised by the finding that NE activity in BAL fluid in early life is associated 
with early bronchiectasis in children with CF (66).  Free NE concentration in the 
airway depends on a number of factors including; the neutrophil burden; the rate of 
NE release (222); NE neutralisation by anti-proteases in the lung (223); the extent 
of neutrophil cell death by necrosis versus apoptosis (220); and the removal of 
dying neutrophils by efferocytosis (220).  TNFα and IL8 in the airway drive 
neutrophils to release significantly increased amounts of NE, and neutrophils from 
people with CF release more Elastase than controls (221, 222).  Free NE 
inactivates a range of protective immune effectors whilst stimulating mucus 
secretion and the liberation of the potent chemo-attractants IL8 and C5a (221).  
 
1.6.6 Macrophages in CF 
Enhanced neutrophil migration in CF mouse models was attributed both to 
epithelial cells and recruited macrophages (179).  Furthermore, enhanced pro-
inflammatory cytokine secretion was particularly attributed to CFTR deficiency in 
macrophages (179).  CFTR is expressed at low copy number by human 
macrophages (126, 224).  Moreover, macrophage functional defects are 
increasingly recognised in CF (225) including; defective cytokine secretion; 
impaired phagocytosis and bacterial killing; and impaired neutrophil efferocytosis.   
 
CF monocytes were reported to secrete excess IL8 in response to bacterial LPS, 
due to lower thresholds for the activation of mitogen-activated protein kinases 
(226).  This finding was corroborated by reports of abnormal TLR4 trafficking and 
degradation leading to increased LPS-induced activation of NFĸB in CF 
monocytes (227).  
 
Impaired phagocytic capacity of human CF, or CFTR inhibited, non-CF 
macrophages, has been reported (127, 228).  Impaired intracellular bacterial killing 
of Pseudomonas aeruginosa has been reported in several studies of human and 
mouse CF macrophages (125-127).  Though debated, this finding has been 
related to; CFTR’s involvement in lysosomal acidification (126, 229, 230); and, 
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altered ceramide concentration affecting the release of reactive oxygen species in 
CF macrophages (230).  Defective endosome to late-endosome/lysosome 
maturation during LPS challenge is also reported (227).   
 
Impaired removal of apoptotic cells (efferocytosis) by macrophages has been 
reported in CF (218, 219).  Neutrophil Elastase was demonstrated to cleave 
calreticulin and inhibit phosphatidylserine mediated ingestion of apoptotic cells, 
thus supressing efferocytosis (220). 
 
1.6.7 Imbalanced airway cytokine profiles in CF  
Cellular crosstalk via peptide and lipid immune mediators is necessary for the co-
ordination of the inflammatory response.  Independent of which cell type initiates 
this cycle, and whether infection predates the inflammatory defect, or vice versa, 
the impact of CF on pro- inflammatory and anti-inflammatory cytokine balance is 
widely reported to be weighed in favour of pro-inflammatory cytokine production 
(illustrated in Figure 1-8) (231).   
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Figure 1-8 An illustration of cellular cross-talk in co-ordinating the airway 
inflammatory response in CF 
Airway epithelial cells (E), neutrophils (N), macrophages (M), lymphocytes (L) and 
bacteria are depicted.  TNFα, IL1, IL2, IL6, IL8, IL9, LTB4, LTE4, Elastase, ROS, 
LPS, GM-CSF concentrations are increased; (depicted by up arrows) in CF 
compared to normal.  Conversely, Interferon-γ, IL10, Lipoxin A4 (LXA4) , RANTES, 
Nitric Oxide (NO) are significantly decreased (depicted by down arrows) 
(reproduced from Ziady et al. (13)).  
 
Elevated airway concentrations of pro-inflammatory bacterial LPS, reactive oxygen 
species, IL-1β and TNFα, in the face of reduced anti-inflammatory IL10 and TGF-β 
concentration, promotes the activation of NFĸB and drives the transcription of 
further pro-inflammatory cytokines including; IL6, IL8 and GM-CSF (232-236).   
Nitric oxide (NO) plays a role in bacterial killing and an anti-inflammatory role via 
NFĸB inhibition (237).  Impaired STAT-1 signalling in CF results in reduced 
production of NO by nitric oxide synthase 2 (NOS2) (237, 238).   
 
1.6.8 Anti-inflammatory strategies  
Several anti-inflammatory strategies have been evaluated for CF, however no anti-
inflammatory has been universally adopted into the core treatment regime (239).   
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Moreover, caution has been exercised in the consideration of anti-inflammatory 
strategies for CF (especially pertaining to the complicating high burden of bacterial 
infection) in light of the lessons learned from an unsuccessful clinical trial of a 
leukotriene antagonist BIIL-284 (53, 240).  A 24 week, placebo-controlled phase II 
trial of BIIL-284 in children and adults with CF was terminated prematurely in 
2004, due to a significantly increased risk of adverse pulmonary events 
(particularly pulmonary exacerbations) in the adult patients receiving active 
treatment (241).  Furthermore, it was recently reported that BIIL284 reduced 
inflammation, but at the expense of bacterial containment in mouse studies (241).   
 
Glucocorticoids are central to anti-inflammatory therapy in several inflammatory 
disorders (242).  Dexamethasone antagonises the pro-inflammatory transcriptional 
response by binding to and activating the glucocorticoid receptor. The activated 
receptor then binds directly to NFĸB, which is bound to its own site on pro-
inflammatory gene promoters.  Activated glucocorticoid receptor physically hinders 
the phosphorylation of RNA polymerase II – preventing the initiation of pro-
inflammatory gene transcription (243).  On the other hand, glucocorticoids have 
been reported to produce anti-secretory effects on airway epithelial cells, which 
would be deleterious in the context of the ASL dehydration central to airways 
disease pathogenesis in CF (95, 244-246).  A systematic review of the risks and 
benefits of Inhaled corticosteroids, concluded that there is insufficient evidence to 
establish whether ICS are beneficial in CF, but withdrawal in those already taking 
them has been shown to be safe (247).  The use of glucocorticoids has further 
been limited by adverse side effect profiles when taken systemically (cataracts and 
growth retardation) (248). 
 
High-dose ibuprofen treatment has been associated with significantly lower annual 
rates of decline in lung function (especially in children), however, its adoption into 
therapy has not been universally accepted due to concerns over side effects (249, 
250).  
 
Compounds currently under evaluation include Sildenafil, KB001-A and Alpha 1 
Anti-trypsin (154).  Sildenafil is in Phase II studies as an anti-inflammatory, 
following reports that PDE type 5 inhibitors may rescue Phe508del-CFTR 
trafficking and attenuate inflammation in mice (154, 251).  KB001-A is a 
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humanized monoclonal Fab fragment that targets the Pseudomonas aeruginosa 
Type III secretion system and is being tested in Phase II studies (154).  Alpha 1 
Anti-trypsin completed Phase II studies in 2013 (NCT01684410).  It is an 
aerosolized protease inhibitor that targets free Neutrophil Elastase released by 
neutrophils in the airway (154). 
 
Given the role played by the vicious cycle of infection and inflammation in the 
development of bronchiectasis in CF (illustrated in Figure 1-9); the problems of 
resistance to conventional antibiotics and their side effects; and the burden of 
morbidity and premature mortality associated with lung disease in CF novel 
strategies to address both bacterial infection and inflammation in CF are sought.  
Identifying novel strategies to meet these clinical needs rests on an improved 
understanding of innate defence, dysregulated inflammatory responses, host -
pathogen and pathogen-pathogen interactions in the CF airway.  Agents that 
prevent, or disrupt biofilm formation, improve the activity of existing antibiotics, or 
augment the host immune response are actively sought (252).   
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Figure 1-9 An illustration of the pathogenesis of CF airway disease 
CF is caused by mutation of the gene encoding the CFTR chloride channel.  This 
results in reduced chloride and bicarbonate secretion, sodium hyper-absorption 
and therefore dehydration and acidification of the ASL.  Innate anti-microbial 
peptide dysfunction and impaired muco-ciliary clearance allow persistence of 
inhaled pathogens and eventually chronic endo-luminal bacterial infection.  Due to 
amplified pro-inflammatory responses and high levels of interleukin 8 in the airway 
there is robust recruitment of neutrophils.  The neutrophil response fails to clear 
the bacterial insult and the burden remains high in the airway compounded by 
impaired clearance of neutrophils by macrophage mediated efferocytosis.  Free 
Neutrophil Elastase in the airway causes tissue damage and bronchiectasis 
ensues.  Macrophages in CF have reduced phagocytic capacity, impaired bacterial 
killing and are impaired in efferocytosis. 
 
1.7 Failure of the Inflammatory Response to Resolve in CF 
Under normal circumstances, lung inflammation should eliminate the original 
threat, and then actively resolve and return the tissue to homeostasis (253).  A key 
feature of CF, is the severe, sustained neutrophil predominant response, which 
persists even if the original inflammatory stimulus is removed (221).  We have 
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considered components of the perpetual cycle of infection & inflammation 
including; innate predisposition to infection and the evolution of chronic 
endoluminal bacterial infection; and, excess neutrophil recruitment via airway 
epithelial and resident immune effector synthesis of pro-inflammatory cytokines. 
However, the underlying basis for the failure of resolution of this infection-
inflammation couple remains incompletely understood.  To this end we move on 
now to consider “active” resolution of inflammation in CF. 
 
1.8 The Active Resolution of Inflammation 
1.8.1 Trans-cellular biosynthesis and the Discovery of the Specialised Pro-
resolution Mediators (SPM’s) 
As early as 1976 it was hypothesized that the production of eicosanoids could be 
the result of the transfer of a biosynthetic intermediate from a donor cell, 
possessing a primary oxidative enzyme such as cyclooxygenase or lipoxygenase, 
to an acceptor cell, that, whilst lacking the ability to produce that intermediate, was 
nevertheless capable of converting it into biologically active metabolites in the 
presence of secondary enzymes (254).  In February 1984 Charles Serhan, Mats 
Hamberg and Bengt Samuelsson, were working on the concept of “trans-cellular 
biosynthesis” at the Karolinska Institute.  They examined the metabolism of 
radiolabelled arachidonic acid in cellular co-incubations (255) and discovered that 
when 15-HPETE (an arachidonic acid derivative) was added to human leucocytes, 
a previously undescribed tetraene was formed (256).  They elucidated the 
structure and later in the same year proposed the trivial name Lipoxin A (since 
they arose from the interactions of multiple lipoxygenase pathways) for the new 
compound (257).  It took more than a decade for the biological action of Lipoxins 
to be described; as stop signals for neutrophil recruitment (258), and their role in 
stimulating macrophage phagocytosis of apoptotic neutrophils (259).   
 
Dr Serhan’s lab went on over the subsequent 30 years to discover several families 
of previously undescribed bioactive oxygenated derivatives of Arachidonic acid 
(AA), Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), formed in 
self-resolving exudates by transcellular biosynthesis (253, 260).  In 2000, a link to 
the omega 3 fatty acids was established with the discovery of Resolvin E1, a 
bioactive oxygenated derivative of EPA (261).  In 2002, three families of DHA 
derived bioactive mediators were discovered; the D-Series Resolvins, Protectins 
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and Aspirin triggered isoforms (262) .  The latest family to be described in 2009 
were the Maresins (263).  Together, these endogenously produced, bioactive lipid 
mediators, biosynthesised in self-resolving inflammatory exudates, in the active 
resolution phase of inflammation comprise the specialised pro-resolution mediator 
(SPM) family (Figure 1-10). 
 
 
 
 
 
Figure 1-10 Specialised Pro-Resolution Mediators (SPM’s) from AA, DHA and 
EPA   
SPM’s are endogenously produced self-resolving inflammatory exudates in the 
active resolution phase of inflammation (264).  Lipoxins and their aspirin triggered 
isoforms are derived from arachidonic acid.  E-Series Resolvins are 
biosynthesised from Eicosapentaenoic acid (EPA).  Protectins, D-Series Resolvins 
and Maresins are formed from Docosahexaenoic acid (DHA) (reproduced from 
(265)). 
 
1.8.2 Omega-3 & 6 Fatty acids – Parent Compounds of the SPM’s 
Whilst AA, DHA and EPA are all examples of poly-unsaturated fatty acids (PUFA), 
DHA and EPA are omega-3 fatty acids, whereas, AA is an omega-6 fatty acid.  
Omega-3 fatty acids are formed from α-Linolenic acid (LNA), and omega-6 fatty 
acids from Linoleic acid (LA), both essential fatty acids that must be obtained from 
the diet.  The principal dietary sources of omega-6 fatty acids are poultry, nuts and 
vegetable oils.  Since cold water oceanic fish concentrate omega-3 fatty acids 
synthesised by microalgae, they are rich sources of omega-3 fatty acids.   
 
Omega-3&6 fatty acids must be first ingested, digested and absorbed to 
biosynthesise PUFA by enzymatic elongation and desaturation.  PUFA are 
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incorporated into membrane phospholipids and liberated by Phospholipase A2 to 
make them available for transformation into active metabolites.  In pro-resolving 
inflammatory exudates, DHA, interestingly, is reported to be delivered to the 
inflammatory site from the circulation in oedema fluid (266).   
 
1.8.3 SPM’s and the Active Resolution of Inflammation  
The acute inflammatory response is a protective mechanism that has evolved to 
eliminate invading organisms and be self-limited.  An active resolution phase 
follows, that is tightly regulated and serves to restore tissue homeostasis.  This 
active resolution phase is implemented by non-immunosuppressive pro-resolving 
lipid mediators (illustrated in Figure 1-11) (267).   
 
Specialised Pro-Resolution Mediators (SPM’s) are lipid mediators which are 
endogenously biosynthesised in self-resolving inflammatory exudates in the active 
resolution phase of inflammation (264).  They are potent anti-inflammatory 
mediators that function to terminate the local acute inflammatory response and 
promote the return of inflamed tissue to homeostasis (257).  They mediate their 
effects on recruited immune effector cells and resident cells (268).  The key bio-
actions which define the SPM’s are; 
 
 To stop neutrophil influx into exudates; stop transmigration and chemotaxis, 
block prostaglandins and leukotrienes and limit pro-inflammatory cytokine 
release (253) 
 Non-phylogistic monocyte recruitment, uptake and removal of apoptotic 
neutrophils (efferocytosis) (253)  
 
If inflammation is delayed or prolonged, insufficient or excessive in amplitude, then 
tissue damage results (268).  CF is a disease characterised by prolonged, 
ineffective acute inflammation with on-going neutrophil recruitment, attendant 
tissue damage and failure of resolution.  In this thesis we exploit advances in our 
understanding of “active resolution” and apply this knowledge to obtain a better 
understanding the failure of active resolution of inflammation in CF.  
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Figure 1-11  The Acute Inflammatory Response and the Role of Lipid 
Mediators in Resolution or Its Failure  
Tissue injury or microbial invasion initiates an acute inflammatory response. 
Arachidonic acid derived Prostaglandins trigger changes in blood flow and 
Leukotrienes stimulate neutrophil recruitment. Neutrophils provide the first line of 
defence by migrating to sites of injury and neutralizing invading microorganisms or 
noxious materials by phagocytosis.  Lipid mediator class switching occurs in 
inflammatory exudates to initiate resolution by activating Lipoxin production.  LXA4 
stops LTB4 stimulated neutrophil influx and regulates non-phylogistic monocyte 
recruitment.  SPM’s limit further neutrophil influx to the site and stimulate 
efferocytosis and the clearance of cellular debris by resolving macrophages.  COX 
production of PGD2 stimulates anti-inflammatory IL-10 production. PGD2 
derivative, 15-dPGJ2 activates PPARγ and activates resolution.  These processes 
are non-redundant and therefore impaired function of any of the receptors or 
chemical mediators can in theory lead to failed resolution and persistent 
inflammation (Reproduced from Buckley et al (269)). 
  
70 
 
1.8.4 Eicosanoid Class Switching 
As the fundamental properties of the SPM’s began to emerge a central conceptual 
question arose pertaining to the mechanisms at play in regulating the temporal 
maturation of inflammatory exudates from acute inflammation to active resolution.  
How does an exudate know when to “stop” the acute inflammatory response and 
“start” active resolution? 
 
In 2001, Levy et al described “eicosanoid mediator class switching” in evolving 
inflammatory exudates (264).  They demonstrated a temporal evolution of 
eicosanoid classes in self-limited inflammatory exudates, and correlated the 
eicosanoid profile with the recruitment of neutrophils into exudates, and ultimately 
to the decline in neutrophil numbers and transition towards monocyte / 
macrophage action within exudates.  The sequence of eicosanoid classes 
appearing as an exudate matures was described as; initiation by prostaglandins; 
amplification mediated by leukotrienes; followed by active resolution mediated by 
lipoxins (264).   
 
Furthermore, Levy et al. reported a molecular mechanism by which this “class 
switching” was achieved.  Prostaglandin E2 was reported to induce 15 
Lipoxygenase expression in neutrophils.  Evidence was presented of PGE2’s role 
in effecting the switch, from 5 Lipoxygenase pathway derivative biosynthesis, to 15 
Lipoxygenase pathway derivatives such as Lipoxins (264).   
 
In this thesis, we present evidence that “eicosanoid mediator class switching” is 
defective in CF. 
 
1.9 SPM’s Nomenclature & Biosynthesis 
1.9.1 15 Lipoxygenase Enzyme in Pro-Resolution Mediator Biosynthesis 
The activity of the 15 Lipoxygenase (15-LO) enzyme plays a key role in the 
biosynthesis of; the Lipoxins (257); D- Series Resolvins (262); the Protectins 
(270); and the PPARγ agonists, 15-HETE, 9 & 13-HODE (271-274).  SPM 
biosynthesis occurs by trans-cellular co-operation of two cell types, each cell 
contributing a separate enzymatic catalysis step.  In the airway 15-LO expression 
can be found in; neutrophils (275), eosinophils (276), alveolar macrophages (277) 
and airway epithelial cells (278).  Two isoforms exist, 15-LO type 1 and 15-LO type 
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2 (279).  15-LO is subject to transcriptional regulation by PGE2 (264), IL4, IL13, 
LPS and hypoxia (280, 281).  Furthermore, 15-LO is also subject to translational 
and allosteric regulation (282, 283).   
1.9.2 Lipoxins Nomenclature & Biosynthesis  
LXA4 is biosynthesised from Arachidonic Acid by the trans-cellular sequential 
action of 5 and either 12 or 15 Lipoxygenase enzymes (257).  LXA4 biosynthesis 
will be explored in detail in Chapter 4.  LXA4 is inactivated by eicosanoid 
oxidoreductases (284).  LXA4 interacts with a GPCR the Formyl Peptide Receptor 
2 (FPR2) (285), and is also an intracellular ligand for the Aryl hydrocarbon 
receptor (AhR) (286, 287).  
 
1.9.3 E-Series Resolvins Nomenclature and Biosynthesis 
Resolvin E1 was the first of the Resolvin family to be discovered in 2000 (261).  
Resolvin E1 and E2 are synthesised from EPA by sequential enzymatic action. 
The action of either acetylated COX2 or cytochrome P450 enzymes generates the 
intermediate 18 HEPE.  Subsequent action of either 5-Lipoxygenase (5-LO) or 
Leukotriene A4 Hydrolase gives rise to the generation of E series Resolvins 1 & 2 
(Figure 1-12) (288). At least four pathways exist for the metabolic inactivation of 
RvE1 and these pathways are species, organ and cell type specific (289).  
Resolvin E1 signals via the CMKLR1 receptor in innate immune cells (290) and 
the LTB4 receptor 1 (BLT1) in neutrophils (291).  
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Figure 1-12  Biosynthesis of Resolvin E1 & Resolvin E2   
Resolvin E1 and E2 are synthesised from EPA by sequential enzymatic action.  18 
HEPE is produced by the action of either acetylated COX2 or cytochrome P450 
enzymes.  Subsequent action of either 5 Lipoxygenase (5-LO) or Leukotriene A4 
(LTA4H) Hydrolase results in the generation of E series Resolvins 1 & 2. 
 
Resolvin E3 (RvE3) 
A third pair of E-series Resolvins (two stereoisomers) were described by Isobe 
and colleagues in Tokyo and collectively named Resolvin E3 (RvE3).  Unlike 
Resolvins E1 and E2, biosynthesized via the 5-LO pathway, these metabolites are 
biosynthesized via the 12/15-lipoxygenase pathways. They were reported to limit 
neutrophil infiltration in zymosan-induced peritonitis (292). 
 
1.9.4 D-Series Resolvins Nomenclature and Biosynthesis 
There are six reported D-series Resolvins, Resolvin D1-6 (RvD1-6), first 
discovered in 2002 (262).  Only the first two; Resolvin D1 (128 published articles 
indexed on Pubmed) and Resolvin D2 (18 published articles on Pubmed), are 
commercially available and therefore a larger body of publication has addressed 
their biology (1-4 published articles on Pubmed each for Resolvins 3-6). 
The biosynthesis of the D-series Resolvins from DHA involves two sequential 
lipoxygenation steps.  15-Lipoxygenase (15-LO) catalyses the conversion of DHA 
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to 17R-HpDHA.  A second lipoxygenation step by 15-LO at the C-7 position gives 
a peroxide intermediate which is either enzymatically hydrolysed to RvD1 and 
RvD2, or reduced to form RvD5.  Alternatively, a second lipoxygenation step at the 
C-4 position by 5-LO gives rise to another peroxide intermediate which can either 
be enzymatically hydrolysed to RvD3 & RvD4 or reduced to RvD6 (Figure 1-13).  
Like the Lipoxins, D series Resolvins are rapidly inactivated by eicosanoid 
oxidoreductases (EOR’s) (284, 293). 
 
Using a β arrestin ligand reporter system, RvD1 was revealed to signal through the 
GPR32 orphan receptor and ALX/FPR2 receptor (294, 295). 
 
In this thesis we explore beneficial physiological effects of RvD1 with direct 
relevance for CF airways pathophysiology including ASL height regulation, IL8 
production and CF alveolar macrophage function.  Furthermore, we relate the 
production of RvD2 in sputum during pulmonary exacerbation to FEV1 recovery.  
74 
 
 
 
 
Figure 1-13  Biosynthesis of the D Series Resolvins   
15-LO catalyses DHA conversion to 17-HpDHA.  A second lipoxygenation step by 
15-LO (right of panel) at the C-7 position gives a peroxide intermediate which is 
either enzymatically hydrolysed to RvD1 and RvD2, or reduced to form RvD5.  A 
second lipoxygenation step at the C-4 position by 5-LO gives rise to another 
peroxide intermediate which can either be enzymatically hydrolysed to RvD3 & 
RvD4 or reduced to RvD6.  (*Indicates compounds which are not commercially 
available). 
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1.9.5 Protectins Nomenclature and Biosynthesis 
Protectins are derived from DHA and trivially named for their protective 
bioactivities for immune structures (they are named Neuroprotectins when 
generated in neural tissues).  Protectin D1 is the main bioactive molecule of this 
group although several stereoisomers can be detected in inflammatory exudates 
with less potency, including Protectin Dx (PDx) (296).  The first step in Protectin 
biosynthesis is the same as that for D-series Resolvin biosynthesis, except for the 
chirality at the carbon 17 position; 15-LO catalyses the conversion of DHA to 17S-
HpDHA (Figure 1-14).  An epoxide intermediate is formed, followed by a second 
enzymatic hydrolase step, giving rise to Protectin D1 (PD1).  PDx is an isomer with 
S chirality at the carbon 10 position.  PDx is generated in exudates from 17-
HpDHA via a second lipoxygenation step by 5-LO (296).  TLR7 stimulation was 
reported to enhance the biosynthesis of D-series SPM’s including PD1 (297). 
 
 
Figure 1-14 Biosynthesis of the Protectins   
15-LO catalyses the conversion of DHA to 17-HpDHA.  An epoxide intermediate is 
formed followed by a second enzymatic hydrolase step which gives rise to 
Protectin D1 (PD1) biosynthesis.  An isomer with S chirality at the carbon 10 
position (PDx) is also generated in exudates and is biosynthesised from 17-
HpDHA via a second lipoxygenation step by 5-LO (296). 
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1.9.6 Maresins Nomenclature and Biosynthesis 
There are currently two described members of the Maresin family (trivially named; 
Macrophage mediator in resolving inflammation); Maresin 1 and Maresin 2.  The 
principal source of Maresins is macrophages (263).  Maresins are produced from 
DHA by initial lipoxygenation with molecular oxygen insertion at the carbon-14 
position to form a hydroperoxide intermediate.   The hydroperoxide intermediate is 
rapidly converted to a bioactive intermediate, 13, 14-epoxy-maresin (13, 14-eMaR) 
(298) which is then enzymatically converted to Maresins 1 and 2 (Figure 1-15) 
(263, 299).  The second Maresin, MaR2, was described this year. 
 
 
Figure 1-15  Biosynthesis of the Maresins 
Maresins are produced by initial lipoxygenation with molecular oxygen insertion at 
the carbon-14 position to form the hydroperoxide intermediate, which is rapidly 
converted to 13S, 14S-epoxide-maresin and enzymatically converted to Maresins 
1 and 2 (263, 299). 
 
Maresin 1 has been described to behave as an autacoid (300, 301).  Macrophage 
biosynthesis of Maresin 1 involves a bioactive intermediate, 13, 14-epoxy-maresin 
(13, 14-eMaR), which stimulates a macrophage phenotype switch from classical to 
alternative activation resulting in enhanced Maresin 1 biosynthesis and the 
inhibition of LTB4  biosynthesis (298).   
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1.10 SPM Functions – Resolution without Immune Suppression 
The central effector functions which define the SPM’s are; to stop neutrophil influx 
into exudates (253), and to enhance non-phylogistic monocyte recruitment, and 
macrophage efferocytosis (253) (illustrated in Figure 1-16).  
 
 
 
Figure 1-16  Key steps in the resolution of inflammation 
The initiation and propagation phases of acute inflammation are attended by rapid 
infiltration of neutrophils.  In the resolution phase, neutrophils undergo apoptosis 
and are ingested by macrophages that emigrate rapidly from the inflamed site to 
achieve “Tissue Resolution” (the disappearance of tissue leukocytes and 
cessation of further neutrophil recruitment (268))  (reproduced from (302)). 
 
1.10.1 SPM’s in the Regulation of Neutrophil Migration  
Despite being first described in 1984, it took a further 12 years for it first to be 
reported that Lipoxins function as a stop signal for neutrophil recruitment (258).  
Subsequently, the majority of the SPM’s described have been reported to 
decrease neutrophil recruitment, and / or, transmigration of neutrophils into 
tissues, in a range of models (mouse models of peritoneal sepsis and the fMLP 
stimulated trans-endothelial migration model); LXA4  (303, 304); Resolvin D1 
(293); Resolvin D2 (288),   Protectin D1 (296), Maresin 1 (296), Maresin 2 (299), 
Resolvin E1 (305), Resolvin E2 (305).  
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Neutrophil migration into the lung provides the first line of defence by neutralizing 
invading microorganisms or noxious materials by phagocytosis.  Neutrophil 
recruitment involves migration across the endothelium, extracellular matrix and the 
alveolar epithelium following a chemotactic gradient (illustrated in Figure 1-17) 
(221).  Trans-endothelial migration involves three stages; rolling adhesion, 
mediated by Selectins; strong adhesion, via the interaction of CD11b and ICAM-1; 
and migration.  The neutrophil must then further migrate through the extracellular 
matrix occurs along fibroblasts and across the alveolar epithelial cell barrier (221).   
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Figure 1-17  Neutrophil Migration into the lung  
Neutrophil migration into the lung involves migration across the endothelium, 
extracellular matrix and the alveolar epithelium following a chemotactic gradient.  
Transendothelial migration involves three stages; (1) rolling adhesion, mediated by 
selectins, including E- and P-selectins on the endothelium and L-selectin on the 
neutrophil; (2) strong adhesion, via the interaction of CD11b and ICAM-1, and; (3) 
migration. (4) Migration through the extracellular matrix occurs along fibroblasts 
and is followed by (5) migration across the alveolar epithelial cell barrier 
(reproduced from Downey et al (221)).   
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LXA4’s role in regulating neutrophil recruitment has received the most attention 
since it was the earliest mediator to be described.  LXA4 stops neutrophil 
recruitment by blocking neutrophil chemotaxis, adhesion, and transmigration 
(304).  LXA4 inhibits chemo-attractant LTB4 induced neutrophil-endothelial cell 
adhesion and potently inhibits P-selectin expression (303, 304).  LXA4 reduces 
CD11b/CD18 expression on the neutrophil surface (306).  Furthermore, the 
mechanism of RvD2 reduced neutrophil infiltration was reported to be via 
endothelial-dependent nitric oxide production and direct modulation of leukocyte 
adhesion receptor expression (288).   
 
In this thesis we explore the relative concentrations of LXA4 and LTB4 in the 
airways of children with CF, directly relevant to the regulation of neutrophil 
migration. 
 
1.10.2 SPM’s enhance macrophage clearance of apoptotic neutrophils 
A critical function of macrophages within the inflammatory milieu is the removal of 
dying cells by a specialized phagocytic process called efferocytosis (307).  
Efferocytosis is a key regulatory check point for the innate immune system, and its 
failure may contribute to disease pathogenesis and impede the active resolution of 
inflammation (220).  More than 1011 circulating neutrophils are eliminated and 
replaced every day and the main scavengers of apoptotic neutrophils are 
macrophages and dendritic cells (219, 220).   
 
First recognised in 2000, a key property of the SPM’s is to enhance macrophage 
phagocytosis and clearance of apoptotic neutrophils, and to stimulate monocyte 
recruitment; LXA4  (258, 259), RvD1 (295), RvD2 (308), Protectin D1 (301), MaR1 
(263, 309), MaR2 (299), Resolvin E1&2 (305). 
 
Efferocytosis physically removes apoptotic cells before cell permeability is 
increased, allowing the release of toxic intracellular contents.  In particular, 
neutrophils store proteases, inflammatory mediators and oxidants.  “Eat me” 
signals are presented by the apoptotic cell, including the exposure of 
phosphatidylserine (normally sequestered to the inner membrane leaflet) and 
calreticulin (310, 311).  A sequence then follows of “tethering” the apoptotic cell, 
followed by “tickling” to engage the “eat me” signals driving the extension of 
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membrane ruffles and internalisation into a large fluid filled phagosome (220).  
This process is inhibited by amiloride and has been reported to involve CFTR 
(220).   
Efferocytosis has noteworthy downstream consequences for SPM biosynthesis.  It 
is reported to drive the polarisation of macrophages towards a pro-resolution 
phenotype (alternative activation), stimulating the production of 15-LO via a 
PPARγ/TGFβ pathway (312) (300).  Furthermore, macrophage efferocytosis 
promotes anti-inflammatory IL-10 and TGF-β cytokine production, thus further 
promoting the active resolution of inflammation (307).  Consistent with this 
concept, “Micro-particles” generated from human neutrophils were shown to 
enhance neutrophil efferocytosis by macrophages and induce de novo SPM 
synthesis (313).  Interestingly, efferocytosis increases anti-protease secretory 
leucoprotease inhibitor production by macrophages (314). 
 
SPM’s enhance macrophage mediated phagocytosis and in this thesis we explore 
the effect of RvD1 on CF alveolar macrophage mediated phagocytosis (known to 
be defective).  Furthermore, efferocytosis drives SPM biosynthesis and we 
examine SPM biosynthesis in the contexts of CF airway disease at baseline and 
during pulmonary exacerbation. 
 
1.10.3 Anti-microbial properties of SPM’s 
As early as 2004 it was recognised that SPM’s improve outcomes from an 
infectious challenge in animal experiments (315).  Karp et al. reported that mice 
treated with analogues of LXA4 and subsequently challenged with P. aeruginosa 
contained that bacterial challenge more effectively (315).  In a mouse model of 
peritonitis Spite et al. reported that RvD2 administration reduced both local and 
systemic bacterial burden, excessive cytokine production (IL6, IL1β, IL23, PGE2, 
LTB4 and TNFα) and neutrophil recruitment, while increasing peritoneal 
mononuclear cells and macrophage phagocytosis (308).  These effects translated 
into improved survival of the mice from sepsis (308).  Chiang et al. subsequently 
reported that in mouse models of peritoneal E. coli infection, RvD1 and RvD5 
reduced bacterial titres in blood and exudates, reduced hypothermia and 
increased survival (316).  Co-treatment of these mice with the antibiotic 
ciprofloxacin and RvD1 accelerated resolution and shortened resolution intervals 
(316).  Adjuvant treatment of ciprofloxacin with a panel of SPM’s (RvD1, RvD5, 
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and Protectin D1) heightened host antimicrobial responses in E-Coli infected mice 
(316).  Furthermore, in skin infections, a panel of SPM’s (RvD1, RvD5, and 
Protectin D1) enhanced vancomycin clearance of Staphylococcus aureus (316).  
In a mouse model of aspiration pneumonia, Resolvin E1 enhanced bacterial 
clearance and was attended by an improvement in survival (317).   
 
In this thesis we explore the effect of RvD1 on intracellular killing of a central CF 
pathogen, Pseudomonas aeruginosa by CF alveolar macrophages. 
 
1.11 SPM mechanisms of action; Intracellular signalling  
1.11.1 Intracellular signalling pathways; LXA4  
In human airway epithelia LXA4 has been reported to stimulate a rise in 
intracellular calcium via adenylate cyclase activity and PKA activation (318).  A 
survey of global epithelial gene expression in human enterocytes uncovered a 
host of genes under NFĸB control whose transcription was reduced by LXA4 (319).  
In neutrophils, LXA4 stimulation leads to an intracellular accumulation of 
Presqualene diphosphate (PSDP), which serves to inhibit phospholipase D 
activation and potently inhibit superoxide anion generation (320).  In dendritic 
cells, Socs2 up regulation (a member of the suppressors of cytokine signalling 
family of proteins) plays a central role in mediating the anti-inflammatory effects of 
LXA4, in a manner dependent upon both AhR and ALX/FPR2 expression (287) 
(illustrated in Figure 1-18). (102) 
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Figure 1-18  Lipoxin A4 signalling   
LXA4 interacts with FPR2 and AhR receptors. AhR dimerizes with ARNT and 
regulates genes involved in xenobiotic metabolism (286, 287).   LXA4 stimulates 
[Ca]i increase via adenylate cyclase activity and PKA activation (318). LXA4 
reduces transcription of genes under NFĸB control (319). LXA4 stimulation leads to 
PSDP accumulation in favour of PSMP, inhibiting PLD activation and superoxide 
anion generation (320). LXA4 stimulation results in AhR and ALX/FPR2 dependent 
Socs2 up-regulation and thus negative regulation of cytokine signalling (287) 
(Reproduced from (102)).   
 
1.11.2 Intracellular signalling pathways; Resolvin D1 
Hsiao et al recently examined the intracellular signalling pathways mediating the 
effects of RvD1.  They reported that RvD1 strongly suppressed IL6 and IL8 
production induced by a viral mimic compound (321).  Pro-inflammatory signalling 
involving MAPKs and NFĸB was supressed via RvD1 mediated inhibition of the 
phosphorylation of TGF-β-activated kinase 1 (TAK1), upstream of both the MAPK 
and NFĸB pathways, by inhibiting the formation of a TAK1 / TAB1 (TAK1 binding 
protein) / TRAF6 (TNF receptor-associated factor 6) signalling complex (321).  
Furthermore, RvD1 regulates microRNA circuits, targeting cytokines and proteins 
involved in the immune system including; miR-146b, targeting NFĸB signalling, 
and miR-219, which regulates 5-LO expression (255). 
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1.12 Pro-Resolution Receptors 
1.12.1 ALX/FPR2 Receptor 
FPR2 (also known as ALX) is a GPCR which conveys the pro-resolving properties 
of LXA4, 15-epi-LXA4, RvD1, aspirin-triggered Resolvin D1, and Annexin A1 (268).  
Unusually, the pro-inflammatory responses elicited by the antimicrobial peptide   
LL-37 and serum amyloid protein A (SAA) are also mediated by ALX/FPR2.  
ALX/FPR2 is expressed in several types of cells including; neutrophils (306), 
alveolar macrophages (259, 322), human bronchial epithelial cells and human 
bronchial biopsy sections (323).  In bronchial epithelial cells the ALX/FPR2 
receptor is located at the apex of the cell (323). 
  
Structurally, ALX/FPR2 has both lipid binding and peptide biding domains (324).  
ALX/FPR2 differentially signals either a pro-resolution cascade, or a pro-
inflammatory cascade depending upon ligand-biased receptor activation and 
either, hetero-dimerization of ALX/FPR2, with related FPRs (pro-inflammatory 
cascade), or, homo-dimerization of ALX/FPR2, to engage pro-resolving signal 
cascades (325).  
 
Functionally, ALX/FPR2 deficient mice respond to an inflammatory challenge with 
increased acute inflammation and delayed resolution (326).  It is noteworthy that 
LXA4 enhances the activity of the ALX/FPR2 promoter (327) and miR-181b binds 
to the 3’ UTR of the ALX/FPR2 gene and regulates its expression (328).  
 
In this thesis we examine the role of the ALX/FPR2 receptor in RvD1 mediated 
effects on ASL hydration. 
 
1.12.2 Aryl hydrocarbon receptor (AhR)  
LXA4 is an intracellular ligand for the Aryl hydrocarbon receptor (AhR) (286, 287).  
AhR is a transcription factor which heterodimerizes with the AhR nuclear 
transporter protein (ARNT) upon ligand binding and interacts with dioxin response 
elements to regulate genes involved in xenobiotic metabolism (286, 287).  
 
1.12.3 GPR32 Receptor 
RvD1 binds to GPR32 (also known as the RvD1 receptor DRV1) (295).  RvD1’s 
receptor activation is reported to be concentration dependent, i.e. low 
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concentration RvD1 employed GPR32 to block neutrophil-endothelial cell 
interaction, whereas high concentration effects were mediated via ALX/FPR2 
(295).  GPR32 expression is reported in peripheral blood leukocytes, vascular 
tissue and small airway epithelial cells (295, 321).  In this thesis we were not able 
to evaluate the role of GPR32 in RvD1 mediated physiological effects in the CF 
airway since pharmacological tools have not yet been developed to interrogate the 
contribution of this receptor. 
 
1.12.4 Peroxisome proliferator-activated receptor gamma (PPARγ) 
PPARγ is a ligand-activated transcription factor that is up-regulated during the 
resolution of inflammation and mediates the anti-inflammatory effects of a number 
of essential fatty acid derived lipid mediators (329, 330).  Potent PPARγ ligands 
include Prostaglandin type pro-resolving lipids (331, 332), 12 and 15 
Lipoxygenase pathway products (274, 331, 332), SPM parent compounds EPA 
and DHA (332), and non-enzymatic oxidation products of linoleic acid (332). 
 
In this thesis we describe a relationship between PPARγ agonist 15-d-PGJ2 and 
recovery of FEV1 during pulmonary exacerbation of CF.  We also develop methods 
to quantify PPARγ expression in CF alveolar macrophages. 
 
1.12.5 SPM’s awaiting Receptor assignments 
RvD2 stimulated vasoprotective prostacyclin in a pertussis toxin sensitive manner, 
implicating a role for GPCR’s (288).  Protectin D1 is reported to specifically bind to 
human neutrophils, but its cognate receptor has not yet been established (268).   
Resolvin E2 interacts with an unidentified leukocyte GPCR (333).  
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1.13 SPM’s in Lung Infection and Inflammation Models 
The biological roles of SPM’s are thought to be non-redundant, tissue and cell type 
specific (253).  Nevertheless, the specific functions of individual mediators within 
the family in different tissues, contexts and disease states remain areas of active 
research.  Therefore we consider the reported actions of SPM’s specifically in a 
pulmonary infectious or inflammatory context.   
 
Pulmonary benefits have been reported for LXA4 (315, 318, 334), RvD1 (335-337), 
Protectin D1 (338, 339) and Resolvin E1 (305, 317).  A pulmonary role for LXA4 
was reported in mice challenged with P. aeruginosa. Mice treated with analogues 
of LXA4 contained the bacterial challenge more effectively (315).  In a mouse 
model of acute lung injury, LPS induced lung injury and cigarette exposure RvD1 
administration was reported to have beneficial effects, including; blocking 
leukocyte infiltration and reduced cytokine levels (335), promoting alternative 
macrophage activation, and stimulating neutrophil efferocytosis (336), and 
attenuation of NFĸB activation (337).  In mouse and human asthma studies, 
Protectin D1 was reported to protect from lung damage, airway inflammation and 
hyper-responsiveness (338), and promoted apoptosis of neutrophils in BALF 
(339).  Protectin D1 was generated by human asthmatic patients and detected in 
exhaled breath condensate (338).  In mouse models, Resolvin E1 administration 
enhanced the resolution of established neutrophil-mediated pulmonary injury 
(305).  In a mouse model of aspiration pneumonia, Resolvin E1 decreased lung 
neutrophil accumulation, enhanced bacterial clearance, decreased lung tissue 
levels of several pro-inflammatory chemokines and cytokines and was attended by 
an improvement in survival (317).   
 
Pulmonary benefits of SPM’s reported in animal models stimulated us to examine 
the human disease specific roles of these compounds.  These reports informed 
the design of the “Pro-Resolution mediators in CF exacerbation” (PRINCE) study 
reported herein. 
 
1.14 SPM’s and Active Resolution in CF 
The acute inflammatory response is a protective mechanism that has evolved to 
eliminate invading organisms and be self-limited (267).  SPM’s serve to terminate 
the local acute inflammatory response and promote the return of inflamed tissue to 
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homeostasis (257).  These processes are non-redundant and therefore impaired 
function of any of the receptors or chemical mediators involved in enacting the 
resolution process can in theory lead to failed resolution and persistent 
inflammation (269).  If inflammation is delayed or prolonged, insufficient or 
excessive in amplitude, then tissue damage results (268).  CF is a disease 
characterised by prolonged, ineffective acute inflammation with ongoing neutrophil 
recruitment, attendant tissue damage and failure of resolution. 
 
In contrast to the key functions of SPM’s; to stop neutrophil influx into exudates, 
limit pro-inflammatory cytokine release and enhance macrophage phagocytosis of 
apoptotic neutrophils (253), in CF, pro-inflammatory cytokines are abundant, 
neutrophils are present in excess and macrophage phagocytosis is impaired (340, 
341).  
 
A number of aspects of SPM biology in CF have been studied to date.  A 
significant body of work has looked at the metabolism of parent compounds AA 
and DHA.  LXA4 biosynthesis has been explored in CF and will be specifically 
addressed further in Chapter 4.  The physiological effects of LXA4 have been 
examined in CF models and SPM’s have been detected in studies of sputum from 
adults with CF.  Lastly, the role of the pro-resolution PPARγ receptor has been 
examined in CF models.   
 
1.14.1 Essential Fatty Acid Imbalance in CF   
The parent compounds of the SPM’s are essential fatty acids and in order to 
contextualize studies reported herein of SPM biosynthesis in CF we must first 
review the literature on the SPM parent compounds in CF.  As early as the 
seventies, fatty acid abnormalities were described in CF (342).  Decreased tissue 
LA concentration is accompanied by increased AA concentration.  This has been 
attributed to increased metabolism of LA to AA via increased expression of Δ5- 
and Δ6-desaturase enzymes in CF cells.  Furthermore, pathological regulation of 
Arachidonic acid release by Phospholipase A2 (PLA2) has been reported in CF 
(343).  Basal cytosolic PLA2 activity was reported to be increased whereas 
restoration of CFTR delivery to the membrane restored normal activity (344). 
DHA concentration has also been reported to be reduced in CF tissues.  Several 
lines of evidence suggest that DHA deficiency in CF is of clinico-pathological 
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significance.  AA / DHA imbalance in CF is thought to play a role in the excessive 
production of AA derived mediators such as prostaglandins and leukotrienes, 
since DHA is reported to suppress Δ5- and Δ6-desaturase enzyme expression.  
Furthermore, experimental addition of DHA was found to decrease desaturase 
enzyme expression and normalize LA to AA metabolism (345-347) in culture 
systems, and high dose oral supplementation of DHA was reported to reverse 
PUFA abnormalities and ameliorate CF related pathology including pulmonary 
inflammation in CFTR null mice (348).   
 
There are similarities between animal descriptions of essential fatty acid deficiency 
and CF related pathology; liver steatosis, increased caloric needs, increased 
bacterial colonisation and decreased immune responses (349).  Strandvik and 
colleagues found an association between serum concentrations of LA and DHA 
and CFTR mutation severity (350).   
 
Prompted by these findings, several small studies have evaluated the effect of 
DHA supplementation in CF and larger scale studies are in progress. There are 
reports of improvement in fatty acid levels, decreases in inflammatory markers, 
improvement in pulmonary function tests and decreased exacerbations (345). 
 
1.14.2 LXA4 biosynthesis in CF 
Platelets from CF patients were reported to generate 40% less LXA4 than controls, 
an observation that was replicated by CFTR inhibition (351).  In this thesis we will 
examine the LXA4 synthetic capacity of airway epithelial cells and isolated alveolar 
macrophages in CF.  
 
1.14.3 SPM’s measured in airways samples from people with CF 
LXA4 concentration in airways samples from patients with CF has been variously 
reported as absent, significantly suppressed, or not significantly different from 
disease controls (315, 352, 353).  A significant increase in LXA4 concentration was 
measured in patients following antibiotic therapy (354).  The presence of Resolvin 
E1 in respiratory tract secretions from adult patients with CF was associated with 
better lung function (353).  In this thesis we will examine LXA4 synthesis in the 
airways of children with CF.  
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1.14.4 Beneficial physiological effects of LXA4 in CF 
In CF models, LXA4 has been shown to; restore airway surface liquid height by 
enhanced Calcium activated Chloride secretion (318, 355) and ENaC inhibition 
(356); stimulate tight junction formation (357); decrease neutrophilic inflammation, 
pulmonary bacterial burden, and disease severity (315); and enhance repair (358) 
(illustrated in Figure 1-19).  Uniquely, LXA4 is reported both to restore airway 
surface liquid hydration, and counter-regulate the pro-inflammatory program of the 
CF airway environment.  Mechanistically, in CF airway epithelial cells, LXA4  
interacts with the ALX/FPR2 receptor to stimulate an intracellular calcium increase 
(318) that activates a compensatory calcium-activated chloride secretory 
mechanism, and overcomes the lack of CFTR mediated chloride transport to 
restores ASL height in vitro (355).   The increased intracellular calcium 
concentration generated in CF airway epithelial cells by LXA4 occurs via 
ALX/FPR2 stimulation, and results in apical ATP release via Pannexin channels, 
resulting in P2Y11 purinoreceptor stimulation (359).  
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Figure 1-19  An illustration of normal airway physiology, the 
pathophysiology of CF, and the physiological properties of LXA4 in CF 
models  
LXA4 augments airway epithelial innate defence by stimulating tight junction 
formation (357); enhancing Calcium activated Chloride secretion (318), ENaC 
inhibition (356) and restoring airway surface liquid height in CF airway epithelial 
cells (355). LXA4 has pro-resolution effector functions and reduces pulmonary 
bacterial burden (315), limits neutrophil recruitment (360) and reduces IL8 
secretion by airway epithelial cells (323).   
 
1.14.5 PPARγ plays a role in the resolution of inflammation and is disrupted in CF  
PPARγ is up-regulated in the active resolution phase and mediates the anti-
inflammatory effects of essential fatty acid derived lipid mediators (329, 330).  
Disrupted PPARγ function has been reported to play a role in CF lung disease 
(331).  In CFTR knockout mice the expression of PPARγ was reported to be down-
regulated at the RNA and protein level, and associated with reduced nuclear 
localisation (361).  PPARγ agonist pioglitazone was reported to normalize 
pulmonary infiltration of neutrophils and pro-inflammatory cytokine levels in the 
lungs of CFTR-deficient mice challenged with Pseudomonas (362).  Recent 
studies demonstrated a role for PPARγ in the expression of carbonic anhydrases 
and bicarbonate transport in the lung (363).   
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In this thesis we describe a relationship between the production of PPARγ agonist 
15-d-PGJ2 in sputum and the extent of recovery of FEV1 following pulmonary 
exacerbation of CF.  We also develop methods to quantify PPARγ expression in 
CF alveolar macrophages. 
 
1.15 SPM’s in Clinical Drug Development Programmes 
The effect of LXA4 inhalation has been evaluated in a pilot study of eight asthmatic 
and healthy adult subjects. The challenge was tolerated, had no adverse effect on 
pulse or blood pressure and demonstrated favourable effects on specific airway 
conductance (364).  More recently, a clinical trial of topical 15(R/S)-methyl-LXA4 
for infantile eczema found that the LXA4 analogue relieved eczema severity (as 
effectively as a topical steroid) and improved quality of life without apparent 
adverse events (364, 365).  
 
The Pharmaceutical industry have reported that Resolvin E1 and synthetic 
analogues have been formulated for oral, IV and subcutaneous routes of 
administration and that Phase I clinical studies have demonstrated potency across 
a range of inflammatory disease models including asthma, colitis, rheumatoid 
arthritis, atherosclerosis, dry eye and retinopathy (103).  Phase I – II clinical trials 
demonstrated efficacy of a Resolvin E1 analogue for the treatment of dry eye and 
phase III studies are reported to be underway (366, 367).  
 
Furthermore, Maresin 1 was reported to be in a clinical drug development 
programme (253) and Protectin D1 is in clinical development for the treatment of 
neurodegenerative disease (253). 
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1.16 Aims and Outcomes of this study 
Given the roles played by ASL dehydration, infection and inflammation in the 
development of bronchiectasis in CF novel strategies to rehydrate the ASL and 
improve muco-ciliary clearance, compliment conventional antibiotics and combat 
excessive inflammation are sought.  Our group had previously demonstrated 
beneficial physiological effects of LXA4 in CF bronchial epithelial cell model 
systems, including the restoration of ASL height via stimulation of the specific 
ALX/FPR2 receptor (85, 356, 359).  RvD1 was reported to be an agonist at the 
ALX/FPR2 receptor (295) and to attenuate NFĸB activation in mouse models of 
lung injury (337).  Furthermore, SPM enhance phagocyte function (253) and 
bacterial clearance (316).    Therefore, we aimed to investigate the potential of 
RvD1 as a candidate therapeutic in CF.   
 
 
Figure 1-20  Illustration of the aim to investigate the translational potential of 
RvD1 for CF therapy 
 
Using live cell confocal microscopy we demonstrate that RvD1 increases ASL 
height in primary CF bronchial epithelia and the CuFi-1 cell line.  By Western 
blotting and ELISA, we show that RvD1 preserves the integrity of IĸB, and 
attenuates IL8 secretion stimulated by TNFα in a CF bronchial epithelial cell line.  
In CF, impaired alveolar macrophage phagocytosis and bacterial killing are 
reported (125-127, 228).  Using primary CF alveolar macrophages we 
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demonstrate that RvD1 enhances macrophage phagocytic capacity and improves 
intracellular killing of Pseudomonas aeruginosa. 
 
The underlying basis for the failure to actively resolve inflammation in the CF 
airway remains incompletely understood.  We noticed significant overlap between 
the pathophysiological characteristics of inflammation in the CF lung, and the 
reported functions of SPM’s in the active resolution of inflammation.  In particular, 
SPM’s limit neutrophil recruitment and enhance tissue neutrophil clearance (253).  
In CF, neutrophil recruitment is excessive, the airway burden is high and 
inflammation is prolonged and ineffective leading to failed bacterial containment 
and tissue damage (221).  LXA4 is the first of a series of SPM’s to be synthesised 
in the resolution phase of inflammation, and is generated by a “class switch” in 
eicosanoid lipid mediator synthesis via up-regulation of 15-LO (264).  Some 
controversy surrounded prior reports of reduced LXA4 concentration in CF airway 
samples (315, 352).  It was our aim to understand the role of eicosanoid mediator 
class switching in the failure to actively resolve inflammation in CF lung disease.   
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Figure 1-21 Illustration of the aim to investigate the role of eicosanoid 
mediator class switching in CF pathogenesis 
 
Using BAL samples from children with CF and controls we measured eicosanoids 
expressed before (LTB4) and after the “class switch” towards active resolution 
(LXA4).  Furthermore, we quantified eicosanoid synthetic enzymes in the cellular 
phase of BAL by qPCR.  We demonstrate impoverished 15-LO type 2 gene 
expression, associated with a depressed LXA4 / LTB4 ratio in the lower airways of 
children with CF.   
 
In order to further investigate how defective 15-LO expression in alveolar 
macrophages could result in the failure to synthesise LXA4 we develop a method 
to isolate a purified alveolar macrophage population from the BAL of children with 
CF and controls.  Furthermore using this method we present pilot data on 15-LO 
expression and macrophage polarisation in this enriched population.  Using qPCR, 
Western blotting and ELISA, we go on to investigate the regulation of 15-LO 
expression and activity in a CF bronchial epithelial cell line and find that it is 
broadly similar to that found in a non-CF bronchial epithelial cell line (NuLi-1). 
 
With an accumulating body of experimental evidence to suggest that SPM’s could 
present therapeutic opportunities in CF lung disease, we aimed to investigate 
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whether pro-resolution lipid mediator expression could be associated with clinically 
meaningful indicators of lung health in children with CF.  In interventional studies 
on animal models of infection, SPM’s; accelerated resolution, and lowered 
antibiotic treatment requirements (316).  Acute exacerbations of infection in the CF 
airway vary in terms of their outcomes, including, variable duration of exacerbation 
and variable extent of recovery of lung function parameters including FEV1 (368, 
369).  Using the lipidomic approach and spirometry, we evaluated the relationships 
between Pro-Resolution lipid mediator expression in sputum during pulmonary 
exacerbation, and the extent of FEV1 recovery following antibiotic treatment for CF 
Pulmonary Exacerbation. 
 
 
Figure 1-22  Illustration of the aim to investigate the role played by SPM’s in 
the clinical resolution of CFPE 
*Graph adapted from Collaco et al. (368) 
 
We report significant positive associations between RvD2 and the PPARγ agonist 
15-d-Prostaglandin-J2 measured in sputum during CFPE and the full recovery of 
FEV1 post exacerbation.  Whilst these findings are novel, and require validation in 
a larger population of both children and adults with CF, they suggest potentially 
exciting new avenues for the development of antibiotic adjuvant therapies in CF. 
  
96 
 
CHAPTER 2 
MATERIALS AND METHODS 
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2 Materials and Methods 
2.1 The SHIELD CF Study 
The SHIELD CF Study (Study of Host Immunity and Early Lung Disease in 
Children with CF) is a longitudinal study established by Dr’s McNally & Linnane 
around the CF preschool surveillance bronchoscopy programs at Our Lady’s 
Children Hospital, Crumlin (OLCHC), The National Children’s Hospital, Tallaght 
and University Hospital Limerick.  Children with CF were recruited when they 
attended for their first annual surveillance bronchoscopy and consented to the 
collection of blood, urine, bronchoalveolar lavage fluid, bronchial brushings and 
clinical data parameters as part of this longitudinal study.  Consent was renewed 
at each annual surveillance visit.  Children with CF remained in the study until they 
were able to reliably expectorate sputum for microbiological surveillance of their 
lung disease and graduated from the pre-school surveillance bronchoscopy 
program.  Children without CF undergoing bronchoscopy for clinical reasons were 
recruited as paediatric controls.  
 
2.1.1 Inclusion & Exclusion criteria & Treatment Characteristics of SHIELD CF 
participants in the work reported in this thesis 
Children were excluded from the studies reported in this thesis if they were taking 
leukotriene receptor antagonists or treatment dose antibiotics in the two weeks 
prior to bronchoscopy.  Annual surveillance assessments were undertaken when 
the children were in a stable clinical condition.  As a matter of local prescribing 
policy, NSAID’s, inhaled steroids and oral corticosteroids are not routinely 
prescribed for young children with CF.  No included participant was on long term 
oral corticosteroids.  As a matter of pragmatism (given the high rate of inhaled 
corticosteroid prescription among referrals to a tertiary paediatric respiratory 
clinic), it was not possible to completely exclude all control children on low dose 
inhaled corticosteroids, however, investigation for moderate / severe asthma was 
not listed as an indication for bronchoscopy among the included control group 
(370). 
 
2.1.2 Bronchoscopy, BAL Collection and Storage 
Flexible fibre optic bronchoscopy and BAL collection were performed as previously 
described (371). Patients were fasted for a minimum of four hours prior to the 
procedure.  All procedures were conducted in the operating room under general 
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anaesthesia.  Prior to introduction of the bronchoscope, lignocaine 4% was applied 
to the airway above the vocal cords, and lignocaine 1% to the vocal cords and 
lower airway to provide local anaesthesia.  The maximum dose of lignocaine did 
not exceed 7mg/kg.  Supplemental oxygen, pulse oximetry, continuous ECG 
recording and intermittent non-invasive blood pressure monitoring was carried out 
throughout.  Before the introduction of the bronchoscope a control lavage was 
performed using sterile saline to control for bacterial contamination of the 
instrument.  The bronchoscope was introduced via a laryngeal mask airway to 
prevent contamination of the bronchoscope and introduction of pathogenic 
bacteria into the lower airways from above.  Suction was not performed until the tip 
of the bronchoscope was past the carina.  In order to control for variations in 
dilution, BAL samples were only included if the 4ml/kg total instillation volume was 
strictly adhered to and a return of 40-60% volume was attained.   
 
BAL was performed by instilling two aliquots of 1ml/kg sterile 0.9% saline into both 
the right middle lobe and lingula.  All four samples were pooled, sealed in a sterile 
container and transported to the laboratory on ice.    BAL was centrifuged at 
3000rpm and the supernatant and cell pellet aliquoted and frozen at -80ºC for 
subsequent experiments. 
 
After the procedure, patients were observed in the recovery area for at least 30 
minutes with pulse oximetry, ECG monitoring and blood pressure measurement 
until fully alert and breathing without difficulty. 
 
2.2 PRINCE Study 
In order to investigate a role for Pro-resolution Mediators as adjuvant therapeutics 
for the treatment of CF pulmonary exacerbation in childhood, we designed a 
prospective paediatric observational cohort study; The Pro-Resolution Mediators in 
CF Exacerbation (PRINCE) study (Figure 2-1).   
 
2.2.1 PRINCE Study Population  
We invited eligible inpatients attending OLCHC with Cystic Fibrosis Pulmonary 
Exacerbation (CFPE) (commencing in February 2013) to participate.  Cases were 
identified by the investigator (FR) by liaising with the multi-disciplinary respiratory 
team and the admitting resident medical staff.  Since this was the first study (to our 
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knowledge) to examine sputum pro-resolution mediator profiles of children with 
airways disease we did not have any information about the extent or timing of the 
production of such mediators in children without CF.  We therefore expanded the 
study protocol to recruit an additional group of inpatients without CF, attending 
OLCHC from whom sputum could be obtained (e.g. community acquired 
pneumonia, Non CF bronchiectasis with infective exacerbation, children with 
tracheostomy in situ) as a “Disease Control” population.  The study was publicised 
within the hospital and among staff.   
 
To be included in this study, participants with CF must:  
 Have a confirmed diagnosis of Cystic Fibrosis 
 Be able to co-operate with spirometry and expectorate sputum 
 Complete at least part of their treatment for CFPE as an inpatient 
 Have a pre-exacerbation baseline* (*defined as best reliable FEV1 recorded 
in the 3 months prior to exacerbation) FEV1> 50% predicted 
 Fulfil Fuchs Criteria for Cystic Fibrosis Pulmonary exacerbation (372) 
 
To be included in this study, control participants must: 
 Be productive of sputum 
 Complete at least part of their treatment as an inpatient 
 Previous diagnosis of other comorbid condition not specifically excluded 
 
2.2.2 Study Design & Sample Size Estimation 
Primary End-Point:  A description of the relationship between airway 
concentrations of Pro-Resolution lipid mediators and the extent of FEV1 recovery. 
 
We based our initial sample size estimates on a study which looked at the 
concentration of one SPM (LXA4) at the start and end of exacerbation.  In that 
study of LXA4 change after completion of antibiotic treatment for CFPE (354) a 
statistically significant (P = 0.003) change in LXA4 concentration from 19.7 - 39.6 
ng/ml was observed with 18 patients.  For this prospective study, we estimated 
that we would need a minimum of 23 patients to to detect a mean difference of 
10ng/ml in the concentration of one SpM.   
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Based on previous studies of FEV1 recovery during exacerbation (368), in order to 
relate SPM production to our primary outcome - the kinetics of FEV1 recovery to 
baseline - we estimated that we would need to recruit a minimum of 60 patients.  
*Statistical support was provided by the National Children’s Research Centre via 
Dr. Gloria Crispino O’Connell. 
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Figure 2-1  Overview of the conduct of the “PRINCE” study 
 
2.2.3 PRINCE Clinical Data Collection 
Clinical data was recorded onto an anonymised standard data collection form 
including; comorbid conditions, age, sex, prior microbiology history and regular 
medications.  For those children hospitalized for CFPE the following additional 
data was collected; weight at baseline and during the course of CFPE, treatment 
antibiotics for CFPE, length of antibiotic course and CF mutations.  A Respiratory 
and Systemic Symptoms Questionnaire© (Boehringer Ingelheim) was 
administered on participants being treated for CFPE at intervals during the course 
of their infection (days (1-2), (4-5), & (6-12)).   
 
2.2.4 Spirometry 
Spirometry was performed by the investigator (FR) on PRINCE study participants 
with CF at intervals during the course of their infection (days (1-2), (4-5), (6-8) & 
(11-12)).  Historical spirometry measurements performed by the pulmonary 
function lab at OLCHC were recorded from the patient’s clinical notes.  An 
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EasyOne™ Diagnostic portable spirometer was used to perform the 
measurements.  The equipment was checked daily for validation and quality 
control.  Patients were asked to wear a nose clip and perform at least three forced 
expiration manoeuvres in a sitting position until at least three acceptable 
spirograms were obtained with between manoeuvre variability of less than 0.15L 
for FVC and FEV1 (373).  The participant’s sex, and most recent height and weight 
recorded during this admission were entered into the spirometer and Forced 
expiratory volume in one second (FEV1) measured in litres was expressed as a 
percentage of that predicted, with calculations performed by the spirometer’s 
software based on reference values used by the spirometer’s manufacturer.   
 
2.2.5 PRINCE Study Sputum Collection & Processing  
Sputum consists of a mixture of mucus, inflammatory and epithelial cells, and 
cellular degradation products from the lower respiratory tract (374).  Sputum 
collection and processing was performed by the investigator (FR).  Patients were 
asked to blow their nose, rinse their mouth and swallow water before 
expectoration to reduce salivary contamination (374).  They were then asked to 
spontaneously expectorate sputum into a sterile container.  This was then capped 
tightly, placed on ice and transported immediately to the lab for processing.  
Sputum samples were collected on a once off basis from control participants and 
at intervals during the course of their infection (days (1-2), (4-5), (6-8) & (11-12)) 
from participants with CF.   
 
Only sputum plugs were used (salivary dilution represents a significant sampling 
variable (375)).  An unprocessed portion of sputum was immediately placed into 
cold HPLC grade methanol, frozen at minus 80 degrees and kept under those 
conditions until transported to Toulouse on dry ice for analysis by LC-MS/MS.     
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Figure 2-2  Overview of the sputum sample processing algorithm for the 
“PRINCE” study  
 
The remaining sputum was then processed according to a modified version of the 
validated protocol of Pavord at al. (376) to obtain a supernatant fraction for the 
quantification of IL8 and a cell pellet in order to obtain a total cell count (Figure 
2-3).  Dithiothreitol (Sputasol) was used to improve cell dispersion.  It is a 
sulphydryl agent which produces mucolysis by opening disulphide bonds 
crosslinking glycoprotein fibres.  Compared with mechanical dispersion it is 
reported to result in easier, quicker, and more reproducible cell counts.  DTT is 
reported to be compatible with IL8 measurement and not to cause appreciable cell 
activation (376, 377). 
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Figure 2-3  Flow chart illustrating the method used to process sputum for 
the PRINCE study  
A modified version of the protocol used by Pavord et al. (376) 
 
2.3 Methodologies common to both SHIELD CF & PRINCE Studies 
2.3.1 Ethics 
Ethical approval for the SHIELD CF study was granted by each participating 
hospital’s research ethics committee.  Ethical approval for the conduct of the 
PRINCE study was obtained from the recognised ethics committee of Our Lady’s 
Children’s Hospital, Crumlin.  An amendment to the original PRINCE study 
application was approved by the same body to allow us to recruit a control cohort.   
  
2.3.2 Consent, Assent and Confidentiality  
Written and oral information were provided with the use of information leaflets.  
Written assent was sought and obtained from the participants in the PRINCE 
study.  Written consent was obtained from the parent / legal guardian of 
participants of both studies prior to enrolment.  Specific provisions were made to 
maintain patient confidentiality and for the observation of the Data Protection 
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guidelines.  Data and biological samples were pseudo-anonymised at collection by 
allocation of a study participant number. 
 
2.3.3 Microbiological testing of airway samples 
For the SHIELD CF Study an aliquot of pooled BAL was sent directly from theatre 
to the microbiology lab at OLCHC.  For the PRINCE Study a separate sputum 
sample was sent directly to the microbiology lab at OLCHC.  Conventional 
bacterial studies were performed according to Clinical Pathology Accreditation 
guidelines.  Selective media for the detection and enumeration of Staphylococcus 
aureus, Methicillin resistant S. aureus, Burkholderia cepacia, Haemophilus 
influenzae and P. aeruginosa were employed.  Viral studies were performed on 
BAL samples including, Indirect Fluorescent Antibody test for Adenovirus, 
Parainfluenza 1, 2 & 3, Influenza A & B, Respiratory Syncytial Virus.  Testing for 
Mycobacterium tuberculosis also was performed on BAL.     
 
2.3.4 Total & Differential Cell Counts 
Total and differential cell counts were obtained by the trypan blue exclusion 
method and light microscopy.  Total cell counts were measured by 1:1 dilution in 
trypan blue and instillation into disposable Countess™ cell counting chamber 
slides.  Automated cell counts were evaluated by the Countess® Automated Cell 
Counter (InvitrogenTM).   
 
For differential cell counts, cytospin slides were prepared with 5x105 cells.  The 
slides were stained with hematoxylin and eosin and examined to evaluate 
homogeneity of the sample.  Representative areas of the sample were selected 
and counted using an eyepiece graticule with mesh and Tally counter.  At least 
300 consecutive cells were counted at high power magnification and the results 
were expressed as percentages of the total nucleated cell count.  For the SHIELD 
CF study, differential cell counts were evaluated by a single consultant 
histopathologist Dr Michael McDermott, at OLCHC.   
 
Neutrophil and macrophage counts were calculated using the absolute cell count 
of the raw BAL and the % neutrophils or macrophages reported on the differential.   
 
106 
 
2.3.5 Sample Transportation 
For the PRINCE study lipid mediator analysis by LC – MS/MS, samples were 
transported on dry ice to the Lipidomic Platform in Toulouse, and immediately 
replaced in minus 80 degrees storage upon receipt in Toulouse. 
 
2.4 Liquid Chromatography / Tandem Mass Spectrometry (LC-MS/MS)  
Chromatography (gas, liquid or thin layer) is used to separate compounds of 
interest before mass spectrometry analysis.  Mass spectrometry (MS) is a 
technique that is used to determine the mass, elemental composition and chemical 
structure of molecules.  The target molecules are ionised to form charged particles 
and introduced into the mass spectrometer.  Separation is performed according to 
their mass to charge ratio using electromagnetic fields under vacuum. The 
separated ions are then recorded by a detector, and the signal is converted into a 
mass spectrum (378).  
 
 
Figure 2-4  Schematic Illustration of the Mass spectrometry method  
(Reproduced from Wheelock et al. (378)). 
 
For the PRINCE Study, lipid mediators were quantified by the metabolo-lipidomic 
approach by the Lipidomic Platform at Toulouse by the previously published Liquid 
Chromatography / Tandem Mass Spectrometry method (379). 
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2.4.1 Extraction 
For extraction, sputum was crushed with a FastPrep ®-24 Instrument (MP 
Biomedical) in 500 µL of HBSS (Invitrogen) and 5 µL of internal standards 
(Deuterium labelled compounds).  After 2 crush cycles (6.5 m/s, 30 s), 20 µL was 
withdrawn for protein quantification and 300 µL of cold methanol was added.  After 
centrifugation at 900g for 15 min at 4°C, supernatants were transferred into 2 mL 
96-well deep plates and diluted in water to 2mls.  Samples were then submitted to 
solid phase extraction (SPE) using HRX 96-well plates (50 mg/well, Macherey 
Nagel), pre-treated with methanol (2mL) and equilibrated with 10% methanol (2 
mL).  After sample application, the extraction plate was washed with 10% 
methanol (2 mL).  After drying under aspiration, lipids mediators were eluted with 2 
mL of methanol.  Prior to LC-MS/MS analysis, samples were evaporated under 
nitrogen gas and reconstituted in 10 µL of methanol (379).  
 
2.4.2 LC-MS/MS 
LC-MS/MS analysis of eicosanoids was performed by our collaborator Dr Justine 
Bertrand-Michel at the Lipidomic Platform in Toulouse as previously described 
(379). Lipid mediators were separated on a ZorBAX SB-C18 column (2.1 mm, 50 
mm, 1.8 µm) (Agilent Technologies) using Agilent 1290 Infinity HPLC system 
(Technologies) coupled to an ESI-triple quadruple G6460 mass spectrometer 
(Agilent Technologies).  Data was acquired in Multiple Reaction Monitoring mode 
with optimized conditions (ion optics and collision energy).  Peak detection, 
integration and quantitative analysis were done using Mass Hunter Quantitative 
analysis software (Agilent Technologies) based on calibration lines built with 
commercially available eicosanoid standards (Cayman Chemicals).  
 
No data was available regarding chemical stability of PUFA metabolites in airways 
samples, however a guide to their chemical stability in human serum after 5 days, 
when preserved in methanol and stored at -20°C and from data reported in the 
Human Serum Metabolome project (380, 381), is presented in Table 2-1, for the 
purposes of understanding their broad chemical stability characteristics in human 
tissues.  The Limit of Detection for each compound by this technique was 
determined by the Lipidomic Platform in Toulouse and reported in Table 2-1, as 
previously published (379).    
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Table 2-1  An indication of the chemical stability and limits of detection of 
key Pro-Resolution PUFA metabolites examined in the PRINCE study  
As no data was available regarding chemical stability of PUFA metabolites in 
airways samples, ⱡStability (expressed as % change in concentration at 5 days) is 
here reproduced from a study on the chemical stability of lipid mediators in human 
serum after 5 days, when preserved in methanol and stored at -20°C (381) and 
from the Human Serum Metabolome project (380, 381).  *Limit of Detection was 
determined by the Lipidomic Platform in Toulouse (as previously published (379)).   
 
Compound Stability (381)ⱡ 
(% change at 5 days) 
Degradation 
Limit of Detection* 
(379) 
LXA4  -5.9% 2.5pg 
LXB4 -5.5% 4.9pg 
RvD1 -1.1% 2.5pg 
RvD2 +1.1% 2.5pg 
18-HEPE Not given 
(RvE1 -13.1% 
RvE3 -4.4%) 
2.5pg 
7-MaR1 -17.8% 4.9pg 
PDx Not given 
(PD1 -10.4%) 
1.3pg 
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2.5 Epithelial Cell culture 
2.5.1 Immortalised Epithelial Cell Line Source 
Immortalised NuLi-1 and CuFi-1 cell lines were used to model human bronchial 
epithelium.  These cell lines were sourced from Prof Joseph Zabner at the 
University of Iowa.  These cell lines were generated by enzymatically isolating 
primary cells from the bronchial epithelium of human donor lungs.  The NuLi-1 
(normal lung, University of Iowa) cells were derived from the airway epithelium of a 
human male with normal genotype (382).  CuFi-1 (cystic fibrosis, University of 
Iowa) cells were derived from human airway epithelium of a female with 
Phe508del / Phe508del genotype (382).  Cells were immortalised by transduction 
the reverse transcriptase component of telomerase, hTERT, and human 
papillomavirus type16 (HPV-16) E6 and E7 genes (382).  These cell lines have the 
advantage that when grown at the air-liquid interface, they are capable of forming 
polarized differentiated epithelia, exhibiting trans-epithelial resistance and 
maintaining the ion channel physiology expected for the genotypes.  They have 
also been demonstrated to retain NFĸB responses to lipopolysaccharide (382).  
 
2.5.2 Primary CF Bronchial epithelial cells 
The methods to establish primary epithelial cell cultures were developed by Dr 
Gerry Higgins and Dr Valia Verriere in the Urbach lab and were performed as 
previously published (85).  Bronchial brushings were obtained from the SHIELD 
CF study cohort at bronchoscopy.  For the studies performed in this thesis all 
participants had Phe508del / Phe508del CFTR mutation genotype.  The airway 
brush with adherent cells was placed directly into Eagles Minimum Essential 
Media (EMEM) (Gibco®) supplemented with 5 ml Penicillin/Streptomycin 
(Gibco®), 80 µg tobramycin (Gibco®), 2.5 µg Fungizone (Gibco®)  and 5 µg 
gentamicin (Gibco®) and transported on ice to the cell culture suite. 
 
The bronchial brush with cells attached was transferred to 5ml of BEGM in a 15 ml 
tube. The media was agitated with a pipette to detach the cells from the brush.  
The cells were pelleted at 1000 rpm for 5 min at 40C and then resuspended in 3-4 
ml BEGM Primary media.  Cells were incubated in a collagen coated T25 flask at 
370C in 5% CO2 (Sanyo CO2 Incubator) in BEGM Primary media.  For the first 3 
days after seeding, unattached cells were removed, pelleted and reseeded into a 
fresh T2 flask to improve yield from the retrieved cells (85).   
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2.5.3 Epithelial Cell Culture Media Used 
 
Cell Line Bronchial Epithelial Cell Growth Medium (BEGM) 
Cell line BEGM was prepared by taking 500mls of Bronchial Epithelial Cell Basal 
Medium (BEBM, Lonza Clonetics®) and adding BEGM® Single Quots Kit® (Lonza 
Clonetics®) containing; Bovine Pituitary Extract 2ml, Insulin 0.5ml, Hydrocortisone 
0.5ml, Retinoic Acid 0.5ml, Transferrin 0.5ml, Tri-iodothyronine 0.5ml, Epinephrine 
0.5ml, and Human Epidermal Growth Factor 0.5ml.  The gentamicin-amphotericin 
B aliquot from this kit was discarded and replaced with 500µl (10mg/ml) 
Gentamicin (Gibco®, Invitrogen).  Finally, 2.5mls of Fungizone (Gibco®, 
Invitrogen) is added. 
 
Primary Bronchial Epithelial Cell Growth Medium (BEGM) 
Primary BEGM was prepared by taking 500mls of Bronchial Epithelial Cell Basal 
Medium (Lonza Clonetics®) and adding BEGM® Single Quots Kit® (Lonza 
Clonetics®) containing; Bovine Pituitary Extract 2 ml, Insulin 0.5 ml, 
Hydrocortisone 0.5 ml, 0.5 ml, Retinoic Acid 0.5 ml, Transferrin 0.5 ml, Tri-
iodothyronine 0.5 ml, Epinephrine 0.5 ml and Human Epidermal Growth Factor 0.5 
ml.  The gentamicin-amphotericin B aliquot from this kit was discarded and 
replaced with 500µl (10mg/ml) Gentamicin (Gibco®, Invitrogen).  Antibiotics and 
anti-fungals were added in the following quantities; 5 ml of Penicillin - 
Streptomycin (Gibco®, 5000 units of penicillin and 5000 µg of streptomycin per 
ml); 500 µl Gentamicin 10 mg/ml (Gibco®) ; and, 2.5 ml fungizone (Gibco®).  
 
Cell Line Day 2 Media (Day 2) 
Cell line Day 2 Media was prepared by mixing 500mls of Dulbecco's Modified 
Eagle Medium (DMEM, Gibco®, Invitrogen) and 500mls of F12 Nutrient Mixture 
(HAM) (Gibco®, Invitrogen).  To this base Ultroser™ G serum substitute (PALL 
Life Sciences) suspended in 20mls of sterile water was added.  The mixture was 
supplemented with antibiotics and antifungals; 10mls Penicillin - Streptomycin 
100X Solution (5000 units of penicillin and 5000 µg of streptomycin per ml) 
(Gibco®, Invitrogen), 1ml Gentamicin (10mg⁄ml) (Gibco®, Invitrogen), and 5mls 
Fungizone® Antimycotic Liquid (Gibco®, Invitrogen) 250 µg /ml amphotericin B.  
The combined mixture is filter sterilized. 
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Primary 50/50 Bronchial Epithelial Media (Primary 50/50) 
Primary 50/50 medium was prepared by adding 250mls of Dulbecco's Modified 
Eagle Medium (DMEM) (Gibco®) to 250 mls of Bronchial Epithelial Cell Basal 
Medium (BEBM) (Lonza Clonetics®).  The base medium was supplemented by 
adding BEGM® Single Quots Kit® (Lonza Clonetics®) containing; Bovine Pituitary 
Extract 2 ml, Insulin 0.5 ml, Hydrocortisone 0.5 ml, Retinoic Acid 0.5 ml, 
Transferrin 0.5 ml, Tri-iodothyronine 0.5 ml, Epinephrine 0.5 ml and Human 
Epidermal Growth Factor 0.5 ml.  The gentamicin-amphotericin B aliquot from this 
kit was discarded.  To this mixture is then added; 5 ml of Penicillin - Streptomycin 
(Gibco®), 500 µl Gentamicin 10 mg/ml, (Invitrogen) 2.5 mls fungizone (Gibco®), 
0.5 ml BSA (1.5mg/ml) (Sigma Aldrich®, USA) and 25 µl of retinoic acid (Sigma 
Aldrich®, USA). The media was filter sterilised and stored at 4 0C until ready for 
use. 
 
2.5.4 Collagen coating of culture surfaces 
Bronchial epithelia were cultured on collagen coated surfaces.  50mg of Collagen 
from human placenta (Bornstein & Traub Type IV, Sigma-Aldrich®) was dissolved 
in 83.3mls of sterile distilled water and 166.6µl of glacial acetic acid (Fisher).  This 
stock solution was filter sterilised and stored at 4˚C.  Collagen stock solution was 
used at a working concentration of 60µg/ml by diluting 1:10 with distilled water. 
Prior to seeding cells, the liquid collagen was aspirated from the plastic surface 
and the surface was rinsed thrice with sterile DPBS.   
  
2.5.5 Bringing cells up from liquid nitrogen 
NuLi-1 and CuFi-1 cell stocks were stored in liquid nitrogen.  To bring cells up from 
storage the vial of cells was removed from the liquid nitrogen and placed in a 
water-bath to thaw at 37˚C.  The cells were placed in a 15ml tube containing 
10mls of pre-warmed BEGM media and centrifuged at 1100rpm for 5 minutes at 
4˚C.  The supernatant was discarded and the cell pellet re-suspended in 10ml of 
BEGM, inverted to mix, and the contents poured into a rinsed, collagen coated, 
labelled T75 flask (Corning®).  Cells were grown to 70-80% confluence (as 
assessed by light microscopy (Olympus CKX41)) in flasks in a Sanyo CO2 
Incubator at 37˚C in 5.0% CO2.  The culture medium was changed every 2-3 days. 
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2.5.6 Splitting and seeding cells  
Bronchial epithelial cells grown in flasks were used to set up two kinds of cell 
preparations depending on the experimental protocol;  
 
 Non-polarised bronchial epithelial cell monolayers, grown submerged under 
media on collagen coated plastic in 6 well plates 
 Polarised, differentiated bronchial epithelial cell preparations, grown on 
collagen coated hanging cell culture inserts (Millipore) at air-liquid interface   
 
To split cells, the old media was aspirated cells were washed twice with calcium 
free sterile DPBS.  5-7 ml of Trypsin / EDTA (Gibco®) was introduced and the 
flask was returned to the incubator (Sanyo CO2 Incubator: 37˚C in 5.0% CO2) for 5 
minutes.  The flask was tapped to aid detachment.  Once the cells were detached, 
1 ml Fetal Bovine Serum (FBS) (Gibco®) was added to the flask to neutralize the 
trypsin.  Detached cells were aspirated and transferred into a fresh 15 ml tube and 
pelleted at (Eppendorf Centrifuge 5810R) 1100rpm for 5 minutes, 4˚C.  The cell 
pellet was re-suspended in pre-warmed BEGM media and apportioned for seeding 
cells into collagen coated (and rinsed) 6 well plates or hanging cell culture inserts 
(Millipore), with the remainder returned to a new flask.   
 
2.5.7 Feeding Undifferentiated Monolayers 
Media was pre-warmed to 37°C in the water-bath.  Every 2-3 days, the old media 
was aspirated and discarded and monolayer cultures were fed with 2mls per well 
of BEGM media.  Cells were incubated at 37°C in 5.0% CO2 (Sanyo CO2 
Incubator). 
 
2.5.8 Liquid-Liquid Interface Cultures in Hanging Cell Culture Inserts 
Media was pre-warmed to 37°C in the water-bath.  Cells were incubated at 37°C in 
5.0% CO2 (Sanyo CO2 Incubator).   Prior to achieving confluence, cultures were 
fed with 1.5 ml of BEGM in contact with the basolateral side of the membrane and 
500µl of BEGM added to the apical compartment.  Following confluence, the 
media was changed to Day 2 media for cell lines, and 50/50 media for primary 
cells to aid differentiation.  Media was changed every 2 days.  A period of liquid-
liquid interface growth is essential to achieve differentiation. 
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2.5.9 Measuring Trans-Epithelial Electrical Resistance (TEER) 
Once cells in hanging cell culture inserts had achieved confluence, regular TEER 
readings were obtained using an EVOMX™ probe (World Precision Instruments, 
Sarasota, FL).  For Liquid-Liquid cultures, the probe of the EVOMX™ was placed 
in contact with the media on either side of the membrane in order to obtain a 
resistance measurement.  Following the Air-Liquid transition, 0.5mls of media was 
transferred from the basolateral compartment into the apical compartment in order 
to perform this resistance measurement.  The media was then removed from the 
apical compartment to restore the air interface. 
 
2.5.10 Air-Liquid Interface Cultures 
When tight junctions began to form in the cultures, evidenced by increasing TEER 
(>200Ω/cm2) the cultures were switched to air-liquid interface.   In this 
arrangement, the apical compartment is exposed to air and media is placed in 
contact with the basolateral side of the porous support.  The air-liquid phase is 
employed to achieve polarisation, cell differentiation and ciliation.  Preparations 
were considered to be fully differentiated and polarised when they had achieved 
TEER values >700Ω/cm2.   
 
2.5.11 Bronchial Epithelial Cell Treatments & Assays 
Differentiated and polarised epithelial cell cultures were used for; airway surface 
liquid height measurements, measurements of IL8 secretion, measurements of 15-
Lipoxygenase (15-LO) mRNA expression and activity in bronchial epithelia.  
Undifferentiated monolayers were used for; measurements of IĸB, ALX/FPR2 and 
15-LO protein expression. 
  
Resolvin D1 was used at a concentration of 1nM or 100nM and obtained from 
Cayman Chemical, MI. LXA4 was used at 1nM and sourced from Calbiochem, 
Merck.  The peptide Boc-Phe-Leu-Phe-Leu-Phe; Boc-2 (Phoenix pharmaceutical, 
Belmont, USA) was used at 10µM as a specific pharmacological inhibitor of the 
ALX/FPR2 receptor. BAPTA-AM (Molecular probes, Leiden, Netherlands) was 
used in calcium free DPBS at a concentration of 10µM as an intracellular calcium 
chelator.  CFTRinh-172 (Sigma) was used as an antagonist of the CFTR channel 
at a concentration of 20µM.  TNFα (eBiosciences, San Diego, USA) was used at a 
concentration of 80ng/ml to stimulate IL8 secretion.  To measure total 15-LO 
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activity by an epithelial monolayer 5(S), 6(R)-dihydroxy-7, 9-trans-11, 14-cis-
eicosatetraenoic acid (DiHETE) (Cayman Chemical) was used as a 15-LO 
substrate at a concentration of 250ng/ml.  Prostaglandin E2 (Cayman Chemical) 
was used at a concentration of 100nM to try to up-regulate 15-LO transcription. 
 
2.6 Primary Alveolar Macrophage Culture 
2.6.1 Primary Alveolar Macrophage Medium 
Primary Alveolar Macrophage Medium was prepared using RPMI 1640 
(Biosciences) as a base and adding; 5mls of 10% Foetal Bovine Serum (Heat 
inactivated at 56°C for 30 mins in water bath, Sigma), 500µl L-Glutamine 2mmol/l 
(Gibco), and 1ml Penicillin - Streptomycin 100X Solution (5000 units of penicillin 
and 5000 µg of streptomycin per ml) (Gibco®, Invitrogen). 
 
2.6.2 Enriching Primary Alveolar Macrophages from BAL Cell Pellet 
BAL fluid from both children with CF and controls was collected and processed to 
obtain a cell pellet as per SHIELD study protocol (Section 2.1.2).  BAL pellet cells 
were re-suspended in primary alveolar macrophage medium at a concentration of 
0.5 million viable cells per ml and placed in a T25 flask, 6 or 96 well tissue culture 
plates (depending on the experimental protocol) and incubated (humidified, 
37.2°C, 21% oxygen, 5% CO2) overnight to attach to tissue culture coated plastic.  
The following morning non adherent cells suspended in the medium were 
aspirated and discarded.  The adherent cells washed twice with pre-warmed 
calcium and magnesium free DPBS.  For some experiments analysis was 
performed directly on the cells adherent to plastic.  Where indicated, Non 
enzymatic cell dissociation solution (Sigma) was applied to detach the cells 
(2mls/T25 flask) and allowed to incubate in the cold for 5-10 minutes.  The flask 
was then tapped to aid detachment.  Detached cells were collected in preparation 
for experiments in a 15ml tube and enumerated by trypan blue exclusion. 
 
2.7 Alveolar Macrophage Functional Assays 
2.7.1 Phagocytosis Assay 
The phagocytic capacity of CF alveolar macrophages was measured by their 
ability to engulf IgG & FITC labelled beads using a Phagocytosis Assay kit 
(Cayman Chemical, Ann Arbour, MI) according to the manufacturer’s instructions.   
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Macrophages were enriched by adherence to tissue culture coated plastic and 
cultured in complete macrophage medium in 12 and 96 well plates.  Macrophages 
were exposed to the Latex beads – rabbit IgG-FITC complex added to the culture 
medium for 1 hour in the dark at 370C in 5.0% CO2 (Sanyo CO2 Incubator).  The 
tissue culture plates were centrifuged for 5mins at 400g and the supernatant was 
discarded.  To quench non-specific staining the cells were washed with a trypan 
blue quenching solution, centrifuged, the supernatant discarded and then 
subjected to analysis.   
 
The degree of phagocytosis in each sample was analysed quantitatively by 
measuring the fluorescence intensity of engulfed FITC labelled complexes in 
triplicate using a fluorescence plate reader (Synergy MX Biotek~® Instruments, 
Winooski, VT).  Qualitative fluorescence microscopy experiments were conducted 
in parallel with a concurrently obtained light microscopy image overlaid in order to 
visualise the cells.   
 
2.7.2 Bactericidal assay against Pseudomonas aeruginosa (PA01)  
CF alveolar macrophages were isolated by adherence to tissue culture plastic and 
cultured in complete macrophage medium in a 12 well plates overnight as 
previously described.  P. aeruginosa strain PAO1 was obtained from Professor 
Fergal O’Gara, University College Cork, Ireland.  Strain PAO1 is a wound isolate 
and is the most widely used P. aeruginosa laboratory strain (383).   
 
PAO1 was grown in LB broth and then switched to antibiotic free macrophage 
medium overnight at 37°C shaking.  The bacteria were grown up to log phase with 
an optical density of ~0.6.  Upon reaching log phase bacteria were equalised to an 
Optical Density of 0.1 in fresh antibiotic free macrophage medium warmed to 
37°C.  Macrophages were washed twice with antibiotic free macrophage medium 
to remove all traces of antibiotic.  PAO1 at an optical density of 0.1 (concentration 
of 2x10^14 CFU/ml) was then added to alveolar macrophage preparations.  The 
inoculating time was 30 minutes, after which the apical medium was removed, the 
cells were washed with medium and gentamicin (400µg/ml) was applied for one 
hour to kill extracellular adherent bacteria.  The macrophages were then washed 
twice and treated with Triton-X 100 (0.4% v/v) for 15min to lyse the macrophages 
release internalised bacteria.  
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Quantification of the viable intracellular bacterial load within macrophages was 
performed by serial dilution of the lysate 1 in 10 in antibiotic free macrophage 
medium.  The lysate dilution series was plated out on LB agar and incubated at 
37°C overnight.  Colony Forming Units were counted (accurate range ≥30 & ≤300) 
and the results were expressed as colony forming units per ml by correction for 
dilution factors. 
 
2.8 ELISA’s 
2.8.1 Lipoxin A4 ELISA 
LXA4 was measured by ELISA using the LXA4 EIA Kit (Oxford Biomedical 
Research) according to the manufacturer’s instructions.  The test kit operates on 
the basis of competition between an enzyme conjugate and the LXA4 in the 
sample for a limited number of antibody binding sites. 
50µl of neat sample was added to the rat anti-LXA4 antibody pre-coated 96 well 
plate.  50µl of diluted lyophilized LXA4 – HRP conjugate was added to each well.  
The plate was incubated at RT for 1 hour to allow competition for binding sites to 
take place.  The microplate was then washed with the supplied wash buffer 5 
times using an Automated Plate Washer (TRI-Continent Scientific Medical Supply 
Co. Ltd) to remove all unbound material.  The bound enzyme conjugate was 
detected with TMB.  After 30 minutes at room temperature the absorbance was 
read at 650nm using a plate reader (Synergy MX Biotek~® Instruments, Winooski, 
VT).  The extent of colour development was inversely proportional to the amount 
of LXA4 in the sample or standard.  Quantitative results were obtained by 
comparing the absorbance reading of the wells of the samples against a standard 
curve. Specificities of antisera are given in Table 2-2.  
 
2.8.2 Leukotriene B4 ELISA 
Leukotriene B4 (LTB4) was measured by ELISA using the LTB4 EIA Kit (Cayman 
Chemical, MI) according to the manufacturer’s instructions.  Briefly, the assay 
principle is based on the competition between LTB4 (in the sample / standard) and 
an LTB4-acetlycholinesterase conjugate (tracer) for a limited amount of LTB4 anti-
serum.  The ELISA plate is pre-coated with a mouse monoclonal anti-rabbit IgG.  
Samples and standards are applied to the wells and incubated with a fixed amount 
of tracer and antiserum.  LTB4-antiserum complexes bound to the IgG on the plate 
reduce the binding of tracer-antiserum complexes to IgG on the plate.  The tracer 
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interacts with Ellman’s reagent and generates a signal measured by 
spectrophotometric absorbance at 412nm.  The intensity of this signal is inversely 
proportional to the amount of free LTB4 in the sample or standard.  Quantitative 
results are obtained by comparing the absorbance reading of the wells of the 
samples against a standard curve.  Specificities of antisera are given in Table 2-2. 
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Table 2-2  Cross-Reactivity of Anti-Sera quoted by manufacturers of ELISA 
Kits  
 LTB4  EIA Kit 
Cayman 
Chemical 
LXA4  EIA Kit 
Oxford Biomedical 
Research 
LXA4  Not given 100% 
15-epi-LXA4  Not given 24% 
Lipoxin B4 Not given 1.0% 
LTB4  100% <0.01% 
5(S)-HETE 6.6% <0.1% 
5(R)-HETE 3.7% <0.1% 
20-hydroxy LTB4  2.7% Not given 
15(R)-HETE 0.98% 0.1% 
15(S)-HETE 0.4% 0.1% 
6-trans-12-epi LTB4  0.31% Not given 
6-trans LTB4  0.11% Not given 
5,6-DiHETE 0.07% 5.0% 
Leukotriene C4/D4/E4 <0.01% <0.01% 
Glutathione, 20-carboxy LTB4 , 19(R)-
hydroxy Prostaglandin B2 
<0.01% Not given 
 
 
2.8.3 Interleukin 8 
IL8 was measured by an in-house ELISA using mouse anti-IL8 capture antibody, 
and biotinylated goat anti-IL8 detection antibody (R&D Systems, Abingdon, Oxon, 
UK) by the previously published method (384).   
 
Voller’s Buffer 
0.16g Sodium Carbonate (15mM) 
0.294g Sodium Bicarbonate (35nM) 
Make up to 100mls with double distilled water and adjust pH to 9.6. 
 
The capture antibody (Human CXCL8/IL-8 monoclonal mouse IgG antibody, 
MAB208, R&D systems) was diluted 1:125 in Voller’s Buffer and 100µl was 
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applied to each well of a 96 well plate.  The antibody was allowed to adhere to the 
plate at 4°C overnight.  The plate was washed thrice with DPBS-0.05% Tween and 
blocked for 1 hour at RT using 300µl per well of blocking buffer (1% BSA in DPBS-
0.05% Tween).  A standard curve was prepared using a known concentration of 
IL8 standard diluted in DPBS.  100µl of sample and standards were loaded and 
incubated at room temperature for 2hours. The plate was then washed thrice and 
incubated with 100µl per well of detection antibody (BAF208, goat polyclonal anti-
human IL8 biotinylated antibody, R&D systems) for 2 hours at room temperature.  
The plate was again washed thrice and incubated with 1:2000 streptavidin 
Horseradish Peroxidase.  The plate was incubated for 30mins at room 
temperature in the dark, washed thrice, and then developed with 2,2'-azino-bis 
(ABTS).  The absorbance was read at 405nm in an automated plate reader. 
Quantitative results were obtained by comparing the absorbance reading of the 
wells of the samples against a standard curve. 
 
2.8.4 Neutrophil Elastase Activity Assay 
Neutrophil Elastase (NE) activity was measured as described previously (371), by 
mixing 50μl of the chromogenic substrate MeOSuc-AAPV-pNA, with each sample 
and measuring absorbance at 405 nm  over time at 37 °C in a 96-well microplate 
reader. The concentration of NE in samples was determined by comparison 
against a standard curve of purified NE (371). 
 
2.9 PCR  
In order to quantify mRNA expression of specific genes by PCR, three steps were 
required; extraction of RNA from cell lysates; RNA reverse transcription into cDNA; 
and quantification by Real Time PCR.  
 
2.9.1 RNA Isolation 
Total RNA was extracted in an RNase free environment from cells using 
RNAqueous® kit (Ambion Inc., Austin, TX) according to the manufacturer’s 
instructions.  The principle of this column method (385) relies on the ability of glass 
fibres to bind nucleic acids in concentrated salt solutions.  Samples are disrupted 
in a high concentration guanidinium salt solution that lyses cells and inactivates 
endogenous RNases. The lysate is diluted with an ethanol solution to allow RNA 
to bind to the glass fibre filter in the filter cartridge. Most other cellular contents 
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flow through the filter cartridge.  The bound RNA is then eluted in a very low ionic 
strength solution (385).   
 
Briefly, cells in suspension were pelleted, whereas, adherent cells were detached 
and pelleted.  Lysis binding solution was applied to the cells and the cells were 
vigorously disrupted by shear force, drawing the lysate through an orange (25G) 
needle several times to homogenise the sample.  An equal volume of 64% Ethanol 
was added to the lysate and the combined mixture was applied to a filter cartridge 
assembled in a collection tube.  The cartridge was then washed thrice with the 
provided wash solutions and then the bound RNA was eluted into a clean, labelled 
collection tube with Elution solution.   
 
The quantity and quality of isolated RNA was analysed by spectrophotometry 
using a Nanodrop (Thermo-scientific).  The principle of this test relies on 
absorption of ultraviolet light (260nm) by RNA / DNA.  Quality was assessed by 
the 260/280 ratio, given that protein impurities absorb UV light at 280nm.  Samples 
with ratios closer to 2.0 were considered to be higher in purity. 
 
2.9.2 Specific provisions for RNA Isolation from Primary Alveolar Macrophages  
Macrophages release RNases (especially when viability declines or activation 
occurs) therefore Lysis Binding Solution must be applied as soon as possible to 
the isolated cells.  Detached cells were pelleted at high speed (3000rpm, 10 mins) 
and then resuspended in 700µl of Lysis Biding Solution (RNAqueous Phenol Free 
total RNA Isolation kit Biosciences).   
 
In addition to improve recovery of RNA, 500µl of LBS was applied to the remaining 
cells still attached inside the T25 flask, scraped with a cell scraper and aspirated.  
The combined lysate was then subjected to homogenisation by shear force using 
an orange needle and stored at -80°C until isolated.  
 
2.9.3 Reverse Transcription    
RNA was reverse transcribed into complementary DNA using a High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems) according to the 
manufacturer’s instructions.   
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Briefly, total isolated RNA of interest is combined with buffer, random primers, 
Deoxyribonucleotide triphosphate Mix (dNTP’s; dATP, dCTP, dGTP and dTTP), 
and Reverse Transcriptase enzymes. The resultant mixture is placed in a Thermal 
Cycler (Applied Biosystems) and undergoes Denaturation, Primer Extension, 
cDNA synthesis and Reaction Termination steps.  cDNA was then stored at -80°C 
until analysis by quantitative PCR. 
 
2.9.4 Real Time PCR 
Real time PCR was performed on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) using TaqMan® Probes (Table 2-3).   
 
Briefly, the principle of the method is as follows; a pre-determined total quantity of 
cDNA of interest is combined with PCR Mastermix containing a polymerase 
enzyme (Applied Biosystems) and the target Taqman(R) probe. The Taqman(R) 
probe is an oligonucleotide sequence with a fluorescent probe attached to the 5' 
end and a quencher to the 3' end. During amplification, the probe binds to the 
target amplicon sequence; the polymerase replicates the target template and 
cleaves the fluorescent probe, separating it from the quencher.  The increase in 
fluorescence intensity is proportional to the number of cleavage cycles, which is 
also directly related to the initial amount of target in the sample.   
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Table 2-3  Taqman(R) Probes used 
All probes used were supplied by Applied Biosystems, and 18S was used as a 
housekeeper probe. *The selected probes were chosen in view of previous reports 
of their differential expression characteristic of M1 and M2 polarised macrophages 
(329). 
 
Human Taqman(R) Probe 
 
NCBI Reference 
Sequences: 
ALOX5 (5 Lipoxygenase) NM_000698.3 
NM_001256153.1 
NM_001256154.1 
ALOX12 (12 Lipoxygenase) NM_000697.2 
ALOX15 (15 Lipoxygenase-1) NM_001140.3 
ALOX15B (15 Lipoxygenase-2) NM_001039130.1 
NM_001039131.1 
NM_001141.2 
LTA4H (Leukotriene A4 Hydrolase) NM_000895.2 
NM_001256643.1 
NM_001256644.1 
M1 Macrophage Polarisation Markers (329)* 
IDO1 (Indoleamine 2,3-dioxygenase 1) NM_002164.5 
IL-12 p35 (Interleukin-12 p35) NM_000882.3 
M2 Macrophage Polarisation Markers (329)* 
CCL22 (CC Chemokine type 22) NM_002990.4 
PPARγ (Peroxisome Proliferator-activated receptor γ) NM_015869.4 
NM_005037.5 
NM_138712.3 
NM_138711.3 
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2.9.5 Calculation of Relative Fold Expression 
The cycle threshold for each target gene was normalized using the cycle threshold 
(Ct) of the endogenous control (18S).  Relative fold expression for each target was 
calculated as (2 ^ (-ΔΔ Ct)) in comparison to a reference sample.  
 
2.10 Western Blotting  
In order to quantify the expression of a target protein Western Blotting was 
performed.  This involves several steps; protein extraction, quantification and 
solubilisation, separation on the basis of molecular weight by electrophoresis, 
transfer onto a membrane, blocking, probing with primary and secondary 
antibodies, and detection. 
 
2.10.1 Whole cell protein extraction 
The cells of interest were washed thrice with DPBS and placed on ice.  The 
protein was then harvested by scraping with a cell scraper in the presence of RIPA 
buffer (Sigma-Aldrich®), supplemented with Halt™ protease and phosphatase 
inhibitor cocktail (Thermo, UK).  The lysed cell suspension was collected by 
pipette and placed into a labelled Eppendorf and centrifuged at 14,000rpm for 20 
minutes at 4˚C.  The protein suspended in the liquid phase was aspirated and 
stored at -80°C.  
 
2.10.2 Membrane expressed protein of interest extraction (Non-Denatured)  
The ALX/FPR2 receptor is a cell membrane associated protein.  In order to 
quantify its expression in bronchial epithelial cells we modified our protein 
extraction protocol to improve the yield of membrane associated proteins. The 
cells of interest were washed thrice with DPBS and placed on ice.  Protein was 
harvested by scraping in the presence of RIPA buffer (Sigma, UK), supplemented 
with Halt™ protease and phosphatase inhibitor cocktail (Thermo, UK) as above 
with the addition of an extra detergent N- lauroylasacrcosine sodium salt (Sigma-
Aldrich®, USA).  The cell lysate and remaining cell fragments were aspirated, 
vortexed and placed on ice for 30 minutes.  Furthermore, the lysate was then 
subjected to sonication at 50% amplitude for 20 sec pulses (Sonics-Vibra CellTM).  
Lammelli buffer (Sigma-Aldrich®, USA) was added in a 1:1 ratio to the protein 
lysate prior to storage at 40C.  
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2.10.3 Bradford assay  
Determination of the protein concentration of the cell lysate was performed by 
Bradford assay (386) using a Pierce BCA Protein Assay Kit (Thermo Scientific, 
USA) according to the manufacturer’s instructions.   
 
Briefly, the prepared Bradford Reagent was gently mixed in the bottle and brought 
to room temperature.  Bovine Serum Albumin was used to prepare protein 
standards by dilution in DPBS.  10µl of each protein standard sample (known 
concentration in the range 0.1 – 1.4mg/ml) or sample of unknown concentration 
was placed in duplicate per well of a 96 well plate.  10µl of DPBS buffer was 
added to the blank wells.  200µl of Bradford Reagent mixture was added to each 
well, gently agitated on a plate shaker for 60 seconds and the placed in an 
incubator at 370C for 30 min. The plate was removed from the incubator and left to 
cool before the absorbance was measured at 595nm on the plate reader (Synergy 
Mx, Biotek® Instruments, Highland Park, Winooski, VT).  The unknown protein 
concentrations were determined by plotting a standard curve of the net 
absorbance versus protein concentration of the standards and interpolating the 
unknown values.  
 
2.10.4 Protein denaturation 
Protein (30µg per well) was solubilised in Lamelli Buffer (Sigma-Aldrich®, USA) 
and where indicated, denatured at 95°C for 5mins (Stuart, Block heater, 
SBH130DC, UK).   
 
2.10.5 Preparation of a Tris-glycine SDS-polyacrylamide gel 
The gel is made by polymerising acrylamide monomers into a network of cross 
linked chains giving a pore size which can be customised to suit the size of the 
molecules being separated (387).  Sodium Dodecyl Sulphate (SDS) is used as an 
anionic detergent used to linearize proteins and impart a negative charge to the 
protein.  Following the application of an electric field, the mobility of a protein then 
depends on its length and mass to charge ratio.  The gel has two components, a 
stacking gel and a resolving gel.  Reagents used in the preparation of a gel are 
described in Table 2-4.   
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Table 2-4  Preparation of reagents for a Tris-glycine SDS-polyacrylamide gel  
Reagents  
30% Acrylamide (Sigma-Aldrich®) 
1.5M Tris (pH 8.8)  Dissolve 181.71g Trizma base 
(Sigma®) in 800mls distilled water.   
Adjust pH to 8.8 with 1mol/l HCl and 
then make up to 1 litre (Stored at 4˚C). 
0.5M Tris (pH 6.8) Dissolve 60.57g Trizma base 
((Sigma®) in 800mls distilled water.   
Adjust pH to 6.8 with 1mol/l HCl and 
then make up to 1 litre (Stored at 4˚C). 
10% Sodium Dodecyl Sulfate (SDS) 10g SDS (Sigma Aldrich®) is dissolved 
in 100mls of distilled water. 
10% Ammonium persulphate  
(10% (w/v) APS) 
1g ammonium persulfate (Sigma-
Aldrich®) is dissolved in 10 mL of H2O 
(stored at -200C). 
Tetramethylethylenediamine (TEMED) (Sigma Aldrich®) 
 
 
Gel reagents were assembled in the quantities indicated in Table 2-5.  The 
TEMED is added last to initiate polymerisation.  The glass plates are assembled in 
a BioRad® rig with the resolving gel being introduced into the space between the 
glass plates prior to setting.  The gel is covered with a thin film of water to prevent 
the gel drying out and allowed to set for 20 – 45 minutes using the excess gel in 
the tube to gauge when the gel has set.  The layer of water is then removed and 
the stacking gel is prepared according to the composition indicated in Table 2-5.  
The stacking gel is introduced on top of the set resolving gel, up to the level of the 
front glass plate and a comb is introduced into the rig to form the wells. 
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Table 2-5  Quantities of reagents used for the preparation of resolving and 
Stacking Tris-glycine SDS-polyacrylamide gels.  
 
 
2.10.6 Electrophoresis 
The gasket (BioRad®) was assembled for electrophoresis and placed in a tank 
ensuring a good seal between the gasket and the gels.  The wells were rinsed with 
running buffer (prepared as indicated in Table 2-6) and the remaining running 
buffer was poured into the gasket / tank.  Solubilised protein was loaded into the 
wells of the gel alongside a Spectra™ Multicolour Broad Range Protein Ladder 
(Thermo-Scientific, MA) used to identify the molecular weight of a protein revealed 
in a specific band.  The gel was run at 80mV (BioRad PowerPacTM) for 20 minutes 
to allow the protein to stack down into the resolving gel and then increased to 
100mV.  The gel was run until the loading dye front fully migrated through the gel.  
 
2.10.7 Protein Transfer  
Protein is transferred from the gel onto a PVDF membrane (Thermo Scientific, 
USA) in the following manner.  Transfer buffer is prepared with the composition 
described in Table 2-6 and cooled to 4°C.  The PVDF membrane is soaked in 
methanol.  The gel containing the separated protein is removed from the 
electrophoresis gasket and assembled into the transfer cassette (BioRad®) in 
contact with the PVDF membrane, sandwiched between sponges and filter paper. 
The cassette is closed taking care to remove bubbles and compact it completely, 
and placed into a transfer rig.  The tank is filled with transfer buffer (with an ice 
pack to cool the buffer) and protein is transferred at 100mV for 1 hour.   
 10% Resolving 
Gel 
12% Resolving 
Gel 
5% Stacking Gel 
ddH2O 2.7 ml 2.3 ml 1.4 ml 
30% acrylamide 2.3 ml 2.8 ml 330 µl 
Tris 1.8 ml 
1.5M Tris (pH8.8) 
1.75 ml 
1.5M Tris (pH8.8) 
250 µl 
0.5M Tris (pH6.8) 
10% SDS 70 µl 70 µl 20 µl 
10% APS 70 µl 70 µl 20 µl 
TEMED 2.8 µl 2.8 µl 2 µl 
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Table 2-6  Composition of running and transfer buffers. 
  Running Buffer 
Quantity 
Transfer Buffer 
Quantity 
Glycine (Sigma®) 14g 14.4g 
Trizma base (Sigma®) 3g 3.03g 
SDS (Sodium Dodecyl Sulphate) 
(Sigma Aldrich®) 
1g - 
Methanol - 200mls 
Distilled Water 1 litre 800mls 
 
 
2.10.8 Membrane Blocking & Antibody Incubation 
The specific conditions for membrane blocking are described (Table 2-7) for each 
Western Blotting experiment.  Primary and secondary antibody pairs, incubation 
conditions and concentrations were optimised for each experiment.   
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Table 2-7  Antibodies and conditions used in Western blotting experiments 
Antibodies Primary Secondary Conditions 
Anti- 15 
Lipoxygenase 1 
ab80221 (abcam) 
Rabbit Polyclonal 
IgG 
1:1000 1hour at RT 
ab97051 (abcam) 
Goat poly-clonal 
Anti-Rabbit IgG 
Antibody  
1:6000 
1 hour at RT 
Blocked and 
probed in BSA 
Anti- 15 
Lipoxygenase 2 
ab23691 (abcam) 
Rabbit Polyclonal 
IgG 
1:625 1hour at RT 
ab97051 (abcam) 
Goat poly-clonal 
Anti-Rabbit IgG 
Antibody  
1:10,000 
1 hour at RT 
Blocked and 
probed in BSA 
IĸB 
 
Mouse monoclonal 
anti-IĸBα antibody  
(gift from Dr Sarah 
Doyle’s lab)  
1:2500 (5% 
Milk/0.1% P-BST) 
Overnight at 4°C 
Anti-Mouse IgG 
rabbit polyclonal 
HRP linked 
secondary antibody  
(Abcam, Cambridge, 
MA)  
1:5000 (5% 
Milk/0.1% P-BST) 1 
hour RT 
Protein 
denatured 
Blocked in  
5% Milk/0.1% P-
BST  
1 hour RT 
ALX/FPR2 Rabbit polyclonal 
anti-FPRL1 
antibody  
(ab63023, Abcam, 
Cambridge, MA)  
1:2000 (2% 
Milk/0.1% P-BST) 
Overnight at 4°C 
Anti-rabbit IgG HRP 
linked secondary 
antibody  
(Cell Signalling, 
USA)  
1:2500 (5% 
Milk/0.1% P-BST) 1 
hour RT 
Non-denatured 
protein 
Blocked in  
5% Milk/0.1% P-
BST  
1 hour RT 
α-Tubulin Mouse monoclonal 
Anti-alpha Tubulin 
antibody  
(Abcam, 
Cambridge, MA)  
1:5000 (5% 
Milk/0.1% P-BST) 1 
hour RT 
Anti-Mouse IgG 
rabbit polyclonal 
HRP linked antibody  
(Abcam, Cambridge, 
MA)  
1:5000 (5% 
Milk/0.1% P-BST) 1 
hour RT 
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Following antibody exposures the membranes were washed for 15 minutes 3-4 
times with PBS-0.1% Tween on a rocker.  In order to reprobe for loading control 
proteins, membranes were stripped using RestoreTM PLUS Western Blot Stripping 
Buffer (Thermo-Scientific, MA), re-blocked, and exposed to primary & secondary 
antibody pairs for the appropriate loading control protein. 
 
2.10.9 Detection by Enhanced Chemi-luminescence 
ECL substrate Super Signal West Dura chemi-luminescent (Thermo, USA) was 
used to develop the blots.  The substrate was prepared according to the 
manufacturer’s instructions and placed in a 50ml tube with the membrane for 5 
minutes.  The membrane was then placed between two acetate sheets in a 
cassette and closed.  In the darkroom, the membrane was exposed to X-ray film to 
detect luminescence and the X-ray film was developed and fixed.  
 
2.10.10 Band densitometry  
Band densitometry was performed using Image J (NIH, USA) and results were 
expressed as Relative Band Intensities following normalisation by the loading 
control band. 
 
2.11 Confocal Fluorescence Microscopy 
Confocal microscopy is an imaging technique that is used to achieve high optical 
image resolution and gather 3-dimensional information.  The technique involves 
point scanning of the laser excitation followed by a spatially filtered fluorescence 
emission signal emitted back from the focal point onto the confocal point.  The 
image is constructed in a point-wise manner with the illuminating laser scanning 
rapidly from point to point one a single focal plane synchronised with the aperture.  
The scan is then repeated for multiple depth-wise focal planes to generate a 3-
dimensional image.  The spatial filtering is the key principle in enhancing the depth 
wise optical resolution by optical slicing (illustrated in Figure 2-5) (388). 
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Figure 2-5  The principle of confocal microscopy using a pinhole aperture as 
a spatial filter 
Confocal microscopy involves point scanning of the laser excitation.  The pinhole 
aperture at the confocal point allows only the emitted fluorescent signal from the 
specific focal point and plane to pass through to the detector (solid lines), and 
filters out light emitted from outside the focal point (dashed lines) (reproduced from 
(388).   
 
Furthermore, fluorescent proteins discovered in marine organisms led to the 
development of exciting biological imaging techniques (389).  In fluorescence 
microscopy, electrons within fluorescent molecules are excited to a higher energy 
state by light of a certain wavelength within an excitation spectrum.  They quickly 
lose this energy and drop back down to their original energy level with the 
emission of light with a characteristically longer wavelength in a phenomenon 
known as the Stokes shift (390).  
 
2.11.1 ASL Height Measurement by Live-cell Confocal Fluorescence Microscopy 
Airway surface liquid (ASL) height measurements were performed as previously 
published by Verriere et al., based on the method of Tarran et al. (85, 391).  Cell 
monolayer cultures used for ASL measurement had obtained a minimum TEER of 
800Ω/cm2.  24 hours prior to imaging, 8µl Texas red®- dextran (10,000MW, 
Invitrogen, Auckland, NZ) at a concentration of 2mg/ml was applied to the centre 
of the insert.  0.7mls of FluorinetTM electronic fluid Perfluorocarbon-72 (FC-72, 3M, 
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St. Paul, USA) was added to the apical compartment of the insert.  
Perfluorocarbon-72 is immiscible with the ASL and was used to prevent ASL 
evaporation during the confocal scanning experiments (85).   
 
The ASL image was captured with a Zeiss LSM 510 Meta using a 40X objective 
and constructed in a point-wise manner.  The illuminating laser (555nm) scanned 
rapidly from point to point on a single focal plane (XY) measuring 160µm x 160µm, 
serially repeated over 30µm at depth intervals (Z-plane) of 1µm to generate a 3-
dimensional image.  Images were captured from 3 randomly selected fields on 
each culture insert after screening the insert for homogeneity.   
 
2.11.2 ASL Image Analysis 
Images were analysed using Zeiss LSM Image Browser (Carl Zeiss Micro-Imaging 
GmbH, Germany).  Measurements were taken of the ASL height in the Z plane at 
nine equally spaced, pre-specified points (defined by their XY co-ordinates) from 
each image.  Each biological repeat represents the mean of 27 height 
measurements per culture insert (nine measurements from each of three fields).  
 
2.12 Statistics 
Graphpad prism® was used to perform statistical analyses.  The specific statistical 
tests used are described with each result.  Results are presented as mean and 
standard error of the mean (SEM) unless specifically stated otherwise.  When we 
wished to evaluate the distribution of biological data the standard deviation (SD) 
was calculated.  Fisher’s exact test was used for categorical variables.  Student t-
test was used to compare pairs of continuous variables.  One-way ANOVA was 
used to compare the means of three or more unmatched groups of continuous 
variables.  Newman-Keuls was used as a Post-test to compare all pairs of means 
following a one-way ANOVA.  Two-way ANOVA was used to determine how a 
variable was affected by two factors.  Following two-way ANOVA, the Bonferroni 
method was used as a Post-test, incorporating correction for multiple 
comparisons.  Correlations were analysed using the Spearman test.  Results were 
reported as statistically significant with P value <0.05*, <0.01**, <0.001***. 
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CHAPTER 3 
THE ROLE OF RESOLVIN D1 IN CYSTIC FIBROSIS AIRWAY DISEASE 
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3 The role of Resolvin D1 in Cystic Fibrosis airway disease 
3.1 Introduction  
There are unmet needs in CF therapy for treatments; to rehydrate the airway, 
improve muco-ciliary clearance, strengthen the host immune response, prevent 
neutrophil mediated inflammatory tissue destruction, and augment the 
effectiveness of existing antibiotics. 
 
3.1.1 ASL Regulation  
Normal mucus clearance from the airways relies on adequate hydration of the 
Airway Surface Liquid (ASL) (Illustrated in Figure 3-1).  This is achieved via 
balanced sodium absorption, mediated by the Epithelial Sodium Channel (ENaC) 
in the apical membrane and the Na/K ATPase localised in the basolateral 
membrane, and chloride secretion, mediated by CFTR and CaCC chloride 
channels in the apical membrane and the Na/K/2Cl co-transporter in the 
basolateral membrane (76).  Water follows passively via aquaporins in the cell 
membrane and the paracellular route.  ASL is composed of a periciliary fluid layer 
(PCL) and a mucus layer riding on top of the PCL. The normal balance between 
Na absorption and Cl- secretion maintains a PCL height of 7-10m which 
corresponds to the height of outstretched cilia.  A PCL height less than 6m 
results in compression of the cilia by the mucus layer and disrupted muco-ciliary 
transport.  Thus the regulation of ASL height by trans-epithelial ion and water 
transport within a very narrow range of a few microns is critical for effective muco-
ciliary clearance (73). 
 
Trans-epithelial ion transport and ASL hydration are regulated by the neuro-
humoral environment (e.g. nucleotides (39, 93), steroid hormones (94, 95), Nitric 
oxide (96), Acetylcholine (97)).  Dynamic stretch, viral infection and inflammation, 
for example, affect the ASL by increasing the ASL concentration of nucleotides, 
which in turn regulate ion transport processes to maintain a functional ASL height 
(76, 98, 99).  In CF, the ASL is dehydrated due to the loss of chloride secretion 
through CFTR and the sodium hyper-absorption which has been postulated to be 
consequent to the loss of ENaC down-regulation by CFTR (67).  
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Figure 3-1 Schematic illustrating the regulation of Airway Surface Liquid 
(ASL) height  
Adequate hydration of the PCL is achieved via balanced trans-epithelial sodium 
absorption and chloride secretion.  Sodium absorption is mediated by apical 
Epithelial Sodium Channels (ENaC) and basolateral Na/K ATPase pump.  
Chloride secretion is mediated by apical CFTR and CaCC chloride channels and 
the basolateral Na/K/2Cl co-transporter.  Water follows passively via aquaporins 
and the paracellular route.  Apical Purino-receptors (P2Y2 and A2b) regulate trans-
epithelial ion transport via calcium and cAMP and subsequently affect ASL 
hydration. 
 
3.1.2 Inflammation 
Excessive NFĸB activation has been observed in CF (65, 188, 189) and variously 
attributed to; persistent bacterial infection and pro-inflammatory cytokine 
stimulation (191); Intrinsic imbalances between pro and anti-inflammatory cytokine 
profiles in CF (231); ER stress due to the accumulation of misfolded CFTR protein 
(196); and, ER calcium store expansion and amplification of the calcium 
dependent inflammatory response (192, 193).  Degradation of IĸB in the cytosol 
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releases NFĸB and permits its translocation to the nucleus where NFĸB binds to 
its site in the promoter region of the IL-8 gene, and rapidly up-regulates synthesis 
of the pro-inflammatory cytokine, IL8 (187).  IL8 is a potent neutrophil chemo-
attractant and is secreted by both tissue resident cells and recruited immune 
effector cells.  Higher IL8 has been associated with worse lung function in CF 
(190).  Tumour necrosis factor α (TNFα) is a potent activator of the pro-
inflammatory nuclear transcription factor NFĸB and its synthesis is induced by LPS 
acting through Toll-like receptor 4 (392).  It is secreted by mononuclear 
phagocytes, natural killer cells, endothelial cells, mast cells, activated 
lymphocytes, and neutrophils.  TNFα concentration was inversely correlated to 
FEV1 in CF (214). 
 
3.1.3 Phagocytosis and bacterial killing in CF 
Macrophage phagocytosis plays an important role in bacterial containment and the 
resolution of acute inflammation by engulfing bacteria and apoptotic neutrophils. In 
CF, impairments in alveolar macrophage-mediated phagocytosis and bacterial 
killing are described (125-127, 228).   
 
3.1.4 Resolvin D1 
Resolvin D1 (RvD1) is an endogenously produced “Specialised Pro-Resolution” 
lipid mediator involved in the “active resolution” phase of inflammation (262).  The 
biosynthesis of RvD1 from DHA involves two sequential lipoxygenation steps; 15 
Lipoxygenase catalyses the conversion of DHA to 17R-HpDHA, and then 15 
Lipoxygenase generates a peroxide intermediate which is enzymatically 
hydrolysed to RvD1 (288).  RvD1 stops neutrophil infiltration in both mouse 
models, and a model of fMLP stimulated trans-endothelial migration, and 
enhances macrophage phagocytosis of apoptotic neutrophils (288, 293).  RvD1 
was reported to attenuate NFĸB activation in a mouse model of lung injury (337).  
In a mouse model of cigarette smoke exposure RvD1 promoted differentiation of 
alternatively activated (M2) macrophages and stimulated neutrophil efferocytosis 
(336).  Using a β arrestin ligand reporter system, RvD1 was revealed to signal 
through the GPR32 orphan receptor and ALX/FPR2 receptor (294, 295).  
Resolvins are rapidly inactivated by eicosanoid oxidoreductases (284, 293). 
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3.1.5 SPM’s in ASL Regulation 
Our group previously demonstrated that the related SPM - LXA4 restores ASL 
height in CF bronchial epithelial cell models via stimulation of the ALX/FPR2 
receptor (85).  The LXA4 mediated ASL rehydration is achieved by; apical ATP 
secretion via Pannexin-1 channels, and activation of P2RY11 purinoreceptors, 
leading to calcium activated chloride secretion (393), and; inhibition of airway 
epithelial sodium absorption through ENaC (356). 
 
3.1.6 ALX/FPR2 Receptor 
ALX/FPR2 conveys the pro-resolving properties of LXA4 and RvD1 (268).  
ALX/FPR2 is expressed in several types of cells including human bronchial 
epithelial cells and bronchial biopsy sections (323).  It is noteworthy that LXA4 
enhances the activity of the ALX/FPR2 promoter, and enhances the apical 
membrane localisation of ALX/FPR2 in CF cells (327, 356). 
 
3.2 Aims & Hypotheses 
We aimed to investigate the potential of RvD1 as a candidate therapeutic for CF 
airways disease.  We set out to investigate the impact of RvD1 upon three key 
pathologic aspects of CF airways disease; airway surface liquid hydration; NFĸB 
mediated inflammation, and; macrophage phagocytosis - key to neutrophil 
efferocytosis and bacterial clearance.  We investigated the following hypotheses;    
 
 RvD1 induces an airway surface liquid (ASL) height increase in normal and 
CF airway epithelia via ALX/FPR2 receptor stimulation 
 RvD1 attenuates NFĸB activation and agonist stimulated IL8 secretion by 
CF airways epithelial cells 
 RvD1 restores phagocytic and bactericidal capacity to CF alveolar 
macrophages 
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3.3 Results 
3.3.1 Resolvin D1 restores ASL height in CF bronchial epithelial cell line CuFi-1 
In order to test the hypothesis that RvD1 induces an ASL height increase in CF 
airway epithelia, we cultured CuFi-1 bronchial epithelial cells as polarised, 
differentiated epithelial layers and stained the ASL with Texas red®-dextran.  
Using live cell confocal microscopy we visualised the ASL and then measured the 
height of ASL on CuFi-1 cell preparations using Zeiss LSM Image Browser (Carl 
Zeiss Micro-Imaging GmbH, Germany).   
 
*Dr Gerard Higgins taught me confocal microscopy.  Master’s student Ahmad 
Moukachar shadowed me in the lab during the initial phase of these ASL 
experiments and in that capacity had hands on experience sitting side by side with 
me doing the cell culture, treatments and capturing the confocal microscopy 
images.  Ahmad made a parallel set of measurements on the early ASL images.  
The data I present here are my own independent measurements. 
 
The mean height of ASL on CuFi-1 cells under non-stimulated (NS) conditions was 
low (5.7 ± 0.3µm) (n=8 inserts) (Figure 3-2A).  The three dimensional structure of 
the ASL visualised upon vehicle control treated CuFi-1 preparations had a patchy, 
discontinuous appearance (Figure 3-2B).  30 minutes basolateral exposure to 1nM 
RvD1 increased the ASL height on CuFi-1 cells (7.1 ± 0.2µm vs. 5.7 ± 0.3µm, 
P<0.01) (n=6 inserts) (Figure 3-2A).  Treatment with a higher concentration of 
RvD1 (100nM) also resulted in an increase in ASL height compared to vehicle 
control conditions (8.3 ± 0.3µm vs. 5.7 ± 0.3µm, P<0.001) (n=5 inserts) (Figure 
3-2A).  After exposure to RvD1 (100nM) the ASL was fuller, with greater continuity 
(Figure 3-2B). 
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Figure 3-2  Resolvin D1 (RvD1) restores airway surface liquid (ASL) height in 
CuFi-1 differentiated bronchial epithelial cells   
ASL height in µm was measured by live cell confocal fluorescence microscopy 
using Texas red®-dextran to stain the ASL.  (A) Differentiated CuFi-1 bronchial 
epithelial cell preparations were stimulated with either vehicle control (NS), RvD1 
1nM or 100nM 30 minutes prior to image acquisition.  Untreated CuFi-1 cells (NS) 
demonstrated reduced ASL height at 5.7µm and disrupted architecture.  RvD1 
1nM and 100nM restored ASL height on CuFi-1 cells to 7.1µm** and 8.3µm*** 
respectively.  (B) Representative images of the 3 Dimensional structure of the ASL 
on CuFi-1 differentiated bronchial epithelial cells treated for 30mins with vehicle 
control (Left of panel) and RvD1 100nM (Right of panel).  Under control conditions 
the ASL is low in volume, patchy and disrupted.  Following treatment with RvD1 
the ASL height and volume were significantly increased, and the continuity was 
restored.  (Results are presented as Mean ± SEM, *P<0.05/**P<0.01/***P<0.001, 
n= 5-8 inserts, Student t test).  *Ahmad Moukachar provided technical assistance.  
Data presented are my own independent measurements.  
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3.3.2 Resolvin D1 restores ASL height upon CuFi-1 bronchial epithelial cells via 
ALX/FPR2 receptor stimulation and intracellular calcium mobilisation   
We hypothesised that RvD1 induces an ASL height increase via ALX/FPR2 
receptor stimulation.  To investigate the role of ALX/FPR2 in the elevation of ASL 
height observed in CuFi-1 cells after RvD1 treatment (1nM) we used Boc2 as a 
pharmacological inhibitor of the ALX/FPR2 receptor (323).   
 
Boc2 treatment alone did not significantly alter ASL height in CuFi-1 cells (5.9 ± 
0.6µm vs. 5.7 ± 0.3µm under NS conditions) (n=6 inserts) (Figure 3-3A).  Pre-
treatment of CuFi-1 cells with Boc2 completely prevented the elevation in ASL 
height seen with 1nM RvD1 alone (5.7 ± 0.5µm; RvD1 (1nM) + Boc2 vs. 7.1 ± 
0.2µm; RvD1 (1nM), P<0.05) (n=7 inserts) (Figure 3-3A).   
 
Two pathways for chloride secretion are commonly recognised in the airways; 
cAMP-dependent (CFTR mediated) and calcium dependent secretory pathways 
(CaCC) (43). Sodium absorption in the airways is mediated by the amiloride-
sensitive epithelial Na+ Channel (ENaC).  ENaC has been reported to be inhibited 
by intracellular calcium (394-396). 
 
In order to investigate the role played by intracellular calcium in the elevation in 
ASL height induced by RvD1 in CuFi-1 cells, we used BAPTA-AM to chelate 
intracellular calcium (Figure 3-3B).  A non-significant reduction in ASL height 
compared to vehicle control was recorded following BAPTA-AM treatment (5.2 ± 
0.4µm vs. 5.7 ± 0.3µm; NS, P=NS) (n=4 inserts) (Figure 3-3B).  The RvD1 
mediated increase in ASL height was completely prevented by co-administration of 
the intracellular calcium chelator BAPTA-AM (4.9 ± 0.2µm; RvD1 + BAPTA vs. 7.1 
± 0.2µm; RvD1, P<0.001) (n=5 inserts) (Figure 3-3B). 
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Figure 3-3 Resolvin D1 (RvD1) restores airway surface liquid (ASL) height in 
CuFi-1 differentiated bronchial epithelial cells via ALX/FPR2 receptor 
stimulation and intracellular calcium mobilisation   
(A)  CuFi-1 differentiated bronchial epithelial cells were treated with either vehicle 
control (NS) or with Boc-2 (10µM) (Specific ALX/FPR2 receptor antagonist) alone, 
or as a 20 minute pre-treatment, followed by RvD1 (1nM) for 30mins.  The RvD1 
associated increase in ASL height was completely abolished by the ALX/FPR2 
receptor antagonist Boc2.  (B) CuFi-1 differentiated bronchial epithelial cells were 
treated with either vehicle control (NS) or with BAPTA-AM (10µM) (intracellular 
calcium chelator) alone, or as a 20 minute pre-treatment, followed by RvD1 (1nM) 
for 30mins.  The RvD1 associated increase in ASL height was completely 
abolished by the intracellular calcium chelation using BAPTA-AM***.  (C) 
Representative images are shown.  (Results are presented as Mean ± SEM, 
*P<0.05/**P<0.01/***P<0.001, n= 5-8 inserts, Student t test).  *Ahmad Moukachar 
provided technical assistance for the Boc2 experiments.  Data presented are my 
own independent measurements.     
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3.3.3 Resolvin D1 restores ASL height in polarised, differentiated Primary CF 
Bronchial Epithelial Cells  
In order to corroborate that RvD1 increases ASL height in CF epithelial cells as 
demonstrated in CuFi-1 cell lines, we cultured Primary CF bronchial epithelia 
(CFBE), obtained from children with CF by bronchial brushing, as polarised, 
differentiated epithelial layers at air-liquid interface.     
 
*Primary bronchial epithelial cells were obtained via the SHIELD CF Study set up 
by Dr’s Paul McNally and Barry Linnane.  Myself, Paul McNally, Des Cox, Ahmad 
Zaid, Sheila Javadpour, Peter Greally and Basil Elnazir performed bronchoscopy 
for the SHIELD CF study. Dr Gerard Higgins taught me primary cell culture and 
Lab technician, Coral Fustero provided technical assistance in primary CF 
bronchial epithelial cell culture for these experiments. 
 
Under vehicle control conditions (NS), the ASL height in CFBE’s was low 
(3.7±0.2µm) (n=6 inserts) (Figure 3-4A).  30 minutes exposure to RvD1 (1nM) 
elevated ASL height on CFBE (6.8±0.3µm; RvD1, vs. 3.7±0.2µm; NS, P<0.001, n= 
7 inserts).  Bronchial Epithelium derived from 2 separate children homozygous for 
the Phe508del CFTR mutation (Figure 3-4A).   
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Figure 3-4  Resolvin D1 (RvD1) restores airway surface liquid (ASL) height in 
polarised, differentiated Primary CF Bronchial Epithelial Cells   
ASL height in µm was measured by live cell confocal fluorescence microscopy 
using Texas red®-dextran to stain the ASL.  Differentiated Primary CFBE 
preparations were stimulated with either vehicle control (NS), or RvD1 1nM 30 
minutes prior to image acquisition.  (A) Untreated CFBE’s (NS) demonstrated low 
ASL height at 3.7±0.2µm.  RvD1 1nM increased ASL height on CFBE to 
6.8±0.3µm***. (B) Representative images are shown.  (Results are presented as 
Mean ± SEM, ***P<0.001, n= 6-7 inserts prepared from Bronchial Epithelium 
derived from 2 separate children with CF, Student t test).  *Primary bronchial 
epithelial cells were obtained via the SHIELD CF Study.  Dr Gerard Higgins taught 
me primary cell culture and Lab technician, Coral Fustero provided technical 
assistance in primary CF bronchial epithelial cell culture for these experiments. 
Data presented are my own independent measurements. 
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3.3.4 Resolvin D1 does not affect net ASL in non-CF NuLi-1 cells, but restores 
ASL height loss associated with CFTR inhibition   
We hypothesised that RvD1 would induce an ASL height increase in both normal 
and CF airway epithelia.  In order to investigate the effect of RvD1 on ASL height 
in non-CF bronchial epithelial cells, we cultured NuLi-1 cells as polarised, 
differentiated bronchial epithelial cell layers.  Again we used the same protocol to 
visualise the ASL and measure its height.  NuLi-1 cell preparations were 
stimulated with either vehicle control or RvD1 (1 & 100nM). The ASL height upon 
vehicle control treated NuLi-1 cells measured 7.2 ± 0.3µm (n=11 inserts) (Figure 
3-5B).  This was significantly higher than the ASL measured under non-stimulated 
conditions in CuFi-1 cells (5.7 ± 0.3µm, P<0.01) (Figure 3-2A).  ASL height did not 
change significantly in NuLi-1 cell preparations following RvD1 exposure in NuLi-1 
cell preparations (7.8 ± 0.3µm; RvD1 (1nM, n=13 inserts) & 7.6 ± 0. 3µm; RvD1 
(100nM, n=7 inserts), P=NS) (Figure 3-5B).   
 
Three key ion transport pathways contribute to the hydration of the ASL in airways 
epithelia; cAMP-dependent chloride secretion via CFTR; calcium dependent 
chloride secretion via CaCC, and sodium absorption via ENaC.  CFTR has been 
reported to regulate both CaCC (stimulation) and ENaC (inhibition) channel activity 
(see section 1.2.3).  In order to further examine the effect of RvD1 on ASL height 
regulation in the setting of CFTR inhibition, we pharmacologically inhibited CFTR 
in NuLi-1 cells using CFTR inhibitor 172. 
 
Selective CFTR inhibition resulted in a significant reduction in ASL height in NuLi-1 
cell preparations (4.7 ± 0.3µm vs. 7.2 ± 0.3µm (NS), P<0.001) (n=6 inserts) 
(Figure 3-5B).  RvD1 (100nM) treatment significantly elevated ASL height in CFTR 
inhibited NuLi-1 cells (6.7 ± 0.3µm; CFTR inh + RvD1 (100nM) vs. 4.7 ± 0.3µm; 
CFTR inh alone, P<0.001) (n=6 inserts) (Figure 3-5B).   
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Figure 3-5  Resolvin D1 (RvD1) does not affect overall airway surface liquid 
(ASL) height but restores ASL height loss associated with CFTR inhibition in 
NuLi-1 differentiated bronchial epithelial cells   
ASL height in µm was measured by live cell confocal fluorescence microscopy 
using Texas red®-dextran.  Differentiated NuLi-1 bronchial epithelial cell 
preparations were stimulated with either vehicle control (NS), RvD1 (1nM), RvD1 
(100nM) alone, CFTR inhibitor 172 (20µM) alone, or RvD1 (100nM) in combination 
with CFTR inhibitor 172 (20µM) 30 minutes prior to image acquisition.  (A) 
Representative images are presented.  (B) Mean ASL height in vehicle control 
treated preparations was 7.3µm.  Mean ASL height did not change significantly 
when treated with 1nM RvD1 (7.8 µm) or 100nM RvD1 (7.6 µm).  CFTR inhibition 
significantly reduced ASL height to 4.7µm***.  Concurrent treatment of CFTR 
inhibitor treated preparations with RvD1 (100nM) resulted in significant increase of 
the ASL height to 6.7µm***.  (Results are presented as Mean ± SEM, ***P<0.001, 
n=6-13 inserts, Student t test).  *Ahmad Moukachar provided technical assistance.  
Data presented are my own independent measurements.    
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3.3.5 Resolvin D1 attenuates TNFα induced IL8 secretion by CuFi-1 cells via 
preservation of IĸB   
We hypothesised that RvD1 attenuates NFĸB activation and agonist stimulated IL8 
secretion by CF airways epithelial cells.  In order to investigate this hypothesis we 
treated CuFi-1 epithelial cells with TNFα alone (in order to stimulate IL8 secretion), 
or in combination with RvD1 (100nM).  Under these conditions, we measured 
apical IL8 secretion by ELISA and quantified IĸB expression by Western blotting 
(Figure 3-6).   
 
Baseline IL8 secretion by CuFi-1 epithelial cells measured 169 ± 54ng/ml (Figure 
3-6A).  A significant induction of IL8 secretion was achieved by treatment with 
TNFα (80ng/ml) (546 ± 39ng/ml vs. 169 ± 54ng/ml, P<0.001) (Figure 3-6A).  
Treatment with RvD1 prevented the stimulation of IL8 secretion induced by TNFα 
in CuFi-1 cells (283 ± 44ng/ml vs. 546 ± 39ng/ml, P<0.01, n=6-7) (Figure 3-6A).   
 
TNFα treatment of CuFi-1 cells resulted in a significant degree of IĸB degradation 
(0.67 ± 0.06; TNFα vs. 1.07 ± 0.04; NS, P<0.01) (Figure 3-6 B&C).  Co-treatment 
with RvD1 significantly prevented IĸB degradation (0.93 ± 0.05; TNFα + RvD1 vs 
0.67 ± 0.06; TNFα, P<0.05, n= 4-5, representative blots are presented) (Figure 3-6 
B&C).   
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Figure 3-6  Resolvin D1 (RvD1) attenuates TNFα induced IL8 secretion by 
CuFi-1 cells via preservation of IĸB   
(A) CuFi-1 differentiated bronchial epithelia cells were exposed to vehicle control 
(NS) or TNFα (80ng/ml) for 24 hours to induce IL8 secretion, either alone or in 
combination with RvD1 (100nM).  Apical IL8 concentration was measured by 
ELISA.  Baseline IL8 secretion by CuFi-1 cells measured 169 ±54 ng/ml.  
Following stimulation with TNFα, IL8 secretion was significantly increased at 
546*** ±39 ng/ml.  Concurrent treatment with RvD1 (100nM) resulted in significant 
inhibition of TNFα induced IL8 secretion (283**± 44 ng/ml).  (B & C)  CuFi-1 
bronchial epithelial cells were grown in monolayers and exposed to either vehicle 
control (NS), TNFα (80ng/ml) alone, or in combination with RvD1 (100nM) for 24 
hours.  IĸB expression was detected by western blotting and quantified by band 
densitometry using α-Tubulin as a loading control.  Results are presented as 
relative band intensities (RBI).  TNF-α treatment resulted in a significant 
degradation of IĸB**, which was significantly prevented* by concurrent treatment 
with RvD1 100nM.  (Results are presented as Mean ±SEM, *P<0.05, **P<0.01, 
***P<0.001, n=6-7 inserts for IL8 experiments, n= 4-5 epithelial preparations for 
IĸB, ANOVA).  *IĸB antibody obtained from Dr Sarah Doyle. 
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3.3.6 Baseline ALX/FPR2 receptor protein expression does not differ between 
NuLi-1 and CuFi-1 cells 
Using Flow Cytometry, Al-Alawi et al. observed higher surface expression of the 
ALX/FPR2 receptor in NuLi-1 cells as compared with CuFi-1 cells, associated with 
a reciprocally higher intracellular localisation of ALX/FPR2 in CuFi-1 cells as 
compared with NuLi-1 cells (356).  Those authors also reported that in CuFi-1 
cells, LXA4 treatment resulted in a very rapid (5 minutes) recruitment of ALX/FPR2 
to the apical membrane (356).  In light of these reports, an important component of 
cell sensitivity to ALX/FPR2 ligands remained outstanding; does the total available 
pool of ALX/FPR2 receptor differ between Nuli-1 and CuFi-1 cell lines?    
 
Using a different approach (Western blotting); we measured whole cell ALX/FPR2 
receptor protein expression by both cell lines.  There was no significant difference 
in whole cell ALX/FPR2 receptor expression between NuLi-1 and CuFi-1 cell lines 
(0.92 ± 0.18; NuLi-1 vs. 1.22 ± 0.45; CuFi-1, P>0.05) (Figure 3-7). 
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Figure 3-7  Baseline ALX/FPR2 receptor expression does not differ between 
NuLi-1 and CuFi-1 cells  
NuLi-1 and CuFi-1 bronchial epithelia cells were grown in monolayers.  ALX/FPR2 
receptor expression was measured by Western Blotting using α-Tubulin as a 
loading control.  Representative blots are shown above.  Band densitometry was 
performed.  The results were normalised by loading control and are presented as 
relative band intensities.  No significant difference in baseline ALX/FPR2 receptor 
expression was observed between NuLi-1 and CuFi-1 cell lines (n=4 epithelial 
preparations quantified on at least 3 different occasions, Student t test). 
 
 
3.3.7 Resolvin D1 does not affect whole cell ALX/FPR2 receptor protein 
expression in NuLi-1 or CuFi-1 cells  
The ALX/FPR2 agonist LXA4 is reported to enhance the activity of the ALX/FPR2 
promoter (327).  We investigated whether chronic exposure (24 hours) to RvD1 
would result in alterations in ALX/FPR2 receptor expression.  We found no 
significant effect of RvD1 (1nM or 100nM) on whole cell ALX/FPR2 receptor 
protein expression on NuLi-1 or CuFi-1 cells (P=NS) (Figure 3-8). 
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Figure 3-8  Resolvin D1 does not affect ALX/FPR2 receptor expression in 
NuLi-1 or CuFi-1 cells   
NuLi-1 (left of panel) and CuFi-1 (right of panel) bronchial epithelia cells were 
grown in monolayers and exposed either to vehicle control (NS) or RvD1 (1 or 
100nM) for 24 hours.  ALX/FPR2 receptor expression was measured by Western 
Blotting using α-Tubulin as a loading control.  Representative blots are shown 
above.  Band densitometry was performed.  The results were normalised by 
loading control and are presented as relative band intensities compared to the 
non-stimulated condition for the same cell line.  No significant effect of RvD1 upon 
ALX/FPR2 receptor expression was observed in either cell line (n=3-4 epithelial 
preparations treated and quantified on at least 3 different occasions, ANOVA). 
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3.3.8 Resolvin D1 enhances the phagocytic capacity of Primary Alveolar 
Macrophages from children with CF 
We hypothesised that RvD1would restore phagocytic capacity to CF alveolar 
macrophages.  In order to investigate this hypothesis, we isolated alveolar 
macrophages from the bronchoalveolar lavage (BAL) of three female children 
under the age of 6 with CF.  All three girls were homozygous for the Phe508del 
CFTR mutation.  Isolated CF alveolar macrophages were treated with either 
vehicle control or RvD1 (100nM) and incubated with fluorescently labelled latex 
beads complexed with rabbit IgG.  The fluorescence intensity from phagocytosed 
beads within alveolar macrophages was imaged, and separately quantified using a 
fluorescence plate reader.   
 
*BAL fluid; the source material for primary alveolar macrophage isolation, was 
obtained via the SHIELD CF Study set up by Dr’s Paul McNally and Barry 
Linnane. Myself, Paul McNally, Des Cox, Ahmad Zaid, Sheila Javadpour, Peter 
Greally and Basil Elnazir performed bronchoscopy for the SHIELD CF study.   
 
A greater proportion of alveolar macrophages treated with RvD1 had associated 
fluorescence, and the intensity of fluorescence per cell was higher when compared 
with NS conditions (Figure 3-9 A-D).  The fluorescence intensity measured from 
RvD1 treated macrophage samples was significantly higher than from vehicle 
control samples (7490 ± 950; RvD1 vs. 4420 ± 1020; NS, P<0.01, n=3 patient 
samples, performed in triplicate) (Figure 3-9 E).   
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Figure 3-9  Resolvin D1 enhances the phagocytic capacity of Primary 
Alveolar Macrophages from children with CF (CFAM)  
CFAM were isolated from BAL and pre-treated for 30mins with either vehicle 
control (A&B) or RvD1 100nM (C&D).  CFAM were exposed to Latex Beads-rabbit 
IgG-FITC complex for 1 hour.  Light microscopy (LM) images were captured 
concurrently with fluorescence images (B&D) from phagocytosed FITC-labelled 
beads (Panels A&C are LM / fluorescence composite).  Representative images are 
presented (scale bar = 100µm).  Engulfed bead fluorescence was more intense 
with RvD1 treatment (C&D) than under vehicle control conditions (A&B).  
Fluorescence intensity of phagocytosed FITC-labelled beads was quantified using 
a fluorescence plate reader (E).  CFAM associated FITC fluorescence was higher 
in RvD1 treated versus control preparations (**P<0.01).  (Results are presented as 
Mean ± SEM, experiments were performed in triplicate on n=3 patient samples, 
**P<0.01, paired Student t-test). * Primary alveolar macrophages were obtained 
via the SHIELD CF Study. 
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3.3.9 Resolvin D1 enhances intracellular killing of Pseudomonas aeruginosa 
(PAO1) by CF Alveolar Macrophages 
Pseudomonas aeruginosa is a key CF pathogen, early acquisition of which 
predicts accelerated lung function decline (155).  Impaired intracellular killing of 
Pseudomonas aeruginosa has been reported in CF alveolar macrophages (125-
127, 228).  We hypothesised that RvD1 would restore bactericidal capacity to CF 
alveolar macrophages (CFAM).   
 
To evaluate this hypothesis, CFAM were isolated from BAL by adherence to tissue 
culture plastic.  CFAM were treated with either vehicle control (NS) or RvD1 
(100nM) for 3 hours and then exposed to Pseudomonas aeruginosa lab strain 
PAO1 (Optical Density=0.1, equivalent to 2x10^14 CFU/ml).  After 30 minutes, 
non-engulfed bacteria were removed and the alveolar macrophages were treated 
with gentamicin to kill residual extracellular and membrane bound bacteria.  CFAM 
were then lysed, and the bacterial load within the lysate was quantified.   
 
*BAL fluid; the source material for primary alveolar macrophage isolation, was 
obtained via the SHIELD CF Study set up by Dr’s Paul McNally and Barry 
Linnane. FR, Paul McNally, Des Cox, Ahmad Zaid, Sheila Javadpour, Peter 
Greally and Basil Elnazir performed bronchoscopy for the SHIELD CF study.  Dr 
Gerard Higgins taught me the technique to quantify bacteria and I conducted the 
quantification of PAO1 under his guidance. 
 
The intracellular viable bacterial load of PAO1 was significantly decreased in 
preparations treated with RvD1 than under vehicle control conditions (1.7±0.6 x106 
CFU/ml; RvD1 100nM vs. 6.0±1.4 x106 CFU/ml; vehicle control, *P<0.05, n=4 
preparations from 2 patients) (Figure 3-10). 
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Figure 3-10  Resolvin D1 enhances intracellular killing of PAO1 by CF 
Alveolar Macrophages   
CFAM were isolated from BAL by adherence to tissue culture plastic.  CFAM were 
treated with either vehicle control (NS) or RvD1 (100nM) for 3 hours and then 
exposed to PAO1 bacteria.  After 30 minutes non-engulfed bacteria were removed 
and CFAM were treated with gentamicin to kill residual extracellular and 
membrane bound bacteria.  CFAM were then lysed and the bacterial load within 
the lysate was quantified.  The intracellular viable bacterial load was significantly 
lower in preparations treated with RvD1 (1.7±0.6 x106 CFU/ml; RvD1 vs. 6.0±1.4 
x106 CFU/ml; NS, Mean± SEM, n=4 preparations from 2 patients, *P<0.05, 
Student’s t-test).   
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3.4 Discussion 
3.4.1 Summary & Key Findings 
We report here for the first time, that RvD1 ameliorates three key components of 
CF lung disease pathogenesis in CF models; ASL height loss, NFĸB driven 
inflammation, and macrophage mediated killing of P. aeruginosa.  We report that 
RvD1 elevated airway surface liquid height in Primary CF and CuFi-1 bronchial 
epithelial cell models.  In CuFi-1 cells, this effect involved ALX/FPR2 receptor 
stimulation and was prevented by intracellular calcium chelation.  We report that 
RvD1 had no net effect on ASL height in non-CF NuLi-1 cells, but rescued ASL 
height loss induced by CFTR inhibition.  RvD1 attenuated IL8 secretion following 
TNFα mediated NFĸB activation via preservation of IĸB integrity in CuFi-1 
bronchial epithelial cells.  Furthermore, RvD1 enhanced the phagocytic capacity of 
primary CF alveolar macrophages and increased their ability to kill engulfed P. 
aeruginosa.  These findings recommend the further development of RvD1 as a 
candidate for the treatment of CF lung disease.    
 
3.4.2 Resolvin D1 in ASL Height Regulation 
We hypothesised that RvD1 would increase ASL height in both normal and CF 
epithelial cell models.  Our group had previously reported that the related SpM, 
LXA4, restored ASL height in non-CF and CF airway epithelial cells (85, 318).  
The effect of LXA4 on ASL was achieved via ALX/FPR2 receptor stimulation and 
raised intracellular calcium concentration, stimulating calcium-activated chloride 
secretion (85). Higgins et al. reported that LXA4 induced an ALX/FPR2 dependent 
apical ATP release via Pannexin channels.  Subsequently it was shown that 
P2RY11 purinoreceptor stimulation increased intracellular cAMP and calcium 
concentration (393).  Al-Alawi et al. demonstrated that LXA4 at physiological 
concentrations also mediated its effect on ASL hydration through ENaC inhibition 
(356).  In the absence of functional CFTR, compensatory strategies proposed to 
overcome ASL dehydration and restore muco-ciliary function include; stimulating 
chloride secretion by Calcium Activated Chloride Channels (CaCC) via raised 
intracellular calcium; inhibition of ENaC mediated sodium hyper-absorption, and 
osmotic agents such as hypertonic saline and mannitol. 
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This is the first study to investigate the effect of RvD1 upon ASL height.  We found 
that in the context of CFTR dysfunction; Primary CF bronchial epithelial cells, 
CuFi-1 cells, NuLi-1 cells in which CFTR was inhibited; RvD1 stimulated a 
significant increase in ASL height.  In CuFi-1 cell preparations, this was paralleled 
by a more uniform appearance of the ASL layer.  In contrast, in NuLi-1 cell 
preparations where CFTR function was intact, RvD1 had no net effect on ASL 
height.  
 
In order to try to interpret these findings it is necessary to consider that three key 
ion transport pathways that contribute to the hydration of the ASL in airways 
epithelia; cAMP-dependent chloride secretion via CFTR; calcium-activated 
chloride secretion via CaCC (43); and, sodium absorption via ENaC (77).   
 
In practice, ion transport processes affect each other via effects on the 
transmembrane electrochemical potential, and there is significant cross-talk 
between intracellular calcium and cAMP signalling cascades, and extracellular 
purine effects  on the regulation of ASL hydration by both chloride secretion and 
sodium absorption (24, 38-40, 77, 103).  In addition, CFTR exerts regulatory 
effects on both ENaC and CaCC (13, 20-43).  Furthermore, the electrical driving 
force for chloride secretion and sodium absorption is provided by basolateral 
potassium channel activity (97).  As such, any attempt to reduce RvD1’s effects 
upon ASL height in the setting of CFTR dysfunction to an isolated effect on either 
chloride secretion via CaCC, or sodium absorption via ENaC, would be to 
oversimplify the biology of the system. 
 
Having recognised that these ion transport processes are interdependent, there 
are cases to be argued that the effect of RvD1 on ASL height in the context of 
CFTR dysfunction is principally mediated either via CaCC activation or ENaC 
inhibition (illustrated in Figure 3-11).   
  
Evidence in favour of the case that the principal effect of RvD1 is mediated via 
calcium activated chloride secretion (CaCC) comes from the observation that 
intracellular calcium chelation by BAPTA-AM prevented the RvD1 mediated ASL 
height increase in CuFi-1 cells.  A precedent exists for LXA4 as an ALX/FPR2 
agonist stimulating intracellular calcium mobilisation and activating calcium 
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activated chloride currents in bronchial epithelial cells (85, 318).  However, 
intracellular calcium chelation with BAPTA-AM also affects off-target cellular 
processes beyond calcium-activated chloride secretion, including tight junction 
stability, basolateral potassium transport, sodium absorption and calcium 
dependent protein kinase activation.  The role of chloride secretion in the RvD1 
mediated ASL height increase in CF cells could be further investigated by; using 
bumetanide to inhibit Na+/K+/2Cl- co-transport (85). The molecular identities of 
several types of calcium-activated Cl channel have been reported in recent years 
and the role of the CLCA family or TMEM16 (or Anoctamin 1) chloride channel in 
the response to RvD1 could be investigated by selective inhibition tools (88, 397). 
 
There is also a case to be argued that the primary effect of RvD1 on ASL height is 
achieved via inhibition of ENaC mediated sodium hyper-absorption.  Amiloride-
sensitive sodium absorption (via ENaC) is elevated by 2- to 3- fold in CF (24), and 
in contrast to observations in non-CF airways epithelia, this channel accounts for a 
major component of the total trans-epithelial current in CF airways epithelia (78, 
356, 398).  If the primary effect of RvD1 on ASL height is achieved via ENaC 
inhibition, it is reasonable to expect that in the presence of functional CFTR, where 
the baseline current through ENaC is low, inhibition of ENaC would not impact 
ASL height significantly.  This is consistent with the absence of an effect of RvD1 
on ASL height in non-CF bronchial epithelial cells that we have observed.  In the 
absence of functional CFTR, the ENaC current is higher (24, 356) and inhibition of 
this higher sodium current would have a more significant impact, and could give 
rise to the elevation in ASL height that we observed in Primary CF and CuFi-1 
bronchial epithelial cells.  Furthermore, intracellular calcium regulates ENaC 
channel activity in a variety of epithelia (394-396).  The inhibition of the ASL height 
increase induced by RvD1 in CuFi-1 cells by BAPTA-AM would also be consistent 
with an inhibition of ENaC channel activity.  Finally, acknowledging the recognised 
role of cAMP in ENaC regulation, a role played by cAMP in contributing the RvD1 
mediated ASL height response cannot be excluded.  The role of ENaC and 
sodium absorption in the RvD1 mediated ASL height increase in CF cells could be 
further investigated by; testing whether RvD1 can generate an additive (implying 
ENaC independent) ASL height increase when used in combination with amiloride 
(ENaC channel blocker); and, examining the contribution of RvD1 to amiloride-
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sensitive ion transport. A candidate effect of RvD1 on basolateral potassium 
transport remains to be studied. 
 
Taking into account the central role intracellular calcium plays in regulating both 
sodium absorption and chloride secretion, the effect of RvD1 on cytosolic calcium 
concentration could be also investigated using fluorescence microscopy (85). 
 
 
 
Figure 3-11 Proposed mechanisms by which RvD1 mediates the ASL height 
increase observed in Primary CF bronchial epithelial cells and CuFi-1 cells 
RvD1 was shown to elevate ASL height in CF cells via ALX/FPR2 stimulation.  
This effect could occur via increased intracellular calcium concentration and 
subsequent calcium activated chloride secretion (CaCC), and/or inhibition of ENaC 
mediated sodium absorption. 
 
In NuLi-1 cell preparations, where CFTR function was intact, RvD1 had no net 
effect on ASL height. In this respect RvD1’s physiological effect on ASL regulation 
in NuLi-1 cells differed from the effect of LXA4 on ASL height in NuLi-1 cells (85, 
318).  The absence of a net effect in NuLi-1 cells could reasonably be explained 
by the observation that CFTR functions to balance chloride secretion and sodium 
absorption, and thus, abrogates any unbalanced effect on one arm of ion transport 
via its regulatory function.  This particular function of CFTR is a subject of 
controversy. 
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The ASL effect of ALX/FPR2 ligand LXA4 was transduced via apical ATP release 
and purinoreceptor stimulation (393).  The role of ATP and purinoreceptor 
stimulation in the RvD1 mediated increase in ASL height in primary CFBE’s and 
CuFi-1 cells could be tested using the published methods employed by Higgins et 
al., demonstrating ALX/FPR2 dependent apical ATP release and purinoreceptor 
stimulation in the ASL height effect of LXA4 (393).  
 
3.4.3 Impact of ASL Rehydration  
Restoration of ASL height might reasonably be expected to give rise to 
improvement in muco-ciliary clearance and thus prevent mucous stasis and 
reduce airways infection.  Rehydration of the ASL could potentially improve the 
ionic composition of the ASL and restore activity to innate anti-microbial peptides 
such as the beta-defensins (128, 129).  During the active resolution of 
inflammation, RvD1 may be playing its part in tissue catabasis by elevating ASL 
height to encourage muco-ciliary clearance to flush inflammatory cells and debris 
trapped in mucous from the airway and restore airway homeostasis. 
 
3.4.4 Resolvin D1 and the ALX/FPR2 Receptor  
RvD1 was reported to signal through the GPR32 orphan receptor and ALX/FPR2 
receptor (294, 295). GPR32 expression is reported in peripheral blood leukocytes, 
vascular tissue and small airway epithelial cells (295, 321).  ALX/FPR2 is 
expressed in several types of cells including; neutrophils (306), alveolar 
macrophages (259, 322), human bronchial epithelial cells and human bronchial 
biopsy sections (323).  
 
Evidence for a role played by the ALX/FPR2 receptor in the RvD1 mediated 
increase in ASL height in CFTR dysfunctional bronchial epithelial cells came from 
the demonstration that Boc-2 (pharmacological inhibitor of ALX/FPR2) completely 
abolished the ASL height increase.  GPR32 expression has not been reported in 
bronchial epithelial cells and a pharmacological inhibitor is not yet commercially 
available.  Further clarification of the involvement of ALX/FPR2 in the effect 
reported could be achieved by selective ALX/FPR2 receptor knockdown using 
siRNA (358). 
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The ALX/FPR2 agonist LXA4 is reported to enhance the activity of the ALX/FPR2 
promoter (327).  Al-Alawi et al. reported differential cellular localisation of the 
ALX/FPR2 receptor between NuLi-1 and CuFi-1 cells, and an effect of LXA4 in 
recruiting ALX/FPR2 to the apical membrane in CuFi-1 cells (356).  We found no 
overall difference in the total protein concentration of ALX/FPR2 receptor between 
Nuli-1 and CuFi-1 cell lines, and no effect of RvD1 on whole cell ALX/FPR2 
receptor protein expression in NuLi-1 or CuFi-1 cells.  In resolving exudates, LXA4 
biosynthesis precedes RvD1 (253), and the effect of LXA4 on ALX/FPR2 
expression and trafficking might be important in sensitising the tissue to be able to 
receive and act upon the RvD1 signal.   
 
3.4.5 Resolvin D1 Inhibited NFĸB activation 
Excessive NFĸB activation has been observed in CF (65, 188, 189).  At rest, NFĸB 
dimers are bound to inhibitory IĸB proteins which sequester NFĸB complexes and 
maintain them in an inactive state in the cytoplasm (399).  TNFα is a pro-
inflammatory cytokine that interacts with its specific receptor to transduce a signal 
that results in phosphorylation, ubiquitination and degradation of IĸB proteins (400, 
401).  Degradation of IĸB releases NFĸB and allows its translocation to the 
nucleus, where it binds to its site in the promoter regions of pro-inflammatory 
genes such as the IL-8 gene, rapidly up-regulating pro-inflammatory cytokine 
synthesis.  RvD1 was shown to supress NFĸB activation in a mouse model of LPS 
induced lung inflammation (335).  In this study we demonstrate that RvD1 
antagonises TNFα mediated IL8 secretion by preserving the integrity of IĸB in 
CuFi-1 bronchial epithelial cells.   
 
Zheng et al. recently reported that TAK1 (TGF-β-activated kinase 1) is an 
indispensable signalling intermediate in the TNF signalling pathway (400, 402).  
TNF stimulation results in TAK1 phosphorylation and activation via the assembly 
of a TAK1 signalling complex, containing; TNF receptor-associated factor (TRAF), 
and TAK1-binding proteins, (TAB1–TAB3) (402, 403).  Activated TAK1 
phosphorylates and activates the IĸB kinase kinase complex, leading to the 
phosphorylation of IĸB and release of NFĸB (401).  Consistent with our findings, 
Hsiao et al. recently identified the mechanism by which RvD1 disrupts pro-
inflammatory signalling pathways.  Although we did not specifically measure TAK1 
phosphorylation, Hsiao identified TAK1 as the physiological target of RvD1 in 
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human small airways epithelial cells (321); RvD1 treatment largely blocked TAK1 
phosphorylation, and the formation of the TAK1 / TAB1 / TRAF6 signalling 
complex (321) (illustrated in Figure 3-12).  Furthermore, RvD1 is reported to 
regulate NFĸB signalling via microRNA circuits, including miR-146b (255). 
 
 
Figure 3-12  Proposed mechanism for RvD1 mediated antagonism of TNFα 
mediated IL8 secretion 
TNF stimulation results in TAK1 phosphorylation and activation via the assembly 
of a TAK1 signalling complex with TNF receptor-associated factor 6 (TRAF6), and 
TAK1-binding protein 1, (TAB1).  Activated TAK1 phosphorylates and activates the 
IĸB kinase kinase complex (IKK Complex), leading to the phosphorylation of IĸB 
and release of NFĸB.  RvD1 blocks TAK1 phosphorylation, and the formation of 
the TAK1 / TAB1 / TRAF6 signalling complex (321, 400).   
 
Excessive NFĸB activation (65, 188, 189) associated with elevated IL8 
concentrations in the CF airway plays a role in the characteristic excess neutrophil 
recruitment into the airway (65, 187), which is attended by the release of tissue 
damaging Neutrophil Elastase (66).  Favourable effects of RvD1 attenuating NFĸB 
activation and IL8 secretion in CF airway epithelial cells might be expected to 
reduce neutrophil recruitment and dampen exaggerated pro-inflammatory 
cascades. 
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3.4.6 Resolvin D1 enhances alveolar macrophage mediated phagocytosis  
Alveolar macrophages play diverse roles in airway innate immunity including; 
phagocytosis of dead cells and debris; phagocytosis and killing of bacteria; 
cytokine synthesis; tissue remodelling and repair (404).  CFTR expression in 
macrophages has been reported (126, 224, 336) and in CF, macrophage defects 
reported include; impaired clearance of apoptotic cells (218, 219), and impaired 
intracellular killing of bacteria (125, 126).   
 
Using primary CF alveolar macrophages and an in vitro phagocytosis assay based 
on the uptake of immunoglobulin labelled beads, we report that RvD1 improves 
the phagocytic capacity of primary CF alveolar macrophages.   
 
Phagocytosis is an actin-dependent process whereby particulate targets are 
specifically internalised via diverse mechanisms.  A major function of SPM’s is to 
enhance phagocyte function, especially macrophage-mediated efferocytosis (253, 
259).  Consistent with this role, RvD1 was reported to increase neutrophil 
efferocytosis in a mouse model of cigarette smoke induced lung inflammation 
(336).  Pseudopod formation and particle engulfment depend on remodelling of the 
actin cytoskeleton.  Notably, LXA4 was reported to stimulate RhoA- and Rac-
dependent cytoskeleton reorganization, enhancing apoptotic neutrophil uptake 
(405).   
 
The in vitro phagocytosis assay used does not discriminate well between 
biological effects on different targets.  Macrophage phagocytic targets may include 
micro-organisms, dead or dying cells or environmental debris (404).  A phagocytic 
target of interest for CF research is neutrophil efferocytosis by macrophages, since 
it plays a key role in the restoration of tissue homeostasis, and initiates the 
synthesis of pro-resolution mediators (300, 301) in a virtuous cycle.  This concept 
will be explored further in Chapter 8 (General Discussion).  
 
3.4.7 Resolvin D1 enhances alveolar macrophage mediated intracellular killing of 
Pseudomonas aeruginosa  
Micro-organisms are a target of macrophage mediated phagocytosis which is 
particularly relevant in CF. Impaired intracellular bacterial killing of Pseudomonas 
aeruginosa has been reported in several studies of human and mouse CF 
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macrophages (125-127).  This has been mechanistically attributed to CFTR’s 
involvement in lysosomal acidification, though some debate surrounds this finding 
depending on the technique used by different investigators (126, 229).  Altered 
ceramide concentration was linked to altered pH and the release of reactive 
oxygen species in CF macrophages (230).  Defective endosome to late-
endosome/lysosome maturation is a feature of  LPS challenge  (227) and impaired 
phagocytic capacity of human CF macrophages  (or CFTR inhibited, non-CF 
macrophages), has been reported (127, 228). 
 
Here we report that RvD1 improved primary CF alveolar macrophage intracellular 
killing of the PAO1 lab strain of Pseudomonas aeruginosa. 
 
Following engulfment and maturation (406), microbicidal mechanisms operating 
within the phagolysosome lumen of a macrophage include; acidification via V-
ATPase proton pumps (407), reactive oxygen and nitrogen species (ROS, RNS) 
generation by NADPH oxidase and inducible nitric oxide synthetase / isoform 2 
(iNOS / NOS2) (406, 408), lactoferrin mediated scavenging of iron, defensin 
mediated antimicrobial effects, and the action of degradative enzymes (406) 
(illustrated in Figure 3-13 ).   
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Figure 3-13 Bacterial killing mechanisms active within the lumen of a 
macrophage phagolysosome 
Microbicidal mechanisms include; acidification via V-ATPase proton pumps, 
reactive oxygen and nitrogen species (ROS, RNS) generation by NADPH oxidase 
and inducible nitric oxide synthetase / isoform 2 (iNOS / NOS2), lactoferrin 
mediated scavenging of iron, defensin mediated antimicrobial effects, and the 
action of degradative enzymes (adapted from (406)).   
 
The SPM’s as a family, are reported to improve bacterial killing in animal models 
of sepsis; LXA4 administration resulted in a reduced bacterial load in a mouse 
model of P. aeruginosa infection (315); a panel of SPM’s, specifically, RvD1, 
Resolvin D5 and Protectin D1 improved the containment of a bacterial challenge in 
mouse models of peritoneal infection, and skin sepsis, acting in synergy with 
antibiotics (316).  The specific cellular mechanisms by which SPM’s enhance 
bacterial killing have yet to be described.   
 
In light of previous reports that LXA4 stimulated cytoskeletal reorganisation, it is 
conceivable that RvD1 improves intracellular killing by accelerated recruitment of 
vesicles via the endocytic pathway to fuse with the phago-lysosome (406).  We 
have observed effects of RvD1 on ion transport in epithelia and so we could 
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hypothesise that RvD1 affects phago-lysosome acidification.  Alterations in 
cytosolic calcium concentration drive granule fusion in phagosomes in neutrophils 
(409, 410).  Another hypothesis could be that RvD1 enhances vesicle recruitment 
to the phago-lysosome via effects on intracellular calcium mobilisation.  Counter-
intuitively, LXA4 was described to inhibit peroxynitrite formation and block 
superoxide anion generation by neutrophils (262, 320).  We do not know if this 
kind of physiological function of SPM’s is ligand specific, or cell type specific, and 
perhaps the opposite effect of enhanced reactive oxygen and nitrogen species 
generation would be seen with RvD1 in macrophages. 
 
RvD1 is synthesised from the parent essential fatty acid DHA which has been 
reported to be deficient in CF (346, 347).  RvD1 biosynthesis involves two 
sequential lipoxygenation steps both catalysed by 15 Lipoxygenase. We have 
previously reported deficient 15LO expression in the CF airway (370).  Therefore, 
it remains to be established whether RvD1 is adequately produced in the CF 
airway.   
 
3.4.8 Limitations of this study 
Whilst the effect of RvD1 on ASL height represents an exciting therapeutic angle 
this work is incomplete.  It remains critical to the application of this work to further 
define which ASL regulatory pathways are involved in transducing this effect.  
Furthermore, demonstrating the effect of RvD1 on a more complex model of 
muco-ciliary clearance (e.g. radiolabelled marker clearance) could provide an 
important clinical research outcome and advance the case for clinical trials (411).  
The studies of alveolar macrophage function were conducted in relatively small 
numbers of patient samples.  These samples were vulnerable to selection bias 
since the method to isolate these samples from BAL relied on a favourable 
neutrophil / macrophage cell differential and a lower burden of infection in BAL.  A 
more clinically relevant strain of Pseudomonas aeruginosa could have been used 
in the study of RvD1 effect on intracellular killing of bacteria by CF alveolar 
macrophages.  
 
3.5 Conclusion 
We report that RvD1 elevates ASL height in CF epithelial cells, attenuates TNFα 
stimulated IL8 secretion by preserving intact IĸB in CuFi-1 cells, enhances the 
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phagocytic capacity of primary CF alveolar macrophages, and, improves primary 
CF alveolar macrophage intracellular killing of Pseudomonas aeruginosa.   
 
There are unmet needs in CF therapy for treatments to rehydrate the airway and 
improve muco-ciliary clearance, augment the effectiveness of existing antibiotics 
and strengthen the host immune response (252).  This work suggests significant 
therapeutic potential for RvD1 in CF lung disease. 
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CHAPTER 4 
ABNORMAL CLASS SWITCHING IN CF BAL: DEFECTIVE LIPOXIN A4 
SYNTHESIS 
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4 Abnormal Class Switching in CF BAL: Defective Lipoxin A4 Synthesis 
4.1 Introduction  
A normal host response to bacterial infection involves neutrophil recruitment and 
inflammation that serves to contain and eliminate the bacterial insult.  In CF, an 
excessive neutrophil burden, persistent inflammation and failure of tissue 
clearance of neutrophils by efferocytosis have been described (412).   
 
This failure to resolve inflammation in CF could be due to abnormal function and / 
or production of the SPM’s central to the active resolution of inflammation.  We 
recently published most of the data presented in this chapter in the European 
Respiratory Journal (370).  
 
4.1.1 Eicosanoid Class Switching 
In the normal regulation of inflammation, the temporal progression of acute 
inflammation from initiation to propagation and finally to active resolution is 
executed via the sequential biosynthesis of eicosanoid classes in inflammatory 
exudates in a process termed “class switching” (264).  Prostaglandins initiate the 
inflammatory response, followed by Leukotrienes, typified by Leukotriene B4 
(LTB4) which amplifies and propagates inflammation (264).  Lipoxin A4 (LXA4) 
biosynthesis initiates the active resolution phase of inflammation (257) and is 
followed by biosynthesis of the Resolvins, Protectins and Maresins.     
 
4.1.2 Lipoxin A4 Effector Functions 
LXA4 inhibits neutrophil effector functions (267), and counter-regulates the effector 
functions of LTB4 (303, 360, 413).  Furthermore, the tendency for neutrophils to 
migrate into tissues is regulated by the relative concentrations of LXA4 and LTB4 
(Figure 4-1) (262, 304, 323, 360, 414).  Mice treated with analogues of LXA4 and 
subsequently challenged with P. aeruginosa contained the bacterial challenge 
more effectively (315). 
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Figure 4-1  Reported inhibition of LTB4 induced endothelial adhesion of 
neutrophils by LXA4   
LXA4 caused a rapid inhibition of LTB4 induced neutrophil adhesion to endothelium 
(reproduced from Papayianni et al (304)).   
 
4.1.3 LXA4 Biosynthesis 
LXA4  is biosynthesised in the respiratory tract by trans-cellular co-operation of 
neutrophils (275), eosinophils (276), alveolar macrophages (277) or airway 
epithelial cells (278), each expressing different Lipoxygenase (LO) enzymes 
(illustrated in Figure 4-2 (415, 416)).  The 15-Lipoxygenase (15-LO) catalysis step 
is key to LXA4 biosynthesis, and up-regulation of 15-LO activity favours LXA4 
biosynthesis at the expense of Leukotriene biosynthesis (264, 417).  This occurs 
both as a result of 15-LO product 15-HETE competing for catalytic sites at the 5-
LO enzyme and thereby reducing the formation of 5(S) HETE, and by competition 
for the common biosynthetic intermediate Leukotriene A4 (264, 278, 416, 417). 
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Figure 4-2  An illustration of LXA4 biosynthesis pathways by trans-cellular 
co-operation in in the airways   
(A) The neutrophil donates LTA4 intermediate formed by the action of 5 
Lipoxygenase on Arachidonic acid to the acceptor airway epithelial cell or alveolar 
macrophage whereby 15 Lipoxygenase catalyses LXA4 formation.  LTB4 is also 
generated from the LTA4 intermediate by the action of Leukotriene A4 Hydrolase.  
(B) Airway epithelial cell or alveolar macrophage 15 Lipoxygenase activity 
catalyses the conversion of Arachidonic acid to 15S H(p)ETE which is donated to 
the acceptor neutrophil and converted to LXA4  by 5 Lipoxygenase catalysis 
(reproduced from (370)).  
 
4.1.4 LXA4 in CF 
In CF bronchial epithelial models, LXA4  augments airway epithelial innate defence 
by stimulating tight junction formation (357),  enhancing Calcium activated 
Chloride secretion (318), inhibiting sodium absorption (356), and restoring airway 
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surface liquid height (355).  LXA4 concentration in CF BAL has been variously 
reported as significantly suppressed or not significantly different from disease 
controls (315, 352).   
 
4.2 Aims 
The underlying basis for the failure to actively resolve inflammation in the CF 
airway remains incompletely understood.  One primary function of SPM’s is to limit 
neutrophil recruitment and enhance tissue neutrophil clearance, thus enacting the 
active resolution of inflammation (253).  In CF, neutrophil recruitment is excessive, 
the airway burden is high and inflammation is prolonged and ineffective and leads 
to tissue damage (221).  LXA4 is the first SPM to be synthesised in the acute 
resolution phase of inflammation and has key regulatory effects on tissue 
neutrophil burden.  LXA4 is generated following a “class switch” in eicosanoid lipid 
mediator synthesis from leukotrienes to lipoxins via up-regulation of the synthetic 
enzyme, 15 Lipoxygenase (264).   
 
It was our aim to examine eicosanoid mediator class switching (critical to the 
transition into active resolution of inflammation) in the CF airway, and to evaluate 
the impact of bacterial infection on this process.  
 
4.3 Hypothesis 
We hypothesised that;  
 
 “Eicosanoid mediator class switching” is defective in CF and may play a 
mechanistic role in the failure to resolve inflammation in CF lung disease.   
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4.4 Results  
In order to investigate the role of eicosanoid mediator class switching in the failure 
to actively resolve inflammation in the CF lung, we examined Bronchoalveolar 
lavage samples (BAL) from participants enrolled in the SHIELD CF study 
(described in more detail in Chapter 2).   
 
The study population for this piece of work included children with CF, and, as a 
comparative, control children without CF who were undergoing bronchoscopy for 
clinical reasons.  Assessments were undertaken when the children were in a 
stable clinical condition.   
 
In order to further understand the influence of bacterial infection in the lung upon 
eicosanoid mediator profiles and synthesis, semi-quantitative conventional 
bacterial and viral studies were performed on BAL by the microbiology lab at 
OLCHC.  We conducted subgroup analysis of our data based on the presence or 
absence of microbial pathogens detected in the BAL fluid.  Samples were 
considered to have positive microbial culture if one or more pathogen was 
detected on viral studies or cultured at a concentration of >104 CFU/ml.   
 
4.4.1 Population Characteristics 
Fifty one BAL samples from children with CF (CF) and twenty two from Paediatric 
Control patients (control) were assessed for eligibility in this study.  Five children 
with CF and three Control children were excluded because of Leukotriene 
Receptor antagonist treatment or recent use of treatment dose antibiotics.  CF and 
control children did not differ significantly in age, sex or BAL neutrophil count 
(Table 4-1)(370). 
 
Looking at the subgroup populations (based on the presence or absence of >104 
CFU/ml pathogenic bacteria cultured from the BAL specimen) in this study; control 
children with positive BAL microbial culture were younger than control children 
with negative BAL microbial culture; whereas, children with CF and positive BAL 
microbial culture were older than children with CF and negative BAL microbial 
culture.   
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Infection in CF BAL samples was associated with a higher mean neutrophil count 
and more frequently detectable Neutrophil Elastase than was found in culture 
negative CF BAL samples (Table 4-1).  The most common bacterial pathogens 
cultured were H. influenza, S. aureus and S. pneumoniae.  P. aeruginosa >104 
CFU/ml was identified in two CF and one Control BAL sample.  Viral studies were 
negative for all 51 BAL samples examined. (370) 
 
Table 4-1 Population Characteristics   
Data are presented for the complete control and CF groups and separately for 
subgroups based on the presence or absence of >104 cfu/ml pathogenic bacteria 
cultured from the BAL specimen.  (*P<0.05 / **P<0.01 within group unpaired 
comparison of subgroups; #P<0.05 between group unpaired comparison of 
subgroups; Student’s t-test) (**P<0.01, within group comparison; Fisher’s Exact 
Test)(Reproduced from (370)). 
 Non-CF Control CF 
 No 
Growth 
Cult(-) 
Pathogen 
Cultured 
Cult(+) 
All 
Control 
No 
Growth 
Cult(-) 
Pathogen 
Cultured 
Cult(+) 
All  
CF 
Procedures n=7 n=12 n=19 n=24 n=22 n=46 
Subjects   n=19   n=34 
Mean Age  
(SD) 
8.2** 
(4.3) 
2.7** 
(1.6) 
4.5 
(3.6) 
2.7* 
(1.5) 
3.8* 
(1.4) 
3.2 
(1.6) 
Male Sex  
(%) 
2 
(28.6) 
8 
(66.7) 
10 
(52.6) 
12 
(50) 
12 
(54.5) 
24 
(52.2) 
Neutrophils 
x105/ml  (SEM) 
0.8# 
(0.6) 
8.1 
(4.0) 
5.7 
(2.8) 
3.5** 
(1.0) 
12.8**/# 
(2.8) 
8.0 
(1.6) 
Detectable NE  
(%) 
3 
(42.9) 
5 
(41.7) 
8 
(42.1) 
9# 
(37.5) 
17# 
(77.3) 
26 
(56.5) 
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4.4.2 Baseline inflammatory parameters & their relationship to pulmonary 
infection  
LTB4 is associated with the propagation of inflammation and predominates before 
the “eicosanoid class switch (264)” towards resolution of inflammation.  After the 
“class switch” LXA4 is the sentinel pro-resolution mediator synthesised (264).  
LXA4 directly counter-regulates LTB4 effector functions (303, 360, 413).  IL8 is a 
key neutrophil chemoattractant and pro-inflammatory cytokine which is 
suppressed by LXA4 (262, 323, 414). We measured the concentration of LXA4, 
LTB4 and IL8 in BAL supernatant by ELISA and compared the results obtained 
between non-CF and CF samples, and those with either positive or negative 
bacterial culture results. 
 
We found no significant differences between control (n=19) and CF samples 
(n=46) in mean LXA4 or LTB4 concentration (Figure 4-3A & C).  Furthermore, 
comparison of culture negative and culture positive samples from control or CF 
BAL revealed no significant difference in LXA4  concentration (Figure 4-3B).   
 
LTB4 concentration was significantly higher in infected BAL samples within a group 
(control/cult(+): 155 ±40pg/ml, n= 12 vs. control/cult(-): 26 ±12pg/ml, n=7, P<0.05 
& CF/cult(+): 1383 ±454pg/ml, n=22 vs. CF/cult(-): 156 ±35pg/ml, n=24, P<0.01) 
(Figure 4-3D).   
 
IL8 was higher in CF (n=46) than in control (n=19) BAL samples (1198 ± 149ng/ml 
vs. 379 ±110ng/ml, P<0.01) (Figure 4-3E).  IL8 was higher in culture negative CF 
samples (n=n=24) than in culture negative control samples (n=7) (817 ±178ng/ml 
vs. 110 ±28ng/ml, P<0.05) (Figure 4-3F).  Culture positive CF BAL samples had 
higher IL8 concentrations than either culture negative CF samples (1614 
±215ng/ml, n=22 vs. 817 ±178ng/ml, n=24, P<0.01) or culture positive control 
samples (1614 ±215ng/ml, n=22 vs. 536 ±159ng/ml, n=12, P<0.01).     
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Figure 4-3  Baseline inflammatory parameters & their relationship to 
pulmonary infection   
Left Panel: Comparison of mean (A) LXA4 (ng/ml), (C) LTB4 (pg/ml), and (E) 
Interleukin 8 (ng/ml) values measured in Control (n=19) and CF (n=46) BAL.  Right 
Panel: Subgroups of the Control and CF cohorts based on the presence or 
absence of >104 CFU/ml pathogenic bacteria cultured from the BAL specimen.  
Mean (B) LXA4 (ng/ml) (D) LTB4 (pg/ml), and (F) Interleukin 8 (ng/ml).  Lighter 
shaded bars represent BAL from which no pathogens were grown (n=7 control, 
n=24 CF samples) and darker shaded bars represent BAL from which pathogens 
were cultured (n=12 controls, n=22 CF samples).  (Error bars represent SEM; 
*P<0.05, **P<0.01, ***P<0.001; Student’s t test). (Reproduced from (370)). *BAL 
was obtained via the SHIELD CF study. 
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4.4.3 LXA4 relative to LTB4 and IL8   
Looking at relative LXA4  and LTB4 concentrations, expressed as a ratio, allows us 
to evaluate the extent of eicosanoid mediator transition from propagation phase 
mediators to early resolution mediators.  Children with CF (n=46) had lower LXA4 
/LTB4 ratios in BAL fluid compared with control children (n=19) (2.9 ±0.7 vs. 7.1 
±1.9, P<0.01) (Figure 4-4A).  Among control samples, the LXA4 /LTB4 ratio in 
sterile samples (n=7) was significantly higher (3.7 ±1.31 vs. 3.1 ±3.6, P<0.01) than 
that measured in BAL samples from which pathogens were cultured (n=12) (Figure 
4-4).  In CF BAL (n=46), the LXA4 /LTB4 ratio was uniformly depressed, and did 
not vary with infection status (P=0.98).  The LXA4 /LTB4 ratio measured in culture 
negative CF samples (n=24) was significantly depressed in comparison to culture 
negative control BAL samples (n=7) (CF/cult(-): 2.9 ±0.7 vs. Control/cult(-): 13.1 
±3.6, P<0.001). (370) 
 
Furthermore, since LXA4 counter-regulates IL8 synthesis and function LXA4 /IL8 
ratios were also calculated.  The LXA4 /IL8 ratio was significantly higher in control 
BAL than in CF BAL (3.5x10-3 ±1.7x10-3, n=19 vs. 0.5x10-3 ±0.1x10-3, n=46, 
P<0.01) (Figure 4-4C).  The LXA4 /IL8 ratio was significantly higher in culture 
negative control BAL (n=7) than culture positive control BAL (n=12) (7.9x10-3 
±4.2x10-3 vs. 0.9x10-3 ±0.2x10-3, P<0.05) (Figure 4-4D).  The LXA4 /IL8 ratio 
measured in culture negative CF BAL (n=24) was significantly low compared with 
culture negative control BAL (n=7) (0.6x10-3±0.2x10-3 vs. 7.9x10-3 ±4.2x10-3, 
P<0.01).  In CF BAL, the LXA4 /IL8 ratio was uniformly depressed and the 
correlation with infection seen in control BAL was absent. (370) 
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Figure 4-4  LXA4 relative to LTB4 and IL8   
(A)  Mean LXA4 (pg/ml) / LTB4 (pg/ml) ratio measured in Control (n=19) and CF 
BAL (n=46).  (B) Mean LXA4 (pg/ml) / LTB4 (pg/ml) ratio compared between No 
Growth and Pathogen Cultured subgroups of the Control and CF cohorts.  (C)  
Mean LXA4 (pg/ml) / IL8 (ng/ml) ratio measured in Control and CF BAL. (D) Mean 
LXA4 (pg/ml) / IL8 (ng/ml) ratio compared between No Growth and Pathogen 
Cultured subgroups of the Control and CF cohorts. Growth defined as >104 cfu/ml 
pathogenic bacteria cultured from the BAL specimen.  Lighter shaded bars 
represent No Growth (n=7 Control, n=24 CF Samples) and darker shaded bars 
represent Pathogen Cultured BAL (n=12 Control, n=22 CF samples).  (Error bars 
represent SEM; *P<0.05, **P<0.01, ***P<0.001; Student’s t test). (Reproduced 
from (370)).  *BAL was obtained via the SHIELD CF study. 
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4.4.4 Abundance of transcripts for enzymes involved in eicosanoid synthesis 
quantified in the cellular phase of BAL  
15-Lipoxygenase (15-LO) catalysis is key to LXA4 biosynthesis, and up-regulation 
of 15-LO activity favours LXA4 biosynthesis at the expense of Leukotriene 
biosynthesis (264, 417).  In order to study the expression of genes involved in 
LXA4  and LTB4 biosynthesis in the airway lumen, we measured the relative 
expression of mRNA transcripts for; 5-LO, 12-LO, 15-LO 1/2 and Leukotriene A4 
Hydrolase (LTA4H), in BAL cell pellets by qPCR.  Samples from children with CF 
were compared to paediatric controls.   
 
For this analysis, fourteen control samples (7 culture-negative control and 7 
culture-positive control) and eleven CF samples (6 culture-negative CF and 5 
culture-positive CF) with a similar distribution of infection, neutrophil (P=0.95) and 
macrophage (P=0.71) compositions were used (Figure 4-5E & F) (370). 
 
The cellular fraction obtained from the airway lumen contained a full repertoire of 
transcripts required for LXA4 biosynthesis (Figure 4-5).  ALOX15B mRNA was 
significantly less abundant in CF samples (n=11) compared to control samples 
(n=14) (0.44 ± 0.13 vs. 2.63 ± 0.92 fold expression, P<0.05) (Figure 4-5A).  A non-
significant trend towards lower ALOX15 expression was observed in CF BAL 
(n=11) than in control BAL (n=14) (1.92 ± 0.49 vs. 5.51 ± 1.89 fold expressed, 
P=0.09) (Figure 4-5B).   
 
ALOX5 and LTA4H mRNA abundance did not significantly differ between control 
(n=14) and CF samples (n=11) (Figure 4-5C & D).  ALOX12 mRNA was 
measurable in only 6/14 Control samples and in 4/11 of the CF samples. (370) 
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Figure 4-5  Abundance of transcripts for enzymes involved in eicosanoid 
synthesis quantified in the cellular phase of BAL   
(A) ALOX15B, (B) ALOX15, (C) ALOX5 & (D) Leukotriene A4 Hydrolase mRNA 
transcript relative abundances in the cellular component of the bronchoalveolar 
lavage fluid from a subset of the Control (n=14) and CF (n=11) samples.  Results 
are expressed as Fold Expression = 2^(-ΔΔCt) compared to a reference patient 
sample.  (E) Macrophage & (F) and Neutrophil composition of the Control and CF 
cell pellets expressed as % of nucleated cells assessed by light microscopy.  
(Error bars represent SEM; NS = Not Significant, *P<0.05; Student’s t 
test)(Reproduced from (370)).  *BAL differential cell counts in the SHIELD CF 
Study were performed by Dr Michael McDermott.         
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4.4.5 ALOX15B Correlates  
We further explored the relationships between ALOX15B mRNA expression in the 
airway lumen and the ratio of LXA4 /LTB4 in the sample.   
 
In control BAL samples (n=14) there was a significant positive correlation between 
ALOX15B mRNA abundance in the cell pellet and LXA4 /LTB4 ratio (r = 0.66, 
P=0.01) (Figure 4-6A).  In CF samples (n=11) this correlation was absent (P = 
0.31) (Figure 4-6B).   
 
Neutrophils and macrophages are the most abundant cell types in the BAL cell 
pellet.  In order to understand which cell types were most responsible for 
ALOX15B mRNA expression in the airway we studied the correlation between % 
Neutrophil and % Macrophage composition of the BAL cell pellet and the 
expression of ALOX15B mRNA.  In control samples (n=14) ALOX15B mRNA 
abundance correlates positively, strongly and significantly with macrophage 
percentage composition of the pellet (r= 0.82, P=0.0003) and, negatively with 
neutrophil percentage composition (r= -0.82, P=0.0003) (Figure 4-6C&D).  
However, in CF samples (n=11), despite variability in the macrophage composition 
of the samples, the correlation of ALOX15B abundance with macrophage / 
neutrophil composition was absent (P=0.20 & P= 0.17) (Figure 4-6E&F).   
 
Variability in the abundance of ALOX5 mRNA, recognised to be expressed 
abundantly both by neutrophils and alveolar macrophages (418-420), did not 
significantly correlate with cell type for control (n=14) or CF (n=11) samples.   
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Figure 4-6  ALOX15B Correlates   
Correlation between ALOX15B transcript relative abundance and; LXA4  / LTB4  
ratio from (A) Control (n=14) and (B) CF (n=11) samples;  BAL % Neutrophil from 
(C) Control and (E) CF samples;  BAL % Macrophage composition from (D) 
Control and (F) CF samples.  Fold Expression = 2^(-ΔΔCt) of ALOX15B mRNA 
versus reference patient sample.  % Macrophages and Neutrophils represent % of 
nucleated cells in the cellular phase of the bronchoalveolar lavage fluid assessed 
by light microscopy.  LXA4 (pg/ml) / LTB4 (pg/ml) ratio as measured in the BAL 
supernatant.  (Spearman correlation coefficient (r) and associated P value given 
for each analysis). (Reproduced from (370)).  * BAL differential cell counts in the 
SHIELD CF Study were performed by Dr Michael McDermott.   
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4.5 Discussion  
Under normal circumstances, lung inflammation serves to eliminate the original 
threat, and then actively resolve and return the tissue to homeostasis (253).  In 
CF, however, the neutrophil predominant response is severe, sustained and 
persistent even if the original inflammatory stimulus is removed (221).  The 
underlying basis for this failure of active resolution remains incompletely 
understood. 
 
In this study we demonstrated defective eicosanoid class switching, a key step in 
initiating the active resolution of inflammation, in the lower airways of young 
children with CF, despite the absence of recognised pathogens.  We have 
presented in vivo evidence of impoverished 15 Lipoxygenase-2 gene expression 
associated with a depressed LXA4 / LTB4 ratio in the lower airways of children with 
CF.  Furthermore, we found that the correlations between LXA4 /LTB4 ratio, 
infection, abundance of 15-LO2 transcripts and macrophages observed in control 
BAL were lost in CF BAL. This report provides new and important insights into the 
failure to resolve inflammation in CF lung disease (370). 
 
In order to test the hypothesis that eicosanoid class switching is defective in CF 
giving rise to a failure to resolve acute inflammation, we looked at the in vivo 
expression of eicosanoids and their synthetic enzymes.  We compared 
eicosanoids temporally associated with the “switch” from propagation to resolution; 
LTB4 and LXA4, respectively.  Additionally, with the expectation that the phase of 
inflammation would be affected by the infectious context (354), we conducted 
subgroup analysis based on the presence or absence of microbial pathogens 
detected in the BAL fluid.  By comparing relative mediator concentrations 
expressed as a LXA4 /LTB4 ratio, we demonstrate that the balance in eicosanoid 
biosynthesis weighs heavily in favour of LXA4 production over LTB4 production in 
control BAL when compared to CF BAL (Figure 4-4).  This finding indicates an 
abnormality in the active resolution of inflammation in CF and is consistent with the 
reduced LXA4 /IL8 ratio in CF compared to control BAL also reported here (Figure 
4-4) (370).   
 
Consistent with a previous report (352), we did not find significant differences 
when comparing control and CF BAL, directly or in sub-population analyses 
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(based on microbial culture result), as regards the absolute content of LXA4   
(Figure 4-3).   One other study suggested there is a failure to resolve acute 
inflammation in CF and reported a significant suppression in the ratio of LXA4 
/Neutrophils in CF (315).  In our study, we did not find any significant difference in 
LXA4 /Neutrophils ratio between control and CF BAL (data not illustrated).  This 
could potentially be explained by differences in the control population between that 
study and ours, especially with regards to allergic airways disease and infection.   
Although LTB4 concentration did not significantly differ between control and CF 
BAL (Figure 4-3), we found that LTB4 concentration was always higher in infected 
BAL sub-groups consistent with its role in neutrophil recruitment and host defence.  
It is noteworthy that a negative correlation has been described between LTB4 and 
pulmonary function outcome in CF (214, 370). 
 
LXA4 and its synthetic analogues have been shown, in vitro, to suppress IL8 
production by leukocytes and bronchial epithelial cells (262, 323).  As such, the 
LXA4 /IL8 ratio represents a compound outcome incorporating both the local 
concentration of each mediator, and the effectiveness of LXA4 in antagonising IL8 
production.  In control samples the LXA4 /IL8 ratio was significantly lower in the 
presence of infection in BAL, consistent with an appropriate pro-inflammatory 
response to infection.  In contrast, the higher LXA4 /IL8 ratio seen in uninfected 
control BAL, in favour of the resolution of inflammation, was absent in uninfected 
CF BAL where the ratio remained low independent of infection.     
 
In the absence of airway infection in control children, the balance between LXA4 
and LTB4 biosynthesis was skewed in favour of LXA4 production, reflecting on-
going active resolution of inflammation.  Furthermore, the results presented in this 
Chapter provide in vivo evidence that LXA4 /LTB4 balance in control children’s 
lower airways correlates strongly with the abundance of 15-LO2 transcripts in the 
cellular phase of BAL. This finding is consistent with in vitro reports that 15-LO 
enzyme activity promotes LXA4 biosynthesis at the expense of Leukotriene 
biosynthesis (264, 417).  In the control population, we also find a positive 
correlation between 15-LO2 transcript abundance and the percentage 
macrophage composition of the BAL cell pellet, and reciprocally, a negative 
correlation with the percentage neutrophils (Figure 4-6). This is consistent with the 
recognised expression of 15-LO, and 15(S)-HETE and LXA4 generation by human 
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alveolar macrophages (277).  Although both neutrophils and macrophages in 
induced sputum both expressed 15-LO, the majority has been attributed to 
macrophages (421).  Furthermore, 15-LO 2 (ALOX15B) is the predominantly 
expressed Lipoxygenase in human macrophages (280).   (370)      
 
Taken together our observations suggest that macrophages, by expressing 15-
LO2 and participating in trans-cellular co-operation with neutrophils expressing 5-
LO, make a significant contribution to LXA4  synthesis in the bronchial lumen and 
regulate eicosanoid balance in vivo in the airway (370).  This idea will be further 
explored mechanistically in Chapter 5.  
 
In CF, in contrast to our findings in control children’s BAL, the bias in favour of 
LXA4 production in uninfected BAL was absent.  LXA4 /LTB4 and LXA4 /IL8 ratios 
were not significantly different between non-infected and infected CF BAL 
subgroups (Figure 4-4).  In order to further our understanding of impaired 
eicosanoid class switching in CF we considered the roles played by various 
enzymes involved in eicosanoid biosynthesis (12-LO, LTA4H, 5-LO, 15-LO1 and 
15-LO2).  The activity of 12-LO in platelets from CF patients has been reported to 
be reduced (351).  In our study, 12-LO transcripts were detected at very low copy 
numbers in only ten of twenty five airway samples tested.  12-LO is 
characteristically expressed within platelets and therefore this finding might 
possibly represent blood cell contamination from a friable and inflamed airway 
wall.  Over-expression of Leukotriene A4 Hydrolase (LTA4H) could result in a steal 
phenomenon, routing the common immediate Leukotriene A4 away from LXA4 
synthesis towards LTB4 synthesis giving rise to the reduced LXA4 /LTB4 ratio 
observed, however expression was not significantly different in CF BAL than in 
control BAL.  We observed non-significant trends towards lower abundance of 15-
LO1 and 5LO transcripts in CF airway (Figure 4-5) (370). 
 
At the same time as the publication of the results presented in this Chapter, 
Fredman et al. (422) reported that the balance between arachidonic acid-derived 
mediators in leukocytes was regulated by the cellular localization of 5-LO; with 
nuclear 5-LO localisation favouring LTB4 biosynthesis, whereas, cytoplasmic 5-LO 
localisation favours the biosynthesis of LXA4  (422).  They also found that RvD1 
promotes nuclear exclusion of 5-LO and thereby suppresses LTB4 and enhances 
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LXA4 in macrophages.  Whilst this mechanism could potentially impact LXA4 /LTB4 
balance in the CF airway, our archived samples were not preserved in a manner 
such as to be able to evaluate the intracellular localisation of 5-LO, however this 
remains an interesting line of investigation.  
 
Importantly, we found reduced 15-LO2 gene expression in CF BAL samples 
(Figure 4-5).  Furthermore, in BAL from children with CF there was a breakdown in 
the relationships between 15-LO2 transcript abundance, LXA4 /LTB4 ratio, and 
percentage macrophage composition of the BAL.  The macrophage and neutrophil 
content of the CF BAL cell pellets analysed had a wide range of composition and a 
similar distribution to the control samples, thus 15-LO2 reduced expression is not 
attributable simply to the neutrophil cell population simply overwhelming the 
macrophage population numerically.  In fact, reduced 15-LO activity in the face of 
preserved 5-LO activity provides a reasonable explanation for the excess of LTB4 
over LXA4 biosynthesis seen in CF subjects free from infection in this study.    
 
These findings, describing altered eicosanoid mediator balance even in the 
absence of infection in CF, might contribute to the persistence of neutrophil 
mediated inflammation in lieu of its active resolution in CF lung disease. (370) 
 
15-LO expression is a hallmark feature of the alternative activation phenotype 
(M2) in macrophages, induced by the action of interleukins 4 & 13 (produced by T-
helper 2 cells) (423, 424).  Deficient expression of IL4 / 13, delayed or impaired 
macrophage differentiation (such as that seen in bronchial epithelial cells in CF 
(425)) or polarisation classical activation (M1) over alternative activation could all 
contribute to the observed reduction in the expression of 15-LO reported here.  In 
an example of feed-forward amplification, 15-LO product RvD1 promotes M2 
macrophage differentiation, and thus, 15-LO deficiency could lead to reduced 
RvD1 biosynthesis and consequently to reduced M2 macrophage differentiation, 
further compounding the deficiency in 15-LO expression (336).  These ideas will 
be further explored in Chapter 5. 
 
Hostile environmental factors could play a role in the failure to actively resolve 
inflammation observed here. Whilst we examined the impact of conventional 
microbial infection upon eicosanoid balance we cannot exclude the possibility that 
185 
 
sterile inflammatory stimuli (e.g. pulmonary aspiration (384), adherent mucus 
plaques), or non-culturable microbes (426) affected eicosanoid expression and 
synthesis.  (370) 
 
Although there were differences between the mean ages of children with infection 
in their BAL within control and CF subgroups, we found no significant correlation 
between LXA4 /LTB4 ratio and age among control children (P=0.31, n=19) or 
children with CF (P=0.49, n=46).  
 
The measured neutrophil count in our CF cohort is consistently lower than that 
recently reported for another large study of early lung disease in CF, the AREST 
CF cohort (66).  There are differences in lavage sampling protocol between these 
two studies. In our study lavage fluid is obtained from two instillations into the right 
middle lobe and two into the lingula, with the entire lavage then being pooled and 
analysed as a homogenous fluid.  In the AREST study the right middle lobe is 
lavaged thrice, followed by either the lingula or the “most affected lobe on CT” and 
different lavage fractions are used for microbiology and inflammation studies (66).  
These protocol differences may give rise both to dilutional variation and 
differences arising from the selection bias introduced by the selection of lavage 
zone by CT in the AREST study.   
 
In our study the proportion of children, stratified by age, with infection cultured 
from BAL was lower than that reported for the AREST cohort at similar ages; 
14.2% and 33.3% of children in the second and third years of life versus 21.1% 
and 40.2% at the same ages (66).  The definition of infection we have employed 
differs from that used by AREST CF – with a more stringent criterion of 104 
CFU/ml versus 105 CFU/ml for positive culture of pathogenic bacteria, whereas the 
AREST study classified “any” P. aeruginosa cultured as infection.  The overall 
prevalence of P. aeruginosa was low in this cohort with 2 children with CF 
culturing more than 104 CFU/ml and only one further child with CF culturing “any” 
at 900 CFU/ml. Repeat analysis was performed classifying “any” P. aeruginosa 
culture as “infection” but did not significantly affect any outcomes reported.  Whilst 
the ELISA method has good sensitivity and specificity and is widely accepted as a 
method to measure lipid mediators, it is acknowledged that the mass spectrometry 
method yields better specificity. (370) 
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In light of reports that LXA4 /LTB4 balance is disturbed across the spectrum of 
asthma severity (334, 427-429), and in scleroderma lung disease (430) and, given 
that the D-Series Resolvins (431),  Protectin D1 (270) and 15(S) HETE (an agonist 
of the anti-inflammatory nuclear receptor PPARγ) (432), are also 15-LO products, 
these insights may have wider relevance in the pathophysiology of inflammatory 
respiratory disease (370). 
 
4.5.1 Limitations of this study 
Conceptually, “eicosanoid class switching” is relatively new and has only been 
described by a small group of investigators.  This concept has relevance for the 
sequential production of lipid type bioactive mediators, and interactions between 
bioactive lipids and protein based mediators of inflammation have been described.  
However, the place of “eicosanoid mediator class switching” in the hierarchical 
regulation of the inflammatory cascade remains controversial.  This work is based 
around a calculated ratio of LXA4 to LTB4.  Whilst we are not the first group to 
make this comparison (334, 427-429), its mechanistic or disease modifying 
relevance has not been demonstrated in any in vivo animal or human context. 
 
4.6 Conclusions 
This study provides in vivo evidence of impoverished 15 Lipoxygenase-2 gene 
expression associated with a depressed LXA4 / LTB4 ratio in the lower airways of 
children with CF.  We provide new insights into the failure to resolve inflammation 
in early CF lung disease, even in the absence of infection.  
 
4.6.1 Perspectives 
Macrophages play a central role in the regulation the active resolution of 
inflammation in the airway.  In Chapter 5 we describe our attempts to optimize a 
method to explore further the mechanisms operating within alveolar macrophages 
that may underlie aberrant 15 Lipoxygenase 2 expression and LXA4 / LTB4 
imbalance in the CF airway.  
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CHAPTER 5 
DEVELOPING METHODS TO INVESTIGATE 15-LO REGULATION IN CF 
ALVEOLAR MACROPHAGES AND THEIR PHENOTYPIC POLARISATION 
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5 Developing methods to investigate 15-LO regulation in CF Alveolar 
Macrophages and their phenotypic polarisation  
5.1 Introduction 
Macrophages play key regulatory roles in the active resolution of inflammation.  
They receive, interpret and transmit signals to communicate tissue injury or 
invasion, and conversely, containment, resolution, homeostasis and repair.  By 
phagocytosis they remove pathogens, inflammatory and cellular debris(433).   
 
In Chapter 4 we learned that impoverished 15-LO2 gene expression was 
associated with a depressed LXA4  / LTB4 ratio in the lower airways of children 
with CF (370).  In this chapter we explore how (a) 15-LO expression in alveolar 
macrophages (AM), and (b) macrophage polarisation (15-LO is a hallmark of M2 
polarisation / alternative activation) are mechanistically controlled and affected by 
CF.  We develop a method to characterise AM 15-LO expression and AM 
polarisation in airway samples from children with CF and controls ex vivo (pilot 
data is also presented).  Finally, we evaluate methods to perform functional 
studies on AM from people with CF.   
 
5.1.1 Macrophage Polarisation 
Macrophage functional phenotypes have been characterised (434).  These 
activation states exist along a spectrum, and are coupled with plasticity to allow 
them to switch phenotype in response to micro-environmental signals in the local 
milieu (433, 434).  Macrophage phenotype affects the balance between pro-
inflammatory processes and the active resolution of inflammation.  Classically 
activated Macrophages (M1) mediate host defence against micro-organisms, 
produce large amounts of pro-inflammatory cytokines, ROS and nitric oxide, and 
have accentuated anti-microbial activity (433).  They are polarized by cytokines 
characteristic of a T-Helper 1 response, associated with exposure to pathogens, 
e.g. LPS, interferon and TNFα (435).  Alternatively Activated Macrophages (M2), 
are anti-inflammatory in their function and regulate wound healing.  They are 
polarised by cytokines characteristic of a T-Helper 2 response e.g. IL4 & IL13.  M2 
macrophages have higher efferocytic capacity and greater capacity to synthesise 
SPM’s, as illustrated by the distinct pro-resolution lipid mediator profile secreted by 
M2 macrophages (313).  15-LO and PPARγ expression characterise M2 
differentiation in macrophages (433). 
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5.1.2 15-Lipoxygenase in Alveolar Macrophages  
15-LO expression is a hallmark feature of M2 differentiation in macrophages (433).  
Human AM possess 15-LO activity and produce SPM’s including LXA4 (277, 280).  
15-LO 2 (ALOX15B) is the predominantly expressed Lipoxygenase in human 
macrophages where it is regulated by IL4, LPS and hypoxia (280).  Although both 
IL4 and IL13 induce 15-LO type 1 (ALOX15) in human macrophages, the effect is 
most pronounced with IL4 (280).  15-LO activity plays a key role in the 
biosynthesis of the SPM’s; LXA4 (257), Resolvins’ D1, D2 and D5 (262) and 
Protectin D1 (270).  Interestingly, RvD1 and the Maresin 1 precursor 13, 14-epoxy-
Maresin, are also reported to promote M2 macrophage polarisation (298, 336).  
15-LO, in addition to SPM biosynthesis, catalyses the production of PPARγ 
agonists, such as 15-HETE (274), 9-HODE and 13-HODE (271-273).   
 
5.1.3 PPARγ and macrophage polarisation 
PPARγ is a ligand-activated transcription factor and master regulator of 
polarisation in macrophages.  PPARγ expression is up-regulated when monocytes 
differentiate into macrophages, especially M2 polarised macrophages (329) and in 
the resolution phase of wound repair (330).  PPARγ-deficient macrophages are 
resistant to M2 polarization (436).  Additionally, PPARγ inhibits pro-inflammatory 
gene expression through several mechanisms, including the trans-repression of 
NFĸB (331).  PPARγ can be activated by a range of lipid mediators including the 
15-LO products mentioned, and prostaglandin type pro-resolving lipid mediators 
such as 15-d-PGJ2 (332).  Furthermore, PPARγ agonists 9-HODE and 13-HODE 
were reported to up-regulate CD36 expression in monocytes, associated with M2 
polarisation via PPARγ activation (436, 437).   
 
5.1.4 Alveolar macrophages in CF 
Macrophages express CFTR (126, 224).  There are conflicting reports on the 
subject of alveolar macrophage polarisation in CF (225).   Endotoxin tolerance was 
observed in circulating monocytes isolated from cystic fibrosis patients and this 
was taken as evidence of M2 skewing (438).  However, a distinct subpopulation of 
macrophages has been subsequently described called “Satiated macrophages”.  
These arise after ingestion of apoptotic neutrophils and are poorly responsive to 
TLR ligands such as endotoxin (439).  Another study looked at differences 
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between alveolar macrophages isolated from P. aeruginosa non-infected, versus 
infected CF subjects.  They found that subjects infected with P. aeruginosa, and 
who were treated with azithromycin, had elevated M2 markers (440).  However, an 
effect of azithromycin promoting M2 polarisation has also been independently 
reported (441).  In contrast, Krysko et al. examined nasal tissue from patients with 
cystic fibrosis, and observed by immunohistochemistry and cytokine examination, 
findings in favour of the M1 phenotype of macrophages (442).   Reduced 
expression of PPARγ in CFTR knockout mice might be taken as indirect evidence 
in favour of M1 polarisation (361).   
 
5.1.5 15-LO-2 regulation in the CF alveolar macrophages 
A range of explanations for reduced 15-LO 2 transcript abundance in CF 
macrophages (370) are proposed (illustrated in Figure 5-1).  
 
 
 
Figure 5-1  Potential explanations for the finding of reduced ALOX15B mRNA 
expression observed in the CF airway 
 
5.1.6 Interleukin 4 is not depressed in CF BAL 
One explanation for depressed 15LO-2 in the CF airway could be reduced airway 
IL4 concentration, since 15LO-2 is up-regulated by IL4 (280).  IL4 is produced by 
T-helper 2 cells (423, 424), and a bronchial mucosal lymphocytic infiltrate has 
been identified in the CF airway (64).  Unpublished data from the SHIELD CF 
study comparing IL4 concentration in BAL between control children and children 
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with CF demonstrates that IL4 concentration is not depressed in the airways of 
children with CF (Control children; 0.5±0.8 pg /ml, versus Children with CF; 
2.2±2.7pg/ml, *P<0.05) (Figure 5-2).  Conversely, IL4 is elevated when compared 
with controls, which would be expected to yield both an elevation in 15-LO 
expression and favour M2 polarisation in CF alveolar macrophages.  
 
 
Figure 5-2  Interleukin 4 measured in the BAL of control children and 
children with CF 
Unpublished data from the SHIELD CF study.  IL4 concentration compared 
between control children (n=11) and children with CF (n=37) (Results are 
presented as Mean ± SEM, *P<0.05, Student’s t-test). 
 
5.2 Aims 
We sought to develop the methodology to explore the underlying mechanisms 
regulating the resolution of inflammation in CF alveolar macrophages.  We aim to 
specifically examine; 15-LO regulation and phenotypic polarisation in CF alveolar 
macrophages. 
 
5.3 Hypotheses 
We hypothesised that; 
 ALOX15B mRNA expression is reduced in a pure population of alveolar 
macrophages from children with CF. 
192 
 
 That CF alveolar macrophage differentiation is skewed towards an M1 
phenotype. 
 That CF alveolar macrophages do not adequately up-regulate 15-LO 
expression following IL4 stimulation when compared with controls. 
 
5.4 Results 
5.4.1 Developing a method to evaluate native 15-LO expression and polarisation 
phenotype of CF alveolar macrophages 
We attempted three different methodologies to examine 15-LO expression and the 
polarisation phenotype of ex vivo alveolar macrophage samples from the BAL of 
children with CF and controls.  
 
Immunohistochemistry on Historical Cytospin Preparations 
We had a large repository of historical BAL cytospin preparations from the SHIELD 
CF cohort stored in a bio-bank.  We attempted to evaluate the phenotype of 
macrophages within these samples by immunohistochemistry.  The method 
involved using antibodies against 15-LO, and epitopes that are differentially 
expressed between M1 (CD68+/CD80+) and M2 (CD68+/CD163+) polarised 
macrophages.  This method had the advantage that we could both differentiate 
macrophages from neutrophils morphologically, and evaluate double-staining with 
15-LO and either M1 or M2 markers.  Unfortunately, when we attempted to use the 
archived slides we discovered that the method of preservation was inadequate, 
and the samples had deteriorated to the extent that the epitopes could no longer 
be recognised by this method. 
 
Prospective flow cytometry on new BAL cell pellets  
We attempted to perform flow cytometry upon newly obtained BAL cell pellets 
using antibodies against 15-LO and the same differentially expressed epitopes; 
M1 (CD68+/CD80+) versus M2 (CD68+/CD163+) polarisation.  Using adherence 
to tissue culture plastic as the method to enrich the cell population for 
macrophages, the quantitative cell yield from our paediatric samples was too low 
to achieve the minimum reliable event threshold (1000 events) considered 
technically appropriate for a valid flow cytometry result (Mean of 5 million cells 
from whole BAL pellet, Mean of 0.6 million isolated macrophages).  Technical 
limitations affecting the yield of isolated macrophages included; infrequent access 
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to small volumes of BAL fluid; inflammatory milieu affecting pellet cell differential, 
macrophage yield & cell viability; heavily infected samples didn’t survive overnight 
selection in medium containing antibiotics. 
 
Assessment of 15-LO and M1/M2 Differential Gene Expression by PCR 
In view of the sensitivity of the PCR method and the possibility to obtain results 
with a smaller amount of cellular material (Mean RNA yield of 3360ng from BAL 
cell pellets enriched for macrophages by adherence to tissue culture plastic) we 
discovered that we could successfully evaluate 15-LO expression and 
macrophage polarisation profiles by measuring the expression of genes 
characteristic of M1 (IL-12 p35 & IDO1) and M2 phenotype markers (CCL22 & 
PPARγ)(329).  
 
5.4.2 Pilot data; 15-LO1 and 15-LO2 expression in a pure alveolar macrophage 
population 
Alveolar macrophages were enriched from the BAL cell pellets of control children 
and children with CF enrolled in the SHIELD CF study by adherence to tissue 
culture plastic.  We extracted total RNA from the enriched fraction and quantified 
ALOX15 and ALOX15B mRNA transcripts by qPCR, using 18S as a housekeeping 
gene.  ALOX15 mRNA relative abundance ranged from 0.1 – 396 in control BAL 
samples, and from 0.2 – 12.7 in CF BAL samples.  ALOX15B mRNA transcript 
relative abundance ranged from 0.1 – 59.1 in control BAL samples, and from 0.1 – 
2.7 in CF BAL samples (Figure 5-3).   
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Figure 5-3  Abundance of 15 Lipoxygenase type 1 & 2 transcripts quantified 
in alveolar macrophages isolated from the BAL of control children and 
children with CF (pilot data)   
(A) ALOX15 and (B) ALOX15B mRNA transcript relative abundances in alveolar 
macrophages, isolated from bronchoalveolar lavage fluid from Control and CF 
samples by adherence to tissue culture plastic.  Results are expressed as Fold 
Expression = 2^(-ΔΔCt) compared to a reference patient sample (n=5 control 
samples & 5-6 CF samples).   
 
5.4.3 Pilot data; Macrophage phenotype polarisation 
Macrophage polarisation phenotype affects 15-LO expression and the capacity of 
a macrophage to synthesise pro-resolution mediators (280, 313).  In order to 
evaluate macrophage polarisation phenotype, CF alveolar macrophages were 
enriched from the BAL cell pellets of children with CF and controls by adherence 
to tissue culture plastic.  We extracted total RNA and quantified the expression of 
M1 markers IL-12 p35 & IDO1, and M2 phenotype markers CCL22 & PPARγ by 
qPCR (329). 
 
High IL12p35 expression is associated with m1 polarisation (329).  In control BAL 
samples mean IL12p35 relative expression measured 1.5 (± 0.3) as compared 
with 3.3 (± 2.4) in CF samples.  High IDO1 expression is also associated with M1 
polarisation (329).  In control BAL samples mean relative IDO1 expression 
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measured 1.5 (± 0.8) compared with 0.7 (± 0.5) in CF BAL samples (Figure 
5-4A&B).    
 
High CCL22 and PPAR expression are associated with M2 polarisation (329).  
In control BAL samples mean CCL22 relative expression measured 0.6 (± 0.2) 
compared with 2.1 (± 1.6) in CF BAL samples.  Mean PPARγ relative expression 
measured 1.9 (± 0.5) in control BAL samples, and 5.8 (± 4.1) in CF BAL samples 
(Figure 5-4 C&D).   
 
 
Figure 5-4  Pilot data on the abundance of transcripts characteristic of M1 
and M2 polarisation phenotypes in isolated alveolar macrophages from BAL 
samples obtained from control children and children with CF 
M1 phenotype markers; (A) IL-12 p35, and (B) IDO1, and M2 phenotype markers; 
(C) CCL22, and (D) PPARγ mRNA.  Results represent transcript relative 
abundances in isolated alveolar macrophages from Control and CF samples.  
Results are expressed as Fold Expression = 2^(-ΔΔCt) compared to a reference 
patient sample (n=4 control, n=3 CF samples, Lines represent Mean).
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5.4.4 Developing a method for functional studies on CF alveolar macrophages 
To understand the defect underlying impoverished ALOX15B mRNA expression in 
CF alveolar macrophages we sought to evaluate whether CF alveolar 
macrophages can effectively up-regulate the expression of ALOX15B mRNA 
following stimulation with IL4 (280).   
 
In order to conduct this investigation we needed to obtain control and CF 
macrophages upon which to experiment.  It has proved challenging to obtain 
sufficiently large quantities of primary human CF alveolar macrophages to conduct 
these functional studies. 
   
We evaluated the cellular yield of PBMC derived macrophage culture from 10mls 
of paediatric blood obtained through the SHIELD CF Study.  From 10mls of a child 
with CF’s blood we obtained an average of 4 million Peripheral Blood Mononuclear 
Cells (PBMC’s) by the Ficoll density gradient separation method (443, 444).  We 
were successfully able to select Monocytes by adherence to tissue culture plastic, 
and, following culture in Complete Macrophage medium for 7-11 days, the cells 
had the morphological appearance of differentiated macrophages.  Unfortunately, 
however, this method (in our hands), produced an insufficient cell yield for 
functional studies (on average 25,000 - 50,000 cultured macrophages and 225ng 
RNA).   
 
The alveolar macrophage cell yield (quantified in 5.4.1) from BAL would be 
sufficient for a very limited number of experimental conditions to be evaluated by 
qPCR.  Limitations that we encountered in using BAL derived primary CF alveolar 
macrophages as a source for functional studies included; infrequent access to 
sufficiently large volumes of uninfected BAL, and baseline variation due to 
inflammatory exposures in vivo.  
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5.5 Discussion 
Our aim was to develop methodology to explore the underlying mechanisms 
regulating the resolution of inflammation in CF alveolar macrophages.  We have 
optimised a method to perform ex vivo analysis of alveolar macrophage 15-LO 
expression and polarisation phenotype in primary alveolar macrophages obtained 
from BAL obtained from children with CF and controls.  We have also produced 
pilot data to begin to quantify ALOX15BmRNA expression in an enriched alveolar 
macrophage population and evaluate polarisation phenotype in CF.   
 
Furthermore, we evaluated two methods to obtain primary CF alveolar 
macrophages in sufficient quantities for functional studies of 15-LO regulation 
(particularly in response to IL4 stimulation).  To this end, we concluded that PBMC 
derived macrophage culture from paediatric blood samples provided an insufficient 
quantity of cellular material.  BAL derived alveolar macrophages would be 
sufficient in quantity, but pragmatically speaking, this is not an ideal cellular source 
due to the infrequent rate of access to sufficiently large volumes of uninfected BAL 
and baseline variation due to inflammatory exposures in vivo.  
 
New strategies may be necessary to circumvent the technical hurdles posed by 
critically limited access to CFTR deficient alveolar macrophages.  Moving forward 
we could consider; collaborating with our colleagues at the adult CF centres and 
applying for ethical permission to approach adults with CF to obtain larger volumes 
of blood (compared with paediatric volumes) or BAL fluid.  Alternatively, we could 
consider using undifferentiated PBMC’s for functional study, however this strategy 
is limited by the recognition that ALOX15B mRNA expression is characteristic of 
differentiation in macrophage populations. 
 
Another approach would be to knock down or pharmacologically inhibit CFTR in 
macrophages differentiated from healthy donor PBMC’s or a human monocyte cell 
line.  Finally, CFTR deficient alveolar macrophages could be sourced by lavage 
from an animal model of CF.  This approach could be limited by the subtle but 
relevant differences in animal Lipoxygenase repertoires and their regulation (445).  
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5.5.1 Limitations of this study 
This chapter presents pilot data from a small number of children’s airways 
samples.  No conclusions can be drawn from this data until the target number of 
samples have been analysed.  We have calculated a target sample size of 15 
children with CF and 15 controls for the 15-LO expression experiment based on 
the 15-LO differential expression results reported in Chapter 4.  For the evaluation 
of macrophage polarisation, Murphy et al. found skewing of phenotype in a study 
of 48 people with CF (440), and we would need to achieve a similar sample size to 
be able to draw conclusions. Methodological difficulties with isolating 
macrophages from children with CF’s airways samples were explored in this piece 
of work.  In recommending a viable method, a compromise was struck between 
cellular yield and sampling bias, however the characteristics of the sampling bias 
must be acknowledged.  Samples obtained by adherence to tissue culture plastic 
represent those with a high percentage of macrophages in the differential cell 
count, and those relatively free from bacterial infection, since they survive and 
retain functionality ex vivo.  Such samples are more likely to come from a 
healthier, younger cohort of people with CF.  Observational and functional studies 
performed in this way are therefore subject to sampling bias. 
 
5.6 Conclusion 
We have optimised a method evaluate ALOX15B mRNA expression and 
macrophage polarisation phenotype in an ex vivo pure population of alveolar 
macrophages isolated from the BAL of children with CF and controls. 
 
Neither PBMC derived macrophage culture, nor alveolar macrophage isolation 
from BAL yielded reliable access to sufficient quantities of cellular material to 
perform extended functional studies on CF alveolar macrophages. 
 
In the airway 15 Lipoxygenase (LO) expression can be found in; neutrophils (275), 
eosinophils (276), alveolar macrophages (277) and airway epithelial cells (278).  In 
Chapter 6, we describe our investigations of 15-LO activity in bronchial epithelia in 
CF. 
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15 LIPOXYGENASE ACTIVITY IN CF BRONCHIAL EPITHELIUM 
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6 15 Lipoxygenase in CF Bronchial Epithelium 
6.1 Introduction 
6.1.1 15 Lipoxygenase enzyme plays a key role in the biosynthesis of Lipoxins, 
D- Series Resolvins and the Protectins   
The activity of the 15 Lipoxygenase enzyme plays a key role in the biosynthesis of 
the Lipoxins (257) D- Series Resolvins (262) Protectins (270) and the PPARγ 
agonists, 15-HETE, 9 & 13-HODE (271-274).  SPM biosynthesis occurs by trans-
cellular co-operation of two cell types, each cell contributing a separate enzymatic 
catalysis step.  In the airway 15 Lipoxygenase (LO) expression can be found in 
neutrophils (275), eosinophils (276), alveolar macrophages (277) and airway 
epithelial cells (278).  In this chapter we examine how 15-LO expression and 
activity in airway epithelial cells is affected by CFTR deficiency.      
 
6.1.2 15-LO is subject to translational and allosteric regulation 
Pathways for the transcriptional regulation of 15-LO expression associated with 
IL4/IL13, STAT6 signalling, PPARγ and M2 polarisation in macrophages were 
described in Chapter 5.  Beyond these, 15-LO is additionally subject to 
translational and allosteric regulation.  15-LO messenger RNA transcripts contain 
a Differentiation Control Element (DICE element) which allows HNRNPE1 and 
HNRNPK to repress 15-LO mRNA translation by binding to this DICE element, 
and preventing the recruitment of the 60S ribosomal subunit to the 48S pre-
initiation complex (282).  Intracellular calcium concentration regulates 15-LO 
catalytic activity by affecting the degree of membrane insertion, which increases its 
catalytic activity and is necessary for the production of specific products (283).   
 
6.1.3 Lipoxygenase activity, protein expression and intracellular calcium 
regulation are affected by CFTR dysfunction 
In an example of a direct effect of CFTR function upon Lipoxygenase Mattoscio et 
al. reported that by an effect on 12-LO activity, platelets from patients with CF 
generated 40% less LXA4 than platelets from healthy subjects (351).  They 
reported that platelets express a biologically active CFTR and CFTR blockade 
results in a 50% reduction in LXA4 formation during platelet / neutrophil co-
incubations (351).  Furthermore, in CF, calcium signalling is amplified and protein 
synthesis is disturbed.  More specifically, intracellular calcium stores are 
increased, and release from the endoplasmic reticulum and entry through the 
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plasma membrane are amplified in CF airway epithelial cells (192, 193, 206, 209, 
210).  Accumulation of mutant CFTR in the ER is thought to lead to ER stress and 
the activation of the unfolded protein response which leads to a reduction of 
protein synthesis, as an adaptive mechanism to cope with ER stress (196, 446).   
 
6.2 Aim 
The underlying basis for the failure of active resolution of inflammation in CF 
remains incompletely understood.  Airway eicosanoid balance is disturbed in CF 
(370).  15-LO is expressed by bronchial epithelial cells (278) and its activity is 
important in the biosynthesis of several pro-resolution mediators (257, 262, 270-
274).  Furthermore, 15-LO is subject to transcriptional, allosteric and post-
translational regulation.   
 
We sought to investigate the impact of CFTR dysfunction upon 15-LO expression 
and activity in airway epithelial cells.   
 
6.3 Hypothesis 
We hypothesised that CF bronchial epithelial cells would have an impoverished 
ability to produce LXA4 (the best characterised example of a 15-LO derived SPM) 
due to reduced 15 Lipoxygenase expression or activity.   
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6.4 Results 
6.4.1 Transcription of 15-LO1&2 did not differ significantly between NuLi-1 and 
CuFi-1 cells 
In order to investigate the hypothesis that CF bronchial epithelial cells have 
reduced 15 Lipoxygenase expression, we quantified the expression of 15-LO-1&2 
enzymes (ALOX15 & ALOX15B) in well differentiated NuLi-1 and CuFi-1 epithelial 
cell cultures by qPCR.  There was no difference in the relative expression of 
ALOX15 (4.3 ± 2.7; NuLi-1, n=7 vs. 9.8 ± 5.4; CuFi-1, n=9, P=NS) or ALOX15B 
mRNA between NuLi-1 and CuFi-1 differentiated bronchial epithelial cells (1.3 ± 
0.3; NuLi-1, n=5, vs. 1.2 ± 0.3; CuFi-1, n=7, P=NS) (Figure 6-1). 
 
  
 
 
Figure 6-1 The relative quantity of mRNA transcripts for 15 Lipoxygenase-1 
and 15 Lipoxygenase-2 enzymes did not differ significantly between NuLi-1 
and CuFi-1 cells   
(A) ALOX15, and (B) ALOX15B mRNA transcripts expressed by differentiated 
NuLi-1 and CuFi-1 bronchial epithelial cells were quantified by qPCR (n=5-9 
epithelial preparations, normalised to a reference NuLi-1 sample, P=NS, Student’s 
t-test). 
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6.4.2 15-LO1&2 protein expression did not differ between NuLi-1 and CuFi-1 cells  
In order to investigate the hypothesis that CF bronchial epithelial cells would have 
reduced 15 LO expression, we quantified the expression of 15-LO-1&2 enzymes in 
well differentiated NuLi-1 and CuFi-1 epithelial cell cultures by Western Blotting.  
We found no difference in 15-LO 1 (0.9 ± 0.1; NuLi-1, n=7, vs. 0.7 ± 0.2; CuFi-1, 
n=5, P=NS), or 15-LO 2 protein expression (1.1 ± 0.1; NuLi-1, n=3, vs. 1.6 ± 0.4; 
CuFi-1, n=3, P=NS) between NuLi-1 and CuFi-1 cells (Figure 6-2). 
 
 
 
 
Figure 6-2 15-Lipoxygenase 1 and 15-Lipoxygenase 2 protein expression did 
not differ significantly between NuLi-1 and CuFi-1 cells   
(A&B) 15-LO1 and (A&C) 15-LO2 protein expression by NuLi-1 and CuFi-1 
bronchial epithelial cells was quantified by Western Blotting.  (B&C) Band 
densitometry was performed and results are presented as relative band intensities 
normalised by α-Tubulin. Representative blots are presented (upper part of panel), 
(n=3-7 epithelial preparations, P=NS, Student’s t-test). 
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6.4.3 Total 15 LO activity did not differ between NuLi-1 and CuFi-1 cells  
In order to investigate the hypothesis that CF bronchial epithelial cells would have 
an impoverished ability to produce LXA4  due to reduced 15 Lipoxygenase activity, 
we measured the ability of tissue expressed 15-LO to synthesise LXA4  from its 
synthetic precursor 5(S),6(R) Di-HETE.  LXA4 thus produced, was measured by 
ELISA.  There was a non-significant trend towards lower 15-LO tissue activity in 
CuFi-1 cells as reflected by a lower mean LXA4 generated (4.3 ± 0.4ng/ml LXA4; 
NuLi-1 cell preparation (n=21), vs. 3.7 ± 0.24ng/ml LXA4; CuFi-1 cell preparation 
(n=18), P=0.2 (NS)) (Figure 6-3).  
 
 
 
Figure 6-3 Total 15 Lipoxygenase activity did not differ significantly between 
NuLi-1 and CuFi-1 cells   
Total 15-LO activity was measured by exposure of NuLi-1 and CuFi-1 epithelial 
cells to exogenous 5(S),6(R)-DiHETE and LXA4 production was quantified in the 
medium by ELISA.  There was no significant difference between NuLi-1 and CuFi-
1 cells with respect to LXA4 generated (n=18-21 epithelial preparations, P=NS, 
Student’s t-test). 
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6.4.4 LXA4 did not affect the transcription of 15 LO in NuLi-1 or CuFi-1 
differentiated bronchial epithelial cells 
Examination of the kinetics of LXA4 biosynthesis in tissues (reported in mouse 
models by Levy et al.) revealed a pattern whereby a very small amount is 
generated initially, followed by a rapid amplification in its concentration (264).  
Those authors also reported that PGE2 up-regulated 15-LO expression in 
neutrophils. This rapid amplification of LXA4  biosynthesis reported gave rise to the 
hypothesis that LXA4  might stimulate feed forward amplification of its own 
synthetic capacity by up-regulating 15-LO expression.  This hypothesis did not 
bear out in NuLi-1 or CuFi-1 bronchial epithelial cells; LXA4 administration at a low 
concentration (1nM) had no significant effect on ALOX15 (n=7 NuLi-1 preparations 
& n=9 CuFi-1 preparations) or ALOX15B mRNA transcript abundance (n=5 NuLi-1 
preparations & n=7 CuFi-1 preparations) in NuLi-1 or CuFi-1 cells (Figure 6-4).  
Furthermore, PGE2 (4 hours exposure, 100nM) administration did not significantly 
affect ALOX15 or ALOX15B mRNA transcript abundance in NuLi-1 differentiated 
bronchial epithelial cells (n=3, data not presented). 
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Figure 6-4 LXA4 did not affect 15-LO transcription in NuLi-1 or CuFi-1 
differentiated bronchial epithelial cells 
(A&B) ALOX15 mRNA and (C&D) ALOX15B mRNA transcripts were quantified by 
qPCR in (A&C) NuLi-1 and (B&D) CuFi-1 cells exposed to either vehicle control 
(NS) or LXA4  (1nM) overnight (n=5-9, P=NS, Student’s t-test). 
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6.5 Discussion 
In this chapter we report that airway epithelial 15-Lipoxygenase transcription, 
expression and activity is broadly unaffected by CFTR deficiency.  We found no 
evidence of 15-LO transcriptional regulation by LXA4 or by Prostaglandin E2 in 
airways epithelia.   
 
We found no difference in 15-LO type 1 or 2 transcription, protein expression or 
activity between NuLi-1 and CuFi-1 cells.  Our findings are in agreement with the 
findings of Bickford et al. (447) who found no difference in unstimulated ALOX15 
or ALOX15B expression between IB3.1 cells (bronchial epithelial cell line from a 
CF patient (ΔF508/W1282X )) and S9 cells (CFTR-corrected cell line).   
 
Whilst regulation of 15-LO transcription by PGE2 has been described in 
neutrophils (264), we found no evidence for PGE2 regulation of 15-LO in bronchial 
epithelia.  This is consistent with cell type specific regulation of 15-LO 
transcriptional regulation.  Whilst one group reported that 15-LO2 was subject to 
feedback regulation by a related 15-LO product, 15-HETE (448), we found no 
evidence of direct feedback regulation of 15-LO by LXA4.  
 
6.5.1 Limitations of this study 
The method used to evaluate 15-LO activity by an epithelial monolayer has 
limitations.  The ELISA antibody used to detect LXA4 has some crossover affinity 
for the 5(S),6(R)-DiHETE substrate used by 15-LO to produce  LXA4.  Therefore, it 
is possible that a true difference in 15-LO activity between CuFi-1 and NuLi-1 cell 
preparations has been masked by the contaminating effect of 5(S),6(R)-DiHETE 
substrate on the method of LXA4 quantification.  This could be further tested by 
measuring each of these moieties more specifically by LC-MS/MS.  
 
6.6 Conclusions 
In agreement with the findings of Bickford et al. (447) in CF cell bronchial epithelial 
cell lines we found that airway epithelial 15-LO transcription, expression and 
activity are broadly normal in this CF bronchial epithelial cell line.   
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7 Pro-Resolution Mediator characterisation during Pulmonary 
Exacerbation of Cystic Fibrosis in children 
7.1 Exploring the relationship between pro-resolution lipid mediators and 
clinical outcomes of CF Pulmonary Exacerbation  
In this chapter we tested the hypothesis that endogenous Pro-resolution mediator 
production in the airway affects the course of recovery from Cystic Fibrosis 
Pulmonary Exacerbation (CFPE). 
 
The Epidemiologic Study of Cystic Fibrosis, reported that 23% of children under 6, 
32% of 6-12 year olds, and 48% of 13-17 year olds with CF require antibiotic 
treatment for CFPE annually (449).  Pulmonary exacerbations are associated with 
reduced overall survival (450), deterioration in lung function (369) and increased 
bronchiectasis (451, 452) and have a profoundly negative impact on health related 
quality of life (453).   
 
Despite current best practice management, patients may not completely recover 
their baseline lung function after CFPE (368).  Children with CF accumulate 
clinical management problems over time associated with the heavy reliance on 
conventional antibiotic use, such as antibiotic side effects and the emergence of 
multi-drug resistant bacterial species.  In this landscape there is an unmet need for 
new adjuvant therapies in the management of CFPE.  The “ideal” antibiotic 
adjuvant might; hasten the resolution of infection and inflammation; shorten the 
required duration, or minimise the required doses of antibiotic treatment; and / or, 
limit the extent of structural pulmonary damage incurred during exacerbation. 
 
7.1.1 European consensus definition of CFPE 
CFPE is defined as the clinical need for intravenous antibiotics, as indicated by 
presence of at least 4 of 12 possible signs or symptoms (Fuchs criteria (115, 
372));  
 
 Change in sputum volume or colour  
 New or increased haemoptysis  
 Increased cough 
 Increased dyspnoea  
 Increased malaise, fatigue or lethargy  
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 Temperature over 38°C 
 Anorexia or weight loss  
 Sinus pain or tenderness  
 Change in sinus discharge 
 Change in physical ﬁndings on examination of the chest  
 Decrease in pulmonary function by 10% or more  
 Radiographic changes 
 
7.1.2 Pathophysiology of CFPE 
Very little is known about the pathophysiology of CFPE (454).  Exacerbations are 
thought to be related to perturbations in the complex relationship between host 
defence and airway microbiology that impacts on sputum production and airflow 
obstruction (454).  Microbiological factors implicated in the pathogenesis of CFPE 
include; viral infection such as RSV (455, 456); acquisition of new bacterial 
pathogens (454); clonal expansion of colonizing bacteria, especially in those 
chronically infected with P. aeruginosa (457-459).  The inflammatory response to 
bacterial changes in the airway during CFPE is characterised by; increased 
neutrophil abundance, IL8, TNFα, and free Neutrophil Elastase (460, 461).  These 
inflammatory mediators decrease in response to antibiotic treatment of CFPE 
(461). 
 
7.1.3 Current Treatment of CFPE 
Patients with pulmonary exacerbations are frequently hospitalized and treated with 
intravenous antibiotics, augmented airway clearance therapy and nutritional 
support (462).  Consistent with a significant role played by bacterial infection in 
CFPE, intravenous antibiotics have been shown to improve both clinical symptoms 
and lung function (457, 463).  There is debate and active study concerning the 
optimum duration of intravenous antibiotic treatment for CFPE (464).  It is widely 
recognised that the optimal duration of antibiotic therapy may be shorter than is 
current practice (368). 
 
7.1.4 SPM’s as antibiotic adjuvants  
SPM’s including the Lipoxins, D & E Series Resolvins, Protectins and Maresins, 
are differentially and temporally regulated during infection and have both pro-
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resolution and anti-microbial properties (253, 308, 316).  In animal models of 
infection, SPM’s enhance bacterial containment and reduce antibiotic 
requirements for bacterial clearance (316).  In a previous study, Chiron et al 
reported that after antibiotic therapy for CFPE, the levels of LXA4 measured in 
sputum were significantly increased compared to before treatment and this was 
inversely correlated to IL8 content (354).  Mice treated with analogues of LXA4 and 
subsequently challenged with P. aeruginosa were better able to contain the 
bacterial challenge resulting in decreased pulmonary bacterial burden (315).  In 
mouse models of peritoneal E. Coli infection, RvD1 and Resolvin D5 reduced 
bacterial titres in blood and exudates, reduced hypothermia and increased survival 
(316).  Adjuvant treatment with ciprofloxacin and a panel of SPM’s (RvD1, 
Resolvin D5, Protectin D1) heightened host antimicrobial responses, accelerated 
resolution, and shortened resolution intervals in E-Coli infected mice compared to 
antibiotics alone (316).  In mouse skin infection models, the same panel of SPM’s 
enhanced vancomycin clearance of Staphylococcus aureus (316).  In a mouse 
peritoneal sepsis model, Resolvin D2; reduced local and systemic bacterial 
burden, excessive cytokine production (IL6, IL1β, IL23, PGE2, LTB4 and TNFα), 
and neutrophil recruitment; and increased peritoneal mononuclear cells and 
macrophage phagocytosis (308) resulting in improved survival of the mice from 
sepsis (308).  These lipid mediators are thought to be non-redundant in their 
function; however, the tissue and disease specific functional roles of individual 
mediators within this class remain open questions. 
 
7.1.5 SPM’s in clinical drug development 
Several SPM’s are in clinical drug development programmes including Protectin 
D1 (for neurodegenerative diseases), and Maresin 1 (253).  Resolvin E1 and 
synthetic analogues have been formulated for oral, IV and subcutaneous routes of 
administration, and Phase I-II clinical studies have demonstrated efficacy across a 
range of inflammatory disease models, including; asthma, colitis, rheumatoid 
arthritis, atherosclerosis, dry eye and retinopathy (366, 367).   
 
7.1.6 PPARγ ligands as lipid Pro-Resolution Mediators  
PPARγ agonists have also been proposed for therapeutic application in CF (331).  
PPARγ is a ligand-activated transcription factor that mediates the anti-
inflammatory effects of a number of essential fatty acid derived lipid mediators.  
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PPARγ expression and activation is up-regulated during the resolution of 
inflammation where it plays roles in macrophage directed active resolution and 
wound repair (329, 330).   
 
Potent endogenously produced PPARγ ligands include;  
 Prostaglandin type pro-resolving lipid 15-d-Prostaglandin J2 (15-d-PGJ2) 
(331, 332) 
 12/15 Lipoxygenase metabolites, 12-HETE and 15-HETE  (274, 331, 332)  
 SPM parent compounds EPA & DHA (332) 
 Oxidation products of linoleic acid formed either non-enzymatically, or via 
the action of 15 Lipoxygenase, 9-HODE & 13-HODE (332) 
 
7.1.7 PPARγ agonists currently in clinical practice 
The thiazolidinediones are a class of PPARγ agonists which are approved for use 
in diabetes mellitus therapy.  These include; Rosiglitazone, Pioglitazone 
(restricted) and Lobeglitazone. 
 
7.1.8 SPM’s and PPARγ agonists as pro-resolution candidate antibiotic adjuvants 
for CFPE 
Despite accumulating in vitro experimental evidence to suggest that SPM’s and 
PPARγ agonists offer therapeutic opportunities for CF (85, 331, 356-358, 465), to 
our knowledge, neither has been evaluated as an adjuvant to antibiotic therapy in 
CFPE. 
 
7.2 Aims 
Pro-Resolution lipid mediators could represent promising antibiotic adjuvants for 
CFPE therapy.  In order to establish the basis for Pro-Resolution lipid mediator 
application in therapy it was first necessary to characterise their native in vivo 
production during CFPE, and to understand how that relates to clinical resolution 
of CFPE.  Thus, we designed a paediatric observational cohort study (the Pro-
Resolution mediators in CF Exacerbation (PRINCE) study) with the following 
specific aims: 
 
 To characterise the temporal evolution of Pro-Resolution lipid mediators in 
CFPE in childhood. 
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 Compare variations in the Pro-Resolution lipid mediator profile in CFPE to 
clinical outcome measures of the resolution of exacerbation.  
 
7.3 Hypothesis   
The kinetics and amplitude of Pro-Resolution lipid mediator production in the 
airway correlates with the time course of clinical resolution in CFPE. 
 
Primary End-Point 
A description of the relationship between airway concentrations of Pro-Resolution 
lipid mediators and the extent of FEV1 recovery. 
 
7.4 Results 
7.4.1 Population characteristics of PRINCE study participants 
Ten episodes of CFPE were captured in this study from 8 children (Table 7-1).  
Two female children with CF were enrolled twice for distinct episodes separated 
by at least 3 months.  At the time of study conduct there were no reported studies 
describing the normal airway concentrations of pro-resolution lipid mediators in 
children.  In order to characterise pro-resolution mediator production in a non-CF 
airway context, five inpatients (at Our Lady’s Children’s Hospital, Crumlin) that did 
not have CF, but were productive of sputum were recruited as a disease control 
group.   
 
Four children in the control group had tracheostomies in situ; two for severe 
tracheobronchomalacia, one for subglottic stenosis, and a fourth for tracheal 
stenosis.  All of the children with tracheostomies in situ were long term hospital 
inpatients and were stable at the time of sputum sampling.  One child in the control 
group had primary ciliary dyskinesia and was afebrile, but more productive than 
usual at the time of sampling. 
 
All participants contributed at least one sputum sample per episode.  At least three 
sputum samples were captured for eight episodes of CFPE.  One child with CF 
had a nasogastric tube inserted after the first time-point and did not contribute 
further sputum samples due to discomfort and another child with CF was 
transferred to another hospital to complete her treatment after the first time-point.  
During four episodes of CFPE, the child became “dry” of sputum before Day 11 
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and could not contribute a fourth sample by spontaneous expectoration.  A fifth 
child completed treatment and was discharged prior to the last sampling time 
point.  Sputum samples were captured at all four time-points for three episodes of 
CFPE.   
 
Nine out of the ten episodes of CFPE occurred in female children, whereas all of 
the control children were boys.  The mean age of children with CF at the time of 
exacerbation was significantly higher than the mean age of children participating in 
the control group (12.7 ± 2.6 years; CF group, n=10 episodes in 8 children, vs. 2.4 
± 2.7 years; control group, n=5 episodes in 5 children, P<0.001).   
 
Seven episodes of CFPE occurred in 5 children who were homozygous for the 
Phe508del CFTR mutation. Both of the children who were enrolled twice were 
homozygous for the Phe508del CFTR mutation.  Three children were 
heterozygous for the Phe508del CFTR mutation.  
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Table 7-1 Population characteristics of PRINCE participants 
Data is presented for CFPE episodes and the Control cohort.  (***P<0.001 
between group unpaired comparison, Student’s t-test). 
 CF Cohort Control 
Cohort 
Inpatient Episodes Captured (n) 
Children 
10 
8 
5 
5 
Samples Contributed per Episode ≥ 1 Time-point (10/10)  
≥ 2 Time-points (8/10)  
≥ 3 Time-points (8/10)  
≥ 4 Time-points (3/10) 
1 Time-point 
(5/5) 
Sex 1/7 (M/F) 5/0 (M/F) 
Age 
(Range) 
(Mean & SD) 
 
8 – 17 years  
12.7 ± 2.6 years*** 
 
4 months – 7 
years 
2.4 ± 2.7 
years*** 
CFTR Mutations 
(Phe508del / Phe508del) 
(Phe508del / Other CF Mutation) 
 
n=7 episodes in 5 children 
n=3 episodes in 3 children 
 
- 
Relevant Medical Diagnoses - Tracheostomy 
in situ (4) 
Primary Ciliary 
Dyskinesia (1) 
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7.4.2 Clinical characteristics CFPE episodes  
The baseline lung function of participating children with CF was in the range of 
mild - moderate lung disease (8) (Table 7-2).   
 
*I was trained in spirometry by the staff in the pulmonary function lab at OLCHC, 
and I performed the spirometry for the PRINCE Study.  Baseline spirometry 
measurements were obtained from the medical records. 
 
In five out of ten episodes of CFPE among 5 children, the child’s peak post 
exacerbation FEV1 (best FEV1 within a month of the initiation of treatment) 
recovered to at least the pre-exacerbation baseline level.  In five out of ten 
episodes of CFPE among 5 children, the child’s peak post exacerbation FEV1 did 
not recover fully to the pre-exacerbation baseline level.  Both children who were 
re-enrolled had one episode of full recovery and one episode where their peak 
post exacerbation FEV1 did not recover to the pre-exacerbation baseline level.  
There was no significant difference in baseline FEV1 between these two groups of 
children (77.8 ± 17.1% predicted, n=5 episodes in 5 children; Baseline FEV1 
recovered, vs. 84.2 ± 5.2% predicted, n=5 episodes in 5 children; Peak FEV1 < 
Baseline group, Mean ± SD, P=NS, Student t-test) (Table 7-2).   
 
Among the episodes for which the child’s peak post exacerbation FEV1 did not 
recover to the pre-exacerbation baseline level, the mean loss was 6.6% of 
predicted FEV1, with a range from 2% loss to 13% loss (n=5 episodes in 5 
children) (Table 7-2).   
 
During most episodes of CFPE children had two pathogens isolated by 
conventional culture from their sputum (n=8 episodes).  The most common 
organisms isolated were Pseudomonas aeruginosa and Staphylococcus aureus.   
 
Between 9 and 13 days of antibiotic treatment were required for four episodes of 
CFPE among 3 children.  14 or more days of antibiotic treatment (up to a 
maximum of 20 days) were required for six of the CFPE episodes among 5 
children. 
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Table 7-2  Clinical characteristics of CFPE Episodes   
Data is presented on baseline and post exacerbation FEV1 measurements, 
sputum microbiology and duration of antibiotic treatment.  *Baseline FEV1 defined 
as the best reliable FEV1 recorded in the 3 months prior to exacerbation.  
#Peak 
FEV1 Post exacerbation was defined as the best reliable FEV1 recorded for that 
child within a month following the initiation of treatment. 
 Characteristics of CFPE Episodes 
*Baseline FEV1  
(% Predicted) 
51 – 96 % (Range) 
81.0 ± 12.4 % (Mean & SD) 
#Peak Post Exacerbation FEV1:  
≥ Baseline FEV1  
< Baseline FEV1  
 (Number of CFPE Episodes) 
 
5 / 10 among 5 children 
5 / 10 among 5 children 
Δ FEV1 loss (% Predicted)  
Peak Post Exacerbation FEV1 
< Baseline FEV1 sub-group 
 
-6.6 ± 1.8% (Mean & SD) 
-2% → -13% (Range) 
Sputum Microbiology 
Characteristics  
(No. CFPE Episodes) 
1 pathogenic species   (1/10) 
2 pathogenic species   (8/10) 
≥ 3 pathogenic species (1/10) 
 
Pseudomonas aeruginosa (7)  
Staphylococcus aureus (5)  
Candida spp. (3) 
Haemophilus influenzae (2) 
Aspergillus spp. (2) 
Stenotrophomonas maltophilia (1) 
Duration of Antibiotic Rx 
 
 
No. CFPE Episodes 
Range: 9 → 20 Days 
Mode: 14 Days 
 
<14 Days (4/10 episodes, 3 children) 
≥14 Days (6/10 episodes, 5 children) 
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7.4.3 Evolution of symptom scores during CFPE 
In order to quantify perceived changes in the child’s respiratory and systemic 
symptoms during treatment for CFPE, a Respiratory and Systemic Symptoms 
Questionnaire© was administered at three time-points (Day 1-2, Day 3-5, Day 6-
12).  Positive symptom scores represent a symptom that is “more than normal”, 
zero represents a symptom that is “as normal”, and negative scores represent a 
symptom that is “less than normal”. 
 
Children’s symptom scores improved during the course of treatment for CFPE 
(Mean scores ± SEM are reported) (Figure 7-1).  Sputum colour improved from the 
first time-point to the third time-point (1.2 ± 0.2; Day 1-2, n=5 episodes in 5 
children, vs. 0.2 ± 0.4; Day 6-12, n=5 episodes in 5 children) (Figure 7-1A).  
Sputum thickness (1.4 ± 0.3; Day 1-2, n=5 episodes in 5 children, vs. 0.2 ± 0.4; 
Day 6-12, n=5 episodes in 5 children) (Figure 7-1B) and production improved over 
the course of CFPE (1.2 ± 0.4; Day 1-2, n=5 episodes in 5 children, vs. 0.2 ± 0.4; 
Day 6-12, n=5 episodes in 5 children) (Figure 7-1C).   
 
Increased cough frequency was reported at Day 1-2 and normalised by Day 6-12 
(1.0 ± 0.3; Day 1-2, n=5 episodes in 5 children, vs. 0.0 ± 0.4; Day 6-12, n=5 
episodes in 5 children) (Figure 7-1D).  Cough intensity peaked at Day 3-5 and 
normalised by Day 6-12 (0.8 ± 0.3; Day 3-5, n=6 episodes in 6 children, & 0.0 ± 
0.3; Day 6-12, n=5 episodes in 5 children) (Figure 7-1E).  Chest congestion 
improved somewhat over the course of treatment (1.0 ± 0.4; Day 1-2, n=5 
episodes in 5 children, vs. 0.4 ± 0.2; Day 6-12, n=5 episodes in 5 children) (Figure 
7-1F).   
 
Symptom scores for fatigue (1.2 ± 0.4; Day 1-2, n=5 episodes in 5 children, vs. 0.8 
± 0.4; Day 6-12, n=5 episodes in 5 children) (Figure 7-1G) and dyspnoea on 
exertion (0.8 ± 0.4; Day 1-2, n=5 episodes in 5 children, vs. 0.4 ± 0.2; Day 6-12, 
n=5 episodes in 5 children) (Figure 7-1H) did not improve greatly over the time 
course.  Reduced exercise tolerance was not a prominent complaint and changed 
little over the time course (0.2 ± 0.7; Day 1-2, n=5 episodes in 5 children, vs. 0.4 ± 
0.2; Day 6-12, n=5 episodes in 5 children) (Figure 7-1I).   
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Although subjective weight scores increased to a level “better than normal” (-0.8 ± 
0.4; Day 1-2, n=5 episodes in 5 children, vs. 0.4 ± 0.5, Day 6-12, n=5 episodes in 
5 children) (Figure 7-1J), children’s appetites did not improve over the time-course 
(-0.8 ± 0.4; Day 1-2, n=5 episodes in 5 children, vs. -1.0 ± 0.4; Day 6-12, n=5 
episodes in 5 children) (Figure 7-1K).  
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Figure 7-1 Evolution of symptom scores during CFPE   
Respiratory and Systemic Symptoms Questionnaire© was administered at three 
time-points (Day 1-2, Day 3-5, Day 6-12 (y-axis)) to children during CFPE.  
Symptom scores are presented; positive scores represent “more than normal”, 
zero is “as normal”, and negative scores represent “less than normal”; (A) Sputum 
colour, (B) Sputum Thickness, (C) Sputum Production, (D) Cough Frequency, (E) 
Cough Intensity, (F) Chest Congestion, (G) Fatigue, (H) Dyspnoea on Exertion, (I) 
Exercise Tolerance, (J) Weight, and (K) Appetite (Results are presented as Mean 
and 95% Confidence Intervals, children’s responses on Day 1-2 (n=5 episodes in 
5 children), Day 3-5 (n=6 episodes in 6 children), Day 6-12 (n=5 episodes in 5 
children).  
 
221 
 
7.4.4 Total cell count and IL8 concentration in sputum during CFPE 
The inflammatory response during CFPE involves an increase in sputum 
neutrophils and IL8 concentration, which reduce following antibiotic treatment 
(460, 461).  We obtained spontaneously expectorated sputum samples from 
children over the time course of CFPE.  Sputum was processed to obtain a cell 
pellet and supernatant.  A cell count was performed on the cell pellet by trypan 
blue exclusion and IL8 was measured in the supernatant by ELISA.  Cytospin 
slides were prepared from the processed cell pellet and stained with Haematoxylin 
and Eosin.   
 
Examination of cellular morphology revealed the vast majority (>90%) of cells 
found in sputum across the time course of CFPE to be neutrophils with a small 
quantity of squamous epithelial cell contamination.  In agreement with previous 
reports, there was a trend (non-significant) towards a reduction in the total 
cellularity of sputum across the time course of CFPE (71,350 ± 21,940 cells/mg 
sputum; Day 1-2 (n=7 episodes in 6 children), vs. 25,590 ± 8,490 cells/mg sputum; 
Day 6-8 (n=7 episodes in 6 children), Mean ± SEM, P=0.07, ANOVA) (Figure 
7-2A) (460, 461).   
 
Mean IL8 concentration in sputum did not change significantly over the course of 
CFPE (960 ± 306ng/ml; Day 1-2 (n=7 episodes in 6 children), vs. 1080 ± 
510ng/ml; Day 6-8 (n=6 episodes in 5 children), Mean ± SEM, P=NS, ANOVA) 
(Figure 7-2B).  A non-significant trend towards reducing IL8 concentration over 
time may have been masked by one child’s measurements which were particularly 
high and rose over the course of CFPE.  That patient did not recover baseline 
FEV1 post exacerbation. 
 
There was no significant difference in the total sputum cell count or IL8 
concentration measured from sputum at all time-points between full baseline FEV1 
recovery episodes, and incomplete FEV1 recovery episodes (n=5 episodes in 5 
children, data not illustrated, P=NS, Student t-test). 
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Figure 7-2  Total cell count and IL8 concentration measured from sputum of 
children with CF at various time points during CFPE   
Sputum was processed to obtain a cell pellet and supernatant.  A total cell count 
was obtained by the trypan blue exclusion method on the cell pellet and 
normalised by the weight of the original unprocessed sputum sample.  IL8 in the 
processed sputum supernatant was measured by ELISA. (A) Sputum Total cell 
count (cells/mg sputum) at 4 time points during CFPE.  (B) Sputum IL8 at 4 time 
points during CFPE (Day 1-2, n= 7 episodes in 6 children, Day 3-5, n=9 episodes 
in 8 children, Day 6-8, n=6 episodes in 5 children, Day 11-12, n=3-4 episodes in 3-
4 children) (Lines represent Mean, P=NS, ANOVA).  
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7.4.5 SPM’s found in Control and CF Sputum  
In order to characterise the sputum levels of Pro-Resolution lipid mediators during 
CFPE, we obtained spontaneously expectorated sputum samples from children 
over the time course of CFPE.  Specific lipid mediators were quantified in 
unprocessed sputum plugs by the LC – MS/MS method by our collaborator, Dr 
Justine Bertrand-Michel at the Lipidomic Platform in Toulouse.  Spontaneously 
expectorated sputum samples were obtained from control inpatient children and 
analysed by the same method as a baseline comparison. 
 
Fifteen SPM’s have been described in the literature to date (253).  At the time of 
analysis, internal standards were commercially available for only six SPM’s and 
one SPM pathway intermediate.  Consequently, the following were quantified by 
LC – MS/MS; LXA4, LXB4, RvD1, Resolvin D2, 18-HEPE, Protectin Dx and 7-
Maresin 1. 
 
LXB4, RvD1 and 7-Maresin 1 were examined, but not detected in any control or 
CF sputum sample analysed.   
 
LXA4, 18-HEPE and Protectin Dx were identified in a small number of samples.  
LXA4 was detected in one control sample, and three CFPE sputum samples from 3 
children (Figure 7-3A).   
 
18-HEPE is a precursor of the E-Series Resolvins.  It is not itself bioactive, but is 
rapidly converted to RvE1 or E2 via trans-cellular biosynthesis (261).  18-HEPE 
was detected in one control and one CFPE sample on Day 1-2 (Figure 7-3C).   
 
Protectin DX is a bioactive stereoisomer of Protectin D1 (296).  Protectin Dx was 
reported to inhibit platelet activation and block neutrophil infiltration in a mouse 
model of peritonitis (296, 466).  Protectin Dx was detected in one CFPE sample 
(Figure 7-3D).   
 
Resolvin D2 (RvD2) was not detected in any control sample, but was detected in 
11 out of 28 CF samples (Figure 7-3B).  As such, RvD2 was detected in sputum 
with sufficient frequency to allow us to attempt further analysis. 
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Figure 7-3  SPM’s detected in sputum  
Spontaneously expectorated sputum samples were obtained from control inpatient 
children (first column) and children being treated for CFPE at four time-points (Day 
1-2 (n=7 samples), Day 3-5 (n=9 samples), Day 6-8 (n=8 samples) and Day 11-12 
(n=4 samples)).  Specific lipid mediators were quantified in unprocessed sputum 
plugs by the LC – MS/MS method; (A) LXA4 (pg/mg protein), (B) Resolvin D2 
(pg/mg protein), (C) Precursor of the E-Series Resolvins; 18-HEPE (pg/mg 
protein), (D) Protectin Dx (pg/mg protein).  *LC-MS/MS performed by Dr Justine 
Bertrand-Michel at the Lipidomic Platform in Toulouse.   
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7.4.6 Higher Resolvin D2 in sputum was associated with full recovery of pre-
exacerbation baseline FEV1  
The aim of this study was to relate pro-resolution mediator production during 
CFPE to indicators of the clinical resolution of CFPE.  The primary outcome was 
pre-defined as the extent of FEV1 recovery.  Therefore, we conducted a sub-group 
analysis comparing pro-resolution mediators detected in sputum with FEV1 
recovery post CFPE.   
 
CFPE episodes were divided into two sub-groups based on whether the peak 
post-exacerbation FEV1 was less than, or equal to/greater than the pre-
exacerbation baseline measurement.  Five episodes of CFPE occurring in 5 
children were thus designated “full baseline FEV1 recovery” episodes, and five 
episodes of CFPE occurring in 5 children were designated as “incomplete baseline 
FEV1 recovery” episodes. 
 
Sputum RvD2 concentration was compared between sub-groups at all time-points 
(Figure 7-4A) and over the time course of CFPE (Figure 7-4B).  In samples from 
the “incomplete baseline FEV1 recovery” CFPE episodes (n=14 measurements 
during 5 episodes in 5 children), RvD2 was detected only once.  10 of the 14 
sputum samples from “full baseline FEV1 recovery” episodes (n=14 measurements 
during 5 episodes in 5 children) had a measurable amount of RvD2 detected.  The 
mean sputum concentration of RvD2 at all time-points in the “full baseline FEV1 
recovery” subgroup was significantly higher than among the “incomplete baseline 
FEV1 recovery” subgroup (78 ± 25pg/mg protein; FEV1 ≥ Baseline (n=14 
measurements during 5 episodes in 5 children), vs. 3 ± 3pg/mg protein; FEV1 < 
Baseline (n=14 measurements during 5 episodes in 5 children), P<0.01, Student t-
test) (Figure 7-4A).   
 
Mean sputum RvD2 examined over the time course of CFPE was significantly 
higher among the “full baseline FEV1 recovery” subgroup than among the 
“incomplete baseline FEV1 recovery” subgroup (n=14, P<0.05, 2 way ANOVA), 
and higher at Day 6-8 than on any other time-point among children who recovered 
their baseline FEV1 (141.9 ± 71.7pg/mg protein; Day 6-8 (n=4 measurements from 
3 children in each subgroup), baseline FEV1 recovered group, P<0.05, 2-way 
ANOVA, Bonferroni post-test) (Figure 7-4B). 
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Figure 7-4  Relationship between sputum Resolvin D2 concentration during 
CFPE and extent of recovery of pre-exacerbation baseline FEV1  
Spontaneously expectorated sputum samples were obtained from children during 
CFPE at four time-points; Day 1-2, Day 3-5, Day 6-8 and Day 11-12.  Resolvin D2 
was measured in sputum by the LC – MS/MS method.  Sub-group analysis was 
conducted to compare children with “incomplete baseline FEV1 recovery” (left 
hand column (A) and dashed line (B) (n=14 samples from 5 children)) with those 
with “full baseline FEV1 recovery” (right hand column (A) and continuous line 
(B)(n=14 samples from 5 children)).  (A) Sputum Resolvin D2 at all time-points 
(Line represents Mean, **P<0.01, Student t-test).  (B)  Sputum Resolvin D2 over 
the time course of CFPE (Day 1-2, n=7 samples, Day 3-5, n=9 samples, Day 6-8, 
n=8 samples, and Day 11-12, n=4 samples) (Mean plotted, error bars represent 
SEM, *P<0.05, 2 way ANOVA, Bonferroni post-test). *LC-MS/MS performed by Dr 
Justine Bertrand-Michel at the Lipidomic Platform in Toulouse. FR performed the 
spirometry for the PRINCE Study.  Baseline spirometry measurements were 
obtained from the medical records. 
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7.4.7 PPARγ agonists detected in sputum 
PPARγ ligands are lipid anti-inflammatory and Pro-Resolution lipid mediators.  
They play roles in macrophage directed active resolution of inflammation and 
wound repair and have been proposed for therapeutic application in CF (329-331).   
 
We examined the production of five endogenously produced PPARγ ligands that 
were reported to play pro-resolution roles in the active resolution phase of 
inflammation in unprocessed sputum plugs by the LC – MS/MS method, namely; 
12-HETE, 15-HETE, 9-HODE, 13-HODE, and 15-d-Prostaglandin J2.  *LC-MS/MS 
was performed by Dr Justine Bertrand-Michel at the Lipidomic Platform in 
Toulouse.   
 
All five specific PPARγ agonists examined were detected (Figure 7-5).  
 
12-HETE is produced from arachidonic acid by platelet type 12 Lipoxygenase and 
is reported to be an agonist of the anti-inflammatory nuclear receptor PPARγ (274, 
332, 351).  12 Lipoxygenase enzymatic function in platelets was reported to be 
affected by CFTR dysfunction (351).  The mean 12-HETE concentration measured 
in CFPE sputum samples (n=28 measurements during 10 episodes among 8 
children) was not significantly higher than in control samples (n=5 measurements 
among 5 children) (2547 ± 1712 pg/mg protein; Control, vs. 9034 ± 2252; CFPE 
samples) (Figure 7-5A).  Whilst the mean concentration of 12-HETE appeared 
highest in sputum during CFPE at Day 3-5 this was not significant (n=9 
measurements from 8 children, P=NS, ANOVA) (Figure 7-5A), nor did sputum 12-
HETE concentration differ significantly between FEV1 recovery outcome sub-
groups (n=14 measurements from 5 children in each subgroup, not illustrated, 
P=NS, Student t-test).    
 
In humans, 15-HETE is produced from arachidonic acid by 15 Lipoxygenase.  15-
HETE is both bioactive as a PPARγ agonist and a major pathway intermediate in 
the formation of the lipoxins (274, 277).  Mean 15-HETE concentration measured 
from sputum did not differ between control (n=5 measurements among 5 children) 
and CFPE samples (n=28 measurements during 10 episodes among 8 children) 
(1600 ± 590pg/mg protein; Controls, vs. 2000 ± 660pg/mg protein; CF samples, 
P=NS, Student t-test). 15-HETE did not change significantly over time during 
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CFPE (Figure 7-5B) (P=NS, ANOVA) or differ significantly between the “full 
baseline FEV1 recovery” CFPE subgroup and the “incomplete baseline FEV1 
recovery” CFPE subgroup (n=14 measurements from 5 children in each subgroup, 
not illustrated, P=NS, Student t-test). 
 
9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid 
(13-HODE) are both oxidation products of linoleic acid and potent agonists of 
PPARγ (271).   
 
Whilst the mean 9-HODE concentration measured in sputum during CFPE (n=28 
measurements during 10 episodes among 8 children) was lower than that found in 
control sputum (n=5 measurements among 5 children), the difference was not 
significant (3425 ± 1063 pg/mg protein; controls, vs. 1655 ± 375 pg/mg protein; 
CFPE samples, P=NS, Student t-test).  A non-significant trend towards increasing 
9-HODE concentration over the time-course of CFPE was seen (P=NS, ANOVA) 
(Figure 7-5C).  9-HODE concentration did not differ between “full baseline FEV1 
recovery” CFPE episodes and “incomplete baseline FEV1 recovery” CFPE 
episodes (n=14 measurements from 5 children in each subgroup, not illustrated, 
P=NS, Student t-test).   
 
There was no difference in the mean concentration of 13-HODE detected from 
control (n=5 measurements among 5 children) and CFPE samples (n=28 
measurements during 10 episodes among 8 children) (4800 ± 1200pg/mg protein; 
Controls, vs. 4900 ± 890pg/mg protein; CF samples, P=NS, Student t-test).  Mean 
overall 13-HODE concentration in sputum did not change significantly over the 
time-course of CFPE (Figure 7-5D).  Among CFPE samples, there was a wide 
distribution in 13-HODE concentration measured at each time point. 
 
15-deoxy-Prostaglandin J2 (15d-PGJ2) is a prostaglandin type pro-resolving lipid 
mediator and a high affinity ligand of PPARγ formed from PGD2 by the enzymatic 
activity of prostaglandin D2 synthase (PGD2S) (467).  15d-PGJ2 concentration in 
control samples (n=5 measurements among 5 children) was significantly higher 
than that measured from CFPE samples overall (n=28 measurements during 10 
episodes among 8 children) (218 ± 120pg/mg protein; Controls, vs. 14 ± 4pg/mg 
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protein; CF samples P<0.001, Student t-test), as well as at any individual time-
point in CFPE samples (P<0.05-0.01, ANOVA) (Figure 7-5E).   
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Figure 7-5  PPARγ agonists detected in sputum 
Spontaneously expectorated sputum samples were obtained from control inpatient 
children (first column) and children being treated for CFPE at four time-points (Day 
1-2, Day 3-5, Day 6-8 and Day 11-12).  Specific PPARγ agonist lipid mediators 
were quantified in unprocessed sputum plugs by the LC – MS/MS method; (A) 12-
HETE (pg/mg protein), (B) 15-HETE (pg/mg protein), (C) 9-HODE (pg/mg protein), 
(D) 13-HODE (pg/mg protein), & (E) 15-d-Prostaglandin J2 (pg/mg protein) 
(Control, n=5 samples, Day 1-2, n=7 samples, Day 3-5, n=9 samples, Day 6-8, 
n=8 samples, and Day 11-12, n=4 samples, Line represents Mean, *P<0.05, 
**P<0.01, ANOVA, Newman Keuls Post Test). *LC-MS/MS performed by Dr 
Justine Bertrand-Michel at the Lipidomic Platform in Toulouse.   
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7.4.8 PPARγ agonists 13-HODE & 15-d-Prostaglandin J2 and FEV1 Recovery 
post exacerbation 
The aim of this study was to relate sputum levels of pro-resolution mediators 
during CFPE to the extent of FEV1 recovery.  
 
Two PPARγ agonists examined tended to be differentially expressed between “full 
baseline FEV1 recovery” episodes and “incomplete baseline FEV1 recovery” CFPE 
episodes; 15-d-PGJ2 and 13-HODE. 
 
Sputum 15-d-PGJ2 concentration was compared between FEV1 recovery sub-
groups at all time-points (Figure 7-6A) and over the time course of CFPE (Figure 
7-6B).  15d-PGJ2 concentration from “full baseline FEV1 recovery” episodes (n=14 
measurements during 5 episodes in 5 children) was significantly higher than 15-d-
PGJ2 concentration measured from “incomplete baseline FEV1 recovery” CFPE 
episodes (n=14 measurements during 5 episodes in 5 children) at all time-points 
(22 ± 7pg/mg protein; FEV1 ≥ Baseline, vs. 5 ± 2pg/mg protein; FEV1 < Baseline, 
P<0.05, Student t-test) (Figure 7-6A).  Further analysis of 15-d-PGJ2 
concentration, compared between these two sub-groups over the time-course of 
CFPE revealed a higher measured 15-d-PGJ2 concentration among “full baseline 
FEV1 recovery” episodes over time that approached statistical significance 
(P=0.06, 2 way ANOVA) and was highest in “full baseline FEV1 recovery” episodes 
at Day 6-8 (n=4 measurements from 3 children in each subgroup) (Figure 7-6B). 
 
Sputum 13-HODE concentration was compared between FEV1 recovery sub-
groups at all time-points (Figure 7-6C) and over the time course of CFPE (Figure 
7-6D).  There was a non-significant trend towards higher sputum 13-HODE in the 
“full baseline FEV1 recovery” subgroup (6036 ± 1459pg/mg protein; FEV1 ≥ 
Baseline (n=14 measurements during 5 episodes in 5 children), vs. 2863 ± 
408pg/mg protein; FEV1 < Baseline (n=14 measurements during 5 episodes in 5 
children), P=0.05, Student t-test) (Figure 7-6C).  Despite a non-significant trend 
towards higher 13-HODE sputum concentration at all time-points in the “full 
baseline FEV1 recovery” subgroup, 13-HODE concentration did not change 
significantly over the time course of CFPE (P=NS, 2 way ANOVA) (Figure 7-6D). 
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Figure 7-6  Relationship between sputum 15-d-Prostaglandin J2 and 13-
HODE concentration during CFPE and extent of recovery of pre-
exacerbation baseline FEV1.  
Spontaneously expectorated sputum samples were obtained from children during 
CFPE at four time-points.  15-d-Prostaglandin J2 (15-d-PGJ2) and 13-HODE were 
measured in sputum by the LC – MS/MS method.  Sub-group analysis compared 
children with “incomplete baseline FEV1 recovery” (left hand column (A&C) and 
dashed line (B&D)) with those with “full baseline FEV1 recovery” (right hand 
column (A&C) and continuous line (B&D)) (n=14 samples from 5 children in each 
subgroup).  (A) Sputum 15-d-PGJ2 at all time-points (Line represents Mean, 
*P<0.05, Student t-test).  (B)  Sputum 15-d-PGJ2 over the time course of CFPE 
(Mean plotted, error bars represent SEM, P=0.06, 2 way ANOVA). (C) Sputum 13-
HODE at all time-points (Line represents Mean, P=0.05, Student t-test).  (D)  
Sputum 13-HODE over the time course of CFPE. (Mean plotted, error bars 
represent SEM, P=0.11(NS), 2 way ANOVA). (Day 1-2, n=7 samples, Day 3-5, 
n=9 samples, Day 6-8, n=8 samples, and Day 11-12, n=4 samples). *LC-MS/MS 
was performed by Dr Justine Bertrand-Michel at the Lipidomic Platform in 
Toulouse.  FR performed the spirometry for the PRINCE Study.  Baseline 
spirometry measurements were obtained from the medical records. 
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7.5 Discussion 
7.5.1 Resolvin D2 and 15-d-PGJ2 significantly associate with full recovery of pre-
exacerbation FEV1 following CFPE  
We set out to investigate whether pro-resolution mediator production in the 
airways played a relevant role in the natural course of clinical resolution during 
treatment for CFPE.  The rationale being, that, if pro-resolution mediator 
production was found to impact recovery, or to be comparatively sub-optimal, 
adjuvant administration could represent an effective strategy to boost recovery 
from CFPE.  We report for the first time positive relationships between two pro-
resolution mediators that significantly associate with full recovery of pre-
exacerbation FEV1 following CFPE, namely; RvD2, and 15-d-PGJ2.   
 
The degree of loss of lung function among those who failed to regain their baseline 
FEV1 in this small study was at a clinically important level (mean loss of 6.6% 
predicted).  Whilst it is not completely understood why some patients fail to 
recover baseline lung function following exacerbation, it is agreed that to some 
degree treatment factors may play a part, whereas in other cases, irreversible lung 
damage may have occurred (468).  Given that half of all the long-term lung 
function decline in CF has been attributed to pulmonary exacerbations (469), this 
is an important area to study in greater detail, with a significant unmet clinical need 
for therapeutic options.     
 
In the field of cytokine research there is a concept called “redundancy”, meaning 
that in some cases the functions of cytokines overlap (redundant), whereas, in 
other cases, functions are cytokine-specific (non-redundant)(470).  Although pro-
resolution lipid mediators, as a class, are claimed to be non-redundant in their 
function - the specific roles played by individual mediators in health and disease 
remain open questions.  This was the first study of its kind to look at the levels and 
timing of pro-resolution mediator expression in children’s airways during CFPE 
and to understand the relationships between individual mediators and lung 
function recovery.   
 
7.5.2 Resolvin D2 & FEV1 
We found a significant positive association between the detection, and higher 
concentration of RvD2 in sputum and the full recovery of pre-exacerbation 
234 
 
baseline FEV1.  RvD2 concentration peaked at Day 6-8 of treatment during “full 
baseline FEV1 recovery” CFPE episodes.   
 
Only a small body of literature has been published on Resolvin D2 (18 citations on 
Pubmed).  In a mouse model of sepsis, RvD2 was reported to reduce neutrophil 
infiltration, promote phagocyte dependent bacterial clearance and reduce pro-
inflammatory cytokine release (308).  Although evidence suggests that RvD2 
signals via GPCR(s), the specific details have not yet been reported (288).  To 
further evaluate RvD2 in an antibiotic adjuvant role for CFPE, we could consider 
(a) studying RvD2’s anti-microbial effects in CF cell culture models, or (b) an 
interventional study in a CF animal model.  In the latter approach, RvD2 (or a 
stable analogue) could be co-administered (orally, or by inhalation) with an 
antibiotic to a CF animal model faced with an infectious airway challenge and the 
animal could be monitored for the timing and extent of recovery.  Since we found 
that RvD2 was higher among “full baseline FEV1 recovery” episodes (even from 
Day 1-2 and peaking at Day 6-8), co-administration could be initiated at the same 
time as commencing antibiotic treatment.     
 
7.5.3 15-d-PGJ2, 13-HODE & FEV1 
We observed positive relationships between PPARγ ligand concentration in 
sputum during CFPE and the extent of recovery of pre-exacerbation baseline 
FEV1.  In particular, 15-d-PGJ2 was significantly higher among “full baseline FEV1 
recovery” CFPE episodes, and a trend towards higher 13-HODE concentration 
associated with “full baseline FEV1 recovery” CFPE episodes approached 
significance.   
 
Expression of PPARγ itself in CFTR knockout mice was reported to be down-
regulated at the RNA and protein levels, and associated with reduced nuclear 
localisation (361).  Notably, PPARγ agonist pioglitazone was reported to normalize 
pulmonary infiltration of neutrophils and pro-inflammatory cytokine levels in the 
lungs of CFTR-deficient mice challenged with Pseudomonas (362).  Furthermore, 
ion transport effects of PPARγ agonists have been reported (inhibition of chloride 
secretion (471) and intracellular calcium increases (472)).  Recent studies also 
demonstrated a role for PPARγ in the expression of carbonic anhydrases and 
bicarbonate transport in the lung (363).  Moreover, pro-proliferative effects 
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reported on airway epithelial cells could potentially benefit repair (472).  Our 
findings support the previously described therapeutic potential for PPARγ agonists 
in CF (331). 
 
7.5.4 Patient Cohorts 
The Control and CFPE cohorts differed significantly with respect to sex and age.  
Control children were younger and male, in contrast to the older CFPE cohort with 
a majority of female children.  The control participants that we able to recruit were 
clinically stable at the time of sampling.  Whilst their participation provided some 
data to attempt to answer the question – “are pro-resolution mediators found in 
detectable quantities in sputum at clinical baseline?” the cohort did not constitute 
the ideal control group sought.  We actively attempted to recruit children 
undergoing treatment for exacerbation of non-CF bronchiectasis, and able to 
expectorate sputum, however, this presentation is not common in a hospital 
inpatient or outpatient population in childhood and no suitable candidates were 
identified over the study period.   
 
In the CFPE cohort sampling at the fourth time-point (Day 11-12) was sub-optimal.  
A sputum sample was obtained for only three CFPE episodes at Day 11-12.  By 
Day 11-12, one child had transferred to another treatment centre, one child had 
completed therapy and been discharged home and one child withdrew their  
assent to further sputum sampling due to discomfort independent of the study 
conduct.  Children were much less productive of sputum by Day 11-12 of 
treatment and therefore found it difficult to generate a spontaneously expectorated 
sample.  An increased rate of late CFPE sampling could have been achieved if we 
had designed the study to obtain induced sputum samples from the outset.  
 
The microbiological characteristics of the cohort were similar to those widely 
reported (8, 473).  Children reported overall improvement in their symptoms during 
the time course of CFPE.  Sputum and cough related symptoms normalised over 
the time period, however, appetite and fatigue symptoms persisted throughout the 
time course. 
 
There was an over-representation of female children in the CF cohort.  
Unselected, sequentially presenting eligible children presenting with CFPE were 
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approached for consent to participate in the study.  There was no active selection 
procedure, however, given the average age of participants (mean 12.7 years) this 
female over-representation may have reflected the increased rate of presentation 
for exacerbation of CF seen in adolescent girls (the “Gender Gap”) (474).  The 
50% rate of failure to regain baseline FEV1 in this study was higher than the 23.1% 
reported by Sanders et al in a study of 104 children in Seattle (473).  Our sample 
size was small and this 50% failure to regain baseline FEV1 rate likely reflects a 
chance over-representation of more severe CFPE episodes.  Due account must 
be taken of this in the interpretation of the results. 
 
7.5.5 Limitations of the LC-MS/MS Analysis of SpM’s 
We set out to quantify a wider range of pro-resolution mediators in sputum than 
was ultimately achieved.  The first problem pertained to the lack of commercially 
available internal standards.  Specifically, our collaborators at Toulouse were not 
able to quantify; Resolvin E1, Resolvin E2, Protectin D1, Maresin 2, or Resolvins 
D3, D4, D5 & D6.  This could potentially have been addressed by engaging with 
Dr Serhan’s lab at Boston where they have in house internal standards for the 
listed compounds. Whilst we cannot comment on the SpM’s that could not be 
examined for technical reasons, it is important to recognise that Resolvin E1 (353) 
and Protectin D1 (338) have been reported to play relevant roles in the airways.  A 
study of 16 stable adult patients with CF conducted at the University of California 
found that the detectable presence of Resolvin E1 (9 samples) was associated 
with a higher FEV1 (353).  Protectin D1 was reported in exhaled breath 
condensate from healthy volunteers (mean 2.2ng/ml) by Levy et al. who found it to 
be undetectable in asthmatics during exacerbation (n=4) (338).  As such these 
mediators should not be discarded from our ongoing consideration of candidates 
for CFPE therapy but borne in mind for future investigation when this becomes 
technically feasible.   
 
The second limitation related to the low rate of SpM detection in sputum samples. 
LXB4, RvD1 and 7-Maresin 1 were not detected in any control or CF sputum 
sample, and, LXA4, 18-HEPE and Protectin Dx were detected so infrequently such 
that further analysis could not reliably be performed.   
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We have previously reported measurable quantities of LXA4 in BAL from stable 
children with CF, and in sputum from adults with CF during CFPE (354, 370).  
Those studies were conducted on site by ELISA and found mean concentrations 
of 4pg/ml of LXA4 in BAL, and 15.9ng/ml of LXA4 at the beginning of exacerbation 
rising to 45.5ng/ml at the close of treatment (354).  This LC-MS/MS study of 
children during CFPE failed to reliably detect LXA4 with a lower limit of detection 
for the method reported at 2.5pg/ml (379).  However, LXA4 in healthy serum was 
reported to deteriorate at a rate of 5.9% loss over 5 days in serum samples (380).  
In light of this, it is conceivable that the combination of transport on dry ice and the 
inflammatory milieu of sputum might result in degradation rendering it difficult to 
detect.  
 
Ours is not the first study to report difficulty in recovering SPM’s from human 
samples (380, 381).  Whilst investigators at the University of California found 
Resolvin E1 in sputum, they failed to detect LXA4  in any sputum sample analysed 
(353).  Conversely, whereas we did not have access to Resolvin E1 analysis itself, 
we found the pre-cursor 18-HEPE in only 2 samples.  Although Protectin D1 has 
been reported in airways secretions, we found the stereoisomer Protectin Dx in 
only one sample (338).  Even the human serum metabolome reference project 
reported significant variation in the recovery of SPM’s from two different blood 
serum sources examined by the same assay at the same site (381).  For example 
LXB4 and 7-Maresin 1 (we failed to detect either in sputum) in serum were not 
detectable in one serum set and measured 49 / 21 pg/ml respectively in another 
set.  We also failed to detect RvD1 which is found in healthy human serum at a 
concentration of between 3 & 31 pg/ml (381).  The limit of detection for our assay 
was 2.5pg.  I have found no other report in the literature of the detection or 
quantification of RvD1 in human airways secretions. 
 
Storage conditions can have a very significant impact upon degradation (25-85% 
loss over 4 weeks of storage) and in this knowledge, our sputum samples were 
preserved in methanol and stored at minus 80 degrees prior to transport (381).  
Regarding those SpM’s which were infrequently or not detected in sputum in this 
study, to establish whether they are truly synthesised in children’s airways during 
CFPE, protocol modifications could be considered including; sampling of sputum 
on a site which is co-located with the facilities to rapidly perform LC-MS/MS to 
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eliminate decay during storage & transportation; alternative airways sampling 
methods such as Exhaled Breath Condensate to avoid the degradative milieu of 
sputum; the preservation of unstable SpM’s might be improved by storing the 
samples in liquid nitrogen.  
 
7.5.6 Exploring the relationships between Resolvin D2, 15dPGJ2, 13 HODE and 
FEV1 and the resolution of inflammation 
This study was an observational study and as such cannot distinguish between 
association and causation in the relationships between RvD2, 15-d-PGJ2, 13-
HODE and FEV1 and the resolution of inflammation.  Nonetheless, identification of 
these significant relationships in the native setting of CFPE in children lends a 
weight of relevance to further studies attempting to; (a) confirm these findings in a 
larger cohort; (b) to investigate the underlying pathophysiological mechanisms 
operating differentially between full and sub-optimal recovery episodes and the 
role of RvD2, 15-d-PGJ2 and 13-HODE in the active resolution of inflammation in 
CFPE; and, (c) intervene to administer RvD2, an upstream target or stable 
analogue, or a PPARγ agonist in a CFPE model or clinical study. 
 
7.5.7 Overall Limitations of this study 
This study was underpowered due to the failure to achieve the target sample size.  
Spontaneously produced sputum was used to sample the airway.  A higher rate of 
sampling might have been achieved via sputum induction.  The study was 
designed to capture a convenience sample of inpatients, however, recruitment 
might have been bolstered by capturing children with CFPE undergoing home IV 
antibiotic therapy.  A higher rate of control recruitment could have been achieved 
by targetting a cohort of age-matched well children consenting to sputum 
induction.  In this observational study we cannot outrule differences in treatment 
regimen contributing to differences in outcome.  The study population may also 
represent a more severe clinical presentation of CFPE inherent to the recruitment 
bias associated with inpatient children versus “all” children with CFPE, since 
candidates for home IV therapy may have had a less severe presentation. 
 
We did not specifically exclude children who had been previously enrolled and 
therefore there is potential for re-enrollment bias.  Given the large yield of data 
from this type of study there is potential for Type I statistical error due to multiple 
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comparision / multiple analyses.  Whilst the FEV1 subgroup analysis was pre-
determined as an endpoint in the original study design, the risk of Type I errors 
could be reduced by having a more stringent P value to determine statistical 
significance.   
 
 
7.6 Conclusions 
Recurrent pulmonary exacerbations are associated with long-term decline in lung 
function and reduced survival (450). There is an unmet need for adjuvant 
therapies in this landscape to prevent CFPE associated decline in lung function.   
 
We have reported significant positive associations between Resolvin D2 and 15-d-
PGJ2 measured in sputum during CFPE and the full recovery of FEV1 post 
exacerbation.  These findings are novel and require validation in a larger 
population of both children and adults with CF, with a view to determining which 
specific mediators have greatest relevance for CF pulmonary exacerbations. If our 
data can be replicated in a larger patient population it may lead to a potentially 
exciting avenue for development of antibiotic adjuvant therapies in CF. 
 
In the General Discussion we will explore the question of how RvD2, 15-d-PGJ2, 
13-HODE might influence the resolution of inflammation in greater detail.   
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CHAPTER 8 
GENERAL DISCUSSION 
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8 General Discussion 
8.1 Summary and Key findings 
In this thesis we have demonstrated an ALX/FPR2 dependent RvD1 mediated 
increase in ASL height in primary CF and CuFi-1 bronchial epithelial cell models.  
We showed that RvD1 attenuates TNFα stimulated IL8 secretion via IĸB 
preservation in the CuFi-1 bronchial epithelial cell line.  We show that RvD1 
increases the phagocytic capacity of primary CF alveolar macrophages and 
increases their bactericidal capacity against Pseudomonas aeruginosa.  These 
physiological actions of RvD1 in CF bronchial epithelial and alveolar macrophage 
models serve to redress several of the key deficits implicated directly in the 
pathogenesis of CF. 
 
We presented in vivo evidence of deficient 15 Lipoxygenase expression in 
association with LXA4  / LTB4 imbalance in the airways of children with CF, 
indicating the failure to actively resolve inflammation (370).   
 
We reported significant positive associations between the concentrations of 
Resolvin D2 and the PPARγ agonist 15-d-Prostaglandin-J2 measured in sputum 
during CFPE and the full recovery of FEV1 post exacerbation.   
 
These findings; advance the proof of principle that RvD1 could be considered for 
application as an adjuvant in CF therapy; improve our understanding of the failure 
to actively resolve inflammation in the CF airway; and suggest exciting and novel 
approaches to antibiotic adjuvant therapy including Resolvin D2 and PPARγ 
agonists for application in CFPE. 
 
Furthermore, we optimised a method to isolate a purified alveolar macrophage 
population from the BAL of children with CF and controls in order to further 
investigate how defective 15-LO expression in alveolar macrophages could result 
in the failure to synthesise LXA4.  Pilot data were presented on 15-LO expression 
and macrophage polarisation in an enriched alveolar macrophage population from 
children with CF and controls.  We demonstrated that 15-LO expression and 
activity in the CuFi-1 CF bronchial epithelial cell line is broadly similar to that found 
in the NuLi-1 non-CF bronchial epithelial cell line. 
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Figure 8-1 Evidence is accumulating that Pro-resolution mediators have 
beneficial effects on the key elements of airway disease pathogenesis in CF  
 
We will consider the accumulated evidence (presented here and in the literature) 
that SPM’s have beneficial effects on each step in the pathogenesis of airway 
disease in CF, look at avenues to explore moving forwards, and consider how 
these concepts could be applied in therapy.  
 
8.2 SPM’s on ASL Height in CF 
CF is caused by mutation of the CFTR gene which leads to a loss of chloride 
secretion and sodium hyper-absorption, resulting in a lowering of the ASL height 
and impaired muco-ciliary clearance and impaired innate defence.  The restoration 
of ASL height by LXA4 was previously reported (85, 356, 393).  In this thesis we 
demonstrate that RvD1 also restores ASL height in both the CuFi-1 differentiated, 
polarised bronchial epithelial cell model and in primary CF bronchial epithelium.  In 
CuFi-1 cells this effect involves the FPR2 receptor.  This physiological effect of 
SPM’s may have evolved to allow the ASL to respond to the requirement to 
enhance airway clearance as part of restoring tissue homeostasis in the context of 
active resolution after an inflammatory process.  The restoration of ASL height 
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would be expected to lead to improved muco-ciliary clearance.  This “flushing” 
function, enhancing muco-ciliary clearance in the airways would allow irritants and 
inflammatory debris to be cleared from the lungs.  Furthermore, increased ASL 
height might also affect the ionic composition of the ASL (including pH) and by 
dilution create a more favourable environment for the function of innate microbial 
peptides and potentially improve the bactericidal capacity of the ASL in CF.  The 
downstream consequences of increased ASL height on innate defence in the CF 
airway remain to be demonstrated in a more complex model taking account of the 
roles played by ciliary beat frequency in muco-ciliary transport and the specific salt 
and pH range sensitivities of the characteristic CF pathogens.    
 
8.3 SPM’s on Airways Infection in CF 
Predisposition to airways infection is a key element of CF lung disease 
pathogenesis.  Various factors interplay to allow the initial colonisation of the lung 
by characteristic pathogens; impaired muco-ciliary clearance , increased binding of 
pathogens to epithelial surfaces (135), reduced bacterial killing by innate 
antimicrobial peptides (128), reduced macrophage phagocytosis and impaired 
bacterial killing (225), and impaired phagolysosomal acidification (126).  A context 
is generated whereby the microbiome is altered (177), characteristic pathogens 
have established inter-relationships, niches and entered into biofilms, the lung is 
structurally damaged and mucus plugging gives rise to hypoxic micro-
environments which promote further infection of the lung. 
 
A critical consideration for the application of SPM’s in CF therapy will always 
pertain to the safety and appropriateness of active resolution of inflammation in the 
context of the chronically infected CF airway with its intrinsic predisposition to 
infection (53).  Recognising the difference between an anti-inflammatory or 
immune paralysis mechanism of action, versus a pro-resolution mechanism with 
antimicrobial properties becomes both interesting and important (253).  The SPM’s 
are reported to improve bacterial killing in animal models of sepsis; LXA4  
administration resulted in a reduced bacterial load in a mouse model of P. 
aeruginosa infection (315), and a panel of SPM’s (Resolvin D1, Resolvin D5 and 
Protectin D1) improved the containment of a bacterial challenge in animal infection 
models acting in synergy with antibiotics (316).  The function of anti-microbial 
peptides in the ASL are salt and pH-sensitive (128, 129).  SPM’s described to 
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increase the ASL height (LXA4 reported in the literature(355), and RvD1 reported 
in this thesis) might conceivably improve innate antimicrobial peptide function by 
changing the pH by bicarbonate secretion or ionic concentration of the ASL by 
hydration (128).   
 
We have demonstrated that RvD1 increases the phagocytic capacity of primary 
CF alveolar macrophages, and improves intracellular killing of the key CF 
pathogen, Pseudomonas aeruginosa.  Moreover, Resolvin D2, in particular, has 
potent anti-microbial properties (308) and we demonstrated that higher levels of 
Resolvin D2 detected during CFPE in sputum from children was associated with 
better recovery of lung function post CFPE.  Since a higher concentration of RvD2 
with its adjuvant anti-microbial properties was associated with a better outcome in 
our small cohort, we might be more optimistic that SPM’s could conceivably be 
applied safely under antibiotic cover.  This approach is reasonably novel and in 
light of the lessons of prior anti-inflammatory strategies for CF(241), would need to 
be rigorously tested for safety and efficacy in appropriate CF animal models prior 
to taking this consideration any further. 
 
We now recognise that the airway is not sterile (177) and a field of investigation is 
currently emerging to attempt to understand host-microbiome interactions.  The 
possibility that SPM’s might play roles in microbiological house-keeping, or that 
microbes themselves could act synergistically to influence the active resolution of 
inflammation by the host adds a new layer of complexity to our understanding of 
the normal restoration of lung homeostasis following self-limited inflammation. 
 
8.4 SPM’s on Airway Inflammation in CF 
A normal host response to bacterial infection involves neutrophil recruitment that 
serves to contain and eliminate the bacterial insult, and is followed by an active 
resolution phase.  The key features of tissue resolution (performed by SPM’s) 
have been described as; limiting neutrophil recruitment and effector functions, 
limiting the production of pro-inflammatory mediators and initiating macrophage 
phagocytosis and repair (253).  CF is characterised by prolonged, ineffective 
neutrophil mediated inflammation, a hyper-inflammatory phenotype, failure of 
bacterial containment and failed resolution of inflammation – perhaps CF is in fact 
the exemplifier disease for the failure of tissue resolution. 
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The underlying basis for the failure to actively resolve inflammation in the CF 
airway is incompletely understood, and controversy had surrounded prior reports 
of reduced LXA4 concentration in CF airway samples (315, 352).  Furthermore, the 
tendency for neutrophils to migrate into tissues is influenced by the relative 
concentrations of LXA4 and LTB4 (304, 360).  LXA4 is generated by a “class 
switch” in eicosanoid lipid mediator synthesis from Leukotrienes to Lipoxins via up-
regulation of 15 LO (264).  In this thesis (and the associated publication (370)) we 
reported that children with CF have a lower LXA4 to LTB4 ratio than control 
children measured from BAL fluid, even in the absence of recognised culturable 
pathogens, related to deficient 15-LO2 expression.  This finding may in part 
explain the excessive neutrophil burden and the failure to actively resolve 
inflammation observed in CF airways.  
 
The ability of LXA4 to reduce bronchial epithelial IL8 secretion was previously 
reported (323). Here, we reported that RvD1 attenuates TNFα stimulated IL8 
secretion via preservation of IĸB in CuFi-1 bronchial epithelial cells. This 
physiological effect could serve to abate the hyper-inflammatory phenotype of the 
CF bronchial epithelial cell and antagonise IL8 mediated neutrophil chemotaxis. 
 
The activity of the 15-LO enzyme plays a key role in the biosynthesis of the 
Lipoxins (257), D- Series Resolvins (262), Protectins (270) and the PPARγ 
agonists 15-HETE, 9 & 13-HODE (271-274).  We reported that the expression of 
15-LO type 2 was depressed in the cellular fraction of BAL from children with CF.  
We observed positive relationships between 15-LO2 expression and the 
abundance of macrophages in the pellet, and with the LXA4 / LTB4 ratio among 
control children.  These relationships were lost in children with CF.  Moreover, to 
compound the reported SPM biosynthetic defect, essential fatty acid deficiencies 
are reported in CF, affecting the availability of parent compounds such as DHA 
and EPA (345, 346).  The knock-on consequences of the failure to up-regulate 15-
LO expression may be far reaching and include the failure to initiate the active 
resolution of inflammation in CF and arrest of the downstream resolution 
sequence.  Furthermore, it could be involved in the unopposed recruitment of 
neutrophils, their failure to undergo apoptosis and be removed by efferocytosis.  
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8.5 SPM’s in Bronchiectasis & Lung Function Decline in CF? 
Factors centrally associated with the development of bronchiectasis and lung 
function decline in CF include; Neutrophil Elastase burden (66); nutrition (155); 
early acquisition of Pseudomonas aeruginosa (167); and, the frequency of 
episodes of pulmonary exacerbation and the associated acute loss of lung function 
(155, 473).  In our small observational study, we reported significant positive 
associations between the concentrations of Resolvin D2 and PPARγ agonist 15-d-
Prostaglandin-J2 measured in sputum during CFPE and the full recovery of FEV1 
post exacerbation.  The mechanisms by which resolution mediators such as 
Resolvin D2 and 15d-Prostaglandin J2 could protect against loss of lung function 
during CFPE warrant further evaluation.   
 
Whilst the study was small and there were technical issues with the detection of 
other SPM’s, many compounds that demonstrate beneficial effects in mouse 
models or controlled in vitro experiments do not bear out in the complex context of 
human disease.  These findings linked pro-resolution mediators to an important 
outcome among children being treated for CFPE, and highlighted a context for the 
consideration of resolution mediators to be applied as candidate adjuvants to 
antibiotic therapy.  Given that in our study, those children who did not recover their 
pre-exacerbation baseline FEV1 fully lost a mean of 6.6% predicted FEV1, clinically 
meaningful gains in lung health for children with Cystic Fibrosis by adjuvant 
administration during CFPE are credible goals.  In subsequent clinical studies of 
this phenomenon, follow up spirometry post CFPE would be important to evaluate 
whether short term FEV1 decline is attended by irreversible loss of lung function. 
 
An overview of the projected beneficial effects of SPM’s in the context of CF 
airway disease is presented in Figure 8-2. 
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Figure 8-2 An illustration the physiological effects of SPM’s in CF lung 
disease  
SPM’s can restore ASL height and barrier integrity. SPM’s can attenuate NFĸB 
mediated pro-inflammatory signalling and reduce the secretion of neutrophil 
chemo-attractant IL8.  SPM’s limit neutrophil recruitment and promote their tissue 
clearance and efferocytic uptake.  SPM’s have the potential to reduce the release 
of free neutrophil Elastase into the airway by reducing the initial neutrophil burden 
and aiding in the removal of dead and dying neutrophils from the airway.  SPM’s 
can promote CF macrophage mediated phagocytosis and intracellular killing of 
Pseudomonas aeruginosa.  The synthesis of one these mediators, LXA4, is 
defective in CF due to reduced expression of a key enzyme in its production 
pathway.  SPM’s themselves, could potentially drive macrophages towards a 
resolution phenotype, attended by a cascade of de novo SPM synthesis.  
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8.6 Putting it all together – could the resolution defect in the CF airway be 
attributed to alveolar macrophages? 
Macrophages play key regulatory roles in the active resolution of inflammation.  
They receive, interpret and transmit signals to communicate tissue injury or 
invasion, and conversely, containment, resolution, homeostasis and repair.  By 
phagocytosis they remove pathogens, inflammatory and cellular debris (433).  The 
differentiation of a tissue macrophage reflects a complex interplay between 
intrinsic differentiation signalling pathways and environmental inputs received from 
neighbouring cells (434).  Substantial cross-talk operates between; macrophage 
polarisation phenotype; macrophage function in efferocytosis; the local cytokine 
and lipid mediator milieu; PPARγ expression and activation within macrophages; 
the capacity of a macrophage to synthesise pro-resolution mediators, and the lipid 
mediator profile secreted by macrophages.  Many of the findings of this thesis 
share a common signature related to the regulation of the active resolution of 
inflammation by macrophages (roles played by LXA4 /LTB4 balance, 15-LO 
expression, RvD2, and PPARγ agonist 15d-PGJ2 in resolution in CF). A 
consideration therefore of cross-talk in the regulation of macrophage function, 
involved in directing and enacting the active resolution is warranted.  A deeper 
understanding of the regulation of active resolution regulation by airway 
macrophages might provide avenues to progress the study of failed resolution in 
the CF airway. 
 
8.6.1 Cross-talk in M2 Macrophage polarisation - IL4, STAT6, 15-LO, PPARγ, 
and efferocytosis  
IL4 acts through a Jak-STAT6 (Signal Transducer and Activator of Transcription 6) 
signalling pathway (475).  STAT6 is phosphorylated, dimerizes and translocates to 
the nucleus where it acts as a transcription factor, and controls genes associated 
with an Alternative Activation phenotype in Macrophages (M2 polarisation)(434).  
M2 macrophages are anti-inflammatory in their function, regulate wound healing, 
and are polarised by IL4 & IL13, via STAT6 signalling and PPARγ activation (274, 
307, 434).  IL4 and STAT6 signalling also influence the expression of both 15-LO 
(274, 476, 477) and PPARγ (274) (illustrated in Figure 8-3). 
 
15-LO is up-regulated to initiate the “switch” towards resolution of inflammation 
(264), and its expression by macrophages is characteristic of M2 polarisation 
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(307).  15-LO is subject to transcriptional regulation by PGE2, IL4 and IL13 (264, 
282, 477), and SPM biosynthesis (involving 15-LO) both marks, and effects the 
transition towards tissue resolution (264).  
 
Kapoor et al reported that during normal wound repair, there is a shift in the 
metabolism of arachidonate from Prostaglandin E2 during the acute inflammatory 
phase to Prostaglandin D2 during the repair phase.  PGD2 derivative 15-d-
Prostaglandin J2 mediates its pro-resolution effects via PPARγ, which is also up-
regulated during the resolution phase (330).   
 
A core function of SPM’s is to enhance the uptake of apoptotic neutrophils (259) 
whereas in CF, impaired neutrophil efferocytosis is reported (218, 219). Neutrophil 
Elastase was shown to cleave calreticulin, inhibiting phosphatidylserine mediated 
ingestion of apoptotic cells (220).  Neutrophil efferocytosis, however, has important 
downstream consequences.  Efferocytosis drives the polarisation of macrophages 
towards a pro-resolution phenotype stimulating production of 15-LO and 15-HETE 
via a PPARγ/TGFβ pathway (300, 312).  During macrophage differentiation, 
natural PPARγ ligands are formed which increase macrophage mediated 
efferocytosis via the induction of genes such as efferocytic surface receptors 
(478).  Furthermore, efferocytic uptake was shown to enhance neutrophil 
efferocytosis by macrophages and induce de novo SPM synthesis (313) 
(illustrated in Figure 8-3).   
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Figure 8-3  Schematic illustrating elements of the cross-talk in macrophage 
resolution regulation; IL4, STAT6, 15-LO, PPARγ, M2 polarisation and 
apoptotic cell efferocytosis  
(1) IL4 signals via a Jak-STAT6 pathway to up-regulate both (2) 15- LO and 
PPARγ expression, and genes associated with an M2 polarisation phenotype.  (3) 
15-LO activity drives the biosynthesis of SPM’s; LXA4, Resolvins D1, D2 and D5 
and Protectin D1, which in turn have pro-resolution effector functions (4) and 
stimulate neutrophil efferocytosis (5).  PPARγ activation by 15-LO products; 15-
HETE, 9-HODE and 13-HODE (6), or by 15-d-PGJ2 (7) promotes M2 
differentiation (8), and inhibits pro-inflammatory gene expression by trans-
repression of NFĸB.  M2 macrophages have higher efferocytic capacity (9) and 
following exposure to PS (phosphatidylserine) on apoptotic cells accelerate 
resolution of inflammation.  (*Indicates mediators associated with improved lung 
function recovery from CFPE in this thesis. # Indicates mediators with 
demonstrated beneficial physiological effects in CF models and includes both 
findings presented in this thesis and published by other investigators in the 
literature). 
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Taken together the observations that; 15-LO activity is important in LXA4 /LTB4 
balance (disturbed in CF) and required for Resolvin D2 biosynthesis  (associated 
with better recovery); and, that PPARγ activation (associated with better recovery) 
and 15-LO expression play a key role in macrophage polarisation (332), a number 
of the findings of this thesis converge on the role played by macrophage 
polarisation in regulating the active resolution of inflammation.   
 
Moreover, given that under certain conditions (both adaptive and maladaptive) 
inflammation does not “self-resolve” and SPM biosynthesis does not arise, e.g. in 
animal models of peritoneal sepsis when a higher inoculum of bacteria is 
administered (316), or in CF, we reason that there must be an account taken of 
the context in the mechanistic operation of the “switch” towards resolution.  The 
sensory component of this switch may be regulated through an integration of pro-
inflammatory and pro-resolution signals, via the competing influences on STAT 
signalling pathways culminating in macrophage phenotype polarisation (434).  
Contextual factors which might have competing input into this regulation are 
illustrated in Figure 8-4.  It is likely that, in CF, the combination of innate immune 
dysfunction, persistent pathogen colonisation and the intrinsic hyper-inflammatory 
response combine to make it more difficult to reach the tipping point towards 
resolution of inflammation 
 
Improved understanding of the “switch” from propagation of inflammation to its 
active resolution might allow us to identify targets that could be modified to push 
the switch and tip the inflammatory profile into resolution.  The role of alveolar 
macrophages in the active resolution of inflammation requires further study in CF. 
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Figure 8-4 Schematic illustrating contextual factors effecting airway 
macrophages that could play roles in the sensory arm of the “switch”, 
regulating the transition from propagation of inflammation to its active 
resolution 
 
8.7 Future Work - Key Questions to be addressed 
 
 Given that the function of anti-microbial peptides in the ASL are pH-
sensitive (128, 129) - do LXA4 and RvD1, by elevating the ASL height, 
affect the ASL pH / restore the bactericidal activity of innate anti-microbial 
peptides?  
 
Pezzulo et al. used elegant methods to evaluate the ASL pH, using a pH-sensitive 
planar optical probe, and the bacterial killing capacity of ASL using S. aureus 
linked to gold grids placed on the airway surface (128).  Similar methods could be 
employed to evaluate the effects of LXA4 and RvD1 upon ASL pH and bactericidal 
function using the primary CF bronchial epithelial culture model.   
 
 What is the mechanism behind RvD1 mediated enhanced intracellular 
killing of P. aeruginosa by primary CF alveolar macrophages? 
 
Candidate mechanisms by which RvD1 might have enhanced intracellular killing of 
P. aeruginosa by CFAM include; effects on the macrophage actin cytoskeletal 
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network (405) - accelerating internalisation and recruitment of vesicles leading to 
the maturation of the phagolysosome; effects on the acidification of the 
phagolysosome and the consequent activity of defensins ;and, effects on the 
activity of phagolysosome associated Nitric Oxide Synthase (479) in generating 
reactive oxygen species.  The effect of RvD1 on the kinetics of CFAM cytoskeletal 
rearrangement and recruitment of vesicles leading to the maturation of the 
phagolysosome could be studied by treating CFAM’s with RvD1 during bacterial 
exposure and using fluorescence linked antibodies to identify early, intermediate, 
and late phagosomes and phagolysosomes.  Effects of RvD1 on phagolysosomal 
acidification in CFAM’s could be explored by incubating macrophages with dextran 
linked to pH sensitive fluorescein and then measuring fluorescence emission 
(229).  Effects of RvD1 upon ROS production within CFAM could be evaluated by 
measuring changes in the fluorescence of 29,79-dichlorodihydrofluorescein 
diacetate (DCF) (230) which fluoresces after cellular oxidation.   
 
 Could RvD1 improve CFAM mediated killing of other CF pathogens such as 
Staphylococcus aureus, Burkholderia cepacia, or Non-tuberculous 
mycobacteria? 
 What is the rank order of potency of SPM’s with respect to anti-microbial 
function / are there particular synergies with antibiotic classes? 
 
In this piece of work we tested the efficacy of RvD1 in enhancing CFAM mediated 
killing of P. aeruginosa.  However, CF pathogens possess divergent repertoires of 
evasion strategies, for example, B. cepacia in particular, has been described to 
invade and survive inside macrophages (480).  Future experiments could test the 
effect of RvD1 upon the bactericidal capacity of CF alveolar macrophages against 
B. cepacia or S. aureus.   Furthermore, other SPM’s either singly, in combination, 
and or, co-administered with antibiotics could be tested for bactericidal efficacy 
using the CFAM model we have developed, to gain a better understanding of their 
relative potency. 
 
 Does the in vitro effect of RvD1 upon ASL height & CFAM mediated killing 
of P. aeruginosa translate into improved containment of a bacterial 
challenge in an animal model of CF e.g. CF mouse / pig model?  
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A critical step towards translation of this work for therapy involves testing the 
efficacy of the SPM’s in an animal model of CF lung disease. Particular 
compounds within the SPM class are expected to have cell type / tissue type 
specific roles and actions (253).  A good candidate SPM, or panel of SPM’s for 
translation could be that which is most potent in containing a bacterial challenge.  
Candidates could be tested in the context of bacterial challenge in an animal 
model and compared against endpoints such as; clinical condition of the animal, 
resolution indices, reduction in bacterial burden, and airways physiological 
parameters.  
 
 Could the restoration of macrophage mediated neutrophil efferocytosis 
reduce the neutrophil burden and trigger the active resolution of 
inflammation? 
 Would this then cascade the biosynthesis of the whole orchestra of 
resolution mediators? 
 
We demonstrated that RvD1 enhanced phagocytosis by CFAM. Dalli et al. 
reported a rank order of potency of SPM’s with respect to neutrophil phagocytosis; 
the most potent reported to be Protectin D1, followed by Maresin 1 and Resolvin 
D3, then Resolvin D2 and, finally, RvD1 (481).  
 
The effect of SPM’s upon neutrophil efferocytosis by CFAM remains untested.  It 
remains to be determined whether SPM’s could bypass neutrophil elastase 
mediated cleavage of calreticulin expressed upon apoptotic neutrophils, and 
independently improve efferocytic uptake.  To study the effect of SPM’s upon 
CFAM mediated neutrophil efferocytosis, macrophages could be exposed to 
apoptotic neutrophils (either from BAL fluid or aged neutrophils isolated from 
blood) in the presence of Neutrophil Elastase (in BAL fluid or exogenously added) 
(to recapitulate the cleavage of the calreticulin).  Changes in the rate of double 
positivity for macrophage marker CD68 and neutrophil marker Myeloperoxidase 
(MPO) by Flow cytometry would indicate changes in the rate of efferocytic uptake.   
The conditioned culture medium could be captured for the evaluation of the SPM 
profile (by LC-MS/MS) elaborated by the post efferocytosis. 
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Alternatively an SPM could be administered to an animal model of CF by 
inhalation or enterally by gavage (482).  The lungs could then be lavaged to 
assess the neutrophil burden and the quantity of macrophages with evidence of 
neutrophil ingestion by flow cytometry.  The lavage fluid could also be tested for 
the lipidomic footprint (by LC-MS/MS) post SPM administration. 
 
 Is there a role for SPM’s as adjuvant therapeutics in CFPE to hasten the 
resolution of inflammation, shorten the required duration of antibiotic 
treatment or limit the extent of structural pulmonary damage incurred during 
exacerbation? 
 
A significant body of work still lies ahead to achieve the stated aim to evaluate the 
role of SPM’s as adjuvant therapeutics in CFPE. This leads us on to a 
consideration of how to progress this work towards translation into therapy. 
 
8.8 Pathways towards Application of Pro-resolution mediators in CF 
Therapy 
The overarching aim of this work has been to gain a greater understanding of the 
role of SPMs in CF lung disease, with a view to translate new developments in the 
resolution field for therapeutic application in CF. 
 
8.8.1 Proof of Principle 
We have put forward a case “in principle” for the consideration of SPM’s as 
candidate therapeutics for CF.  Notably, we have performed in vitro work on 
primary human CF tissues and observational studies with children with CF.  We 
have illustrated a context for application and demonstrated positive associations 
between the concentrations of pro-resolution mediators and recovery from CFPE.  
To bolster this “proof of principle” an important piece of work, moving forward, is to 
define the best candidate(s) to be tested in the most suitable context for 
application to give the most robust chance for these compounds to fulfil their 
potential as candidate therapeutics.  
 
8.8.2 Which compound / combination? 
The cases for the application of LXA4, RvD1 and RvD2 are the most developed.  
LXA4  enhances ASL height, restores epithelial barrier function, attenuates 
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inflammation, regulates neutrophil recruitment and enhances repair in CF models 
(465).  RvD1 increases ASL height, attenuates IL8 secretion and restores 
phagocytic and bactericidal capacity to CF alveolar macrophages.  RvD2 has 
potent antimicrobial properties and is associated with a favourable outcome from 
CFPE.  The comparison between SPM’s as regards their anti-microbial potency 
has yet to be performed.  If the strategy is to trigger the whole orchestra of SPM 
synthesis by driving macrophage mediated neutrophil efferocytosis, then the SPM 
which does this with the greatest potency is of the greatest interest (481).  Maresin 
1 has autacoid activity and drives feed-forward amplification of SPM synthetic 
capacity (298). Further work is required to understand functional redundancy in 
this class of compounds, their synergies and refine the answer to the question – 
which compound / combination? 
  
8.8.3 Stability 
An important challenge in considering SPM’s for therapy regards the chemically 
unstable nature of the lipid compounds.  They are also rapidly degraded by 
endogenous prostaglandin dehydrogenases (284).  To this end, stable analogues 
have been synthesised (303, 483).  A recent study of the benefit of 15(R/S)-
methyl-LXA4 in the topical treatment of infantile eczema demonstrated both safety 
and efficacy (365).  The efficacy of stable analogues could be tested against their 
naturally occurring counterparts in vitro.  Whether it is safe and desirable to have 
prolonged chemical stability / longer tissue exposure to these potent compounds 
needs to be evaluated. 
 
8.8.4 Which route and dose? 
Both oral and inhalation routes could be considered for administration.  Oral 
administration of RvD1 was reported to result in rapid accumulation in plasma and 
systemic efficacy in a mouse model (482).  Off target pro-resolution effects might 
in fact be considered desirable in CF, since it is a multi-organ disease (e.g. there 
are currently no effective drug therapies for CF associated liver disease).  The 
airway effects of LXA4 inhalation challenge have been evaluated in a pilot study of 
eight asthmatic and healthy adult subjects.  The challenge was tolerated, had no 
adverse effect on pulse or blood pressure and demonstrated favourable effects on 
specific airway conductance (364).  The physiological effects of SPM’s have been 
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described to be potent in the pico to nano-molar range.  Again, further work is 
merited in in-vitro models / in CF animal models. 
 
8.8.5 Contextual Factors 
The most appropriate context for the application of SPM’s in CF therapy could be 
debated.  Our finding that LXA4 production was relatively depressed compared to 
pro-inflammatory mediators at clinical baseline in CF raises the case that a chronic 
administration strategy of a stable SPM analogue might yield clinical benefit.  
However, several issues discourage from this lead approach.  Firstly, safety 
concerns associated with the use of immune modulators outside the context of 
antibiotic co-administration in CF (241).  Secondly, the recognition that the 
evaluation of clinical outcomes for chronic administration of immune modulators in 
a childhood cohort is fraught with difficulties arising particularly from the long lead 
time to detect benefit, and the large number of children needed to treat to show a 
significant treatment effect over time.  Thirdly, the natural context for the liberation 
of SPM’s is in the context of “active resolution” of acute inflammation in concert 
with a host (+/- antibiotic augmented) response to eliminate bacterial pathogens.  
 
Urbach et al. previously reported a significant increase in LXA4 concentration in 
sputum after the completion of antibiotics for CFPE, with inverse correlation to IL8 
concentration (354).  Given reports that SPM’s have both pro-resolving action and 
act as antibiotic adjuvants, we directed our attention to a consideration of SPM’s 
as candidate adjuvants to antibiotic therapy in the context of CFPE.  Developing 
this concept we demonstrated that RvD2 and 15d-PGJ2, in particular, were 
associated with improved FEV1 recovery from CFPE.  There are recognised 
clinical endpoints in CFPE which could be easily evaluated for benefit, including; 
length of stay in hospital, length of antibiotic administration, extent of clinical 
recovery post CFPE (change in FEV1, weight gain).  In the context of chronic lung 
infection, we could consider SPM’s (or their stable analogues) as adjuvant 
treatments in combination with intravenous antibiotic administration, used to 
achieve bacterial containment and creating a context appropriate for the active 
resolution of inflammation. 
 
In considering any strategy to use an SPM to drive a cascade of endogenous SPM 
biosynthesis (by driving efferocytosis), account must be taken of the availability of 
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DHA and EPA as substrates.  Efforts are on-going to evaluate the therapeutic 
benefit of DHA in CF (345).  DHA supplementation alone, as it relates to SPM 
biosynthesis might be limited in its impact due to reduced 15-LO expression and 
thus a limited capacity to utilise DHA to synthesise the downstream bioactive 
SPM’s.   
 
8.8.6 Timing 
In our study of CFPE, RvD2 was detected in sputum even in the early days of 
antibiotic administration.  It peaked in concentration at Day 6-8.  In addition to 
validating these findings in a larger cohort, further work is needed to compare the 
effectiveness of SPM administration given in an animal model throughout the 
duration of antibiotic treatment for CFPE, as compared to initiating treatment after 
day 4-5. 
  
8.8.7 Animal studies 
Well conducted animal studies could serve to answer a number of the outstanding 
questions outlined in this chapter.  Furthermore, conducting these studies would 
advance our progress towards translation by demonstrating safety and efficacy 
and defining the best SPM candidates and refining treatment protocols.  
Furthermore such studies would be essential to satisfy regulatory requirements for 
clinical drug development. 
 
8.8.8 Drug Trials  
One of the biggest hurdles facing the development of any drug for clinical 
application surrounds funding Phase III clinical trials.  The cost of conducting a 
Phase III clinical trial has been estimated at 200-300 million USD, or 8-9 million 
USD for an “orphan disease” (484).  Thus, there must be the potential to recoup 
the costs of developing the drug by making profits from the sale of the drug.  This 
brings several factors to the fore; the size of the population of sufferers of the 
condition, their capacity to pay for the drug, the cost-benefit analysis of treatment, 
patents and intellectual property rights over the development of the drug.   
 
Two pathways to consider in navigating a path through the funding and regulatory 
obstacles to test SPM’s for CF therapy include; (a) CF as the “trail blazer”, and; (b) 
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SPM development for another mass market application and adoption of the 
compounds into the field of CF therapy following licencing for the other application. 
CF therapy has advantages in terms of drug development such as the key role 
played by the CF Association in advocating for and actively participating in drug 
development, including funding early phase clinical drug development (the “CF 
drug development pipeline”). 
 
In CFPE, there is a cost associated with weeks of hospitalisation and antibiotic 
administration.  If there were to be proven benefits in terms of recovery of lung 
function following CFPE, this might potentially translate into survival gains and 
then the cost-benefit analysis includes an examination of the increase in “quality 
adjusted life years”.  
 
In regulatory terms, CF has been categorised as a “rare/orphan” disease and 
Kalydeco was registered as an “Orphan Medicine” (485).  The regulations for 
“orphan diseases” allow for smaller Phase III trials and therefore reduced costs of 
drug development. 
 
Notably, these compounds are not unique to CF application.  Resolution of 
inflammation poses a challenge across the entire spectrum of disease 
pathogenesis.  Significant research effort is underway to investigate the role of 
SPM’s in atherosclerosis, cardiovascular disease, Alzheimer’s disease, sepsis, 
and autoimmune disease to name a few.  There are on-going clinical phase III 
trials of Resolvin analogues being tested for application in the context of dry eye 
disease and periodontal disease.  Should these trials prove that these compounds 
are beneficial in those contexts, it may be possible (and significantly less costly) to 
test their application for “off label” applications in CF therapy.   
 
However, the specific cell targets and tissue type and disease specific roles of this 
class of compounds, has not fully been explored.  To illustrate this point it is 
pertinent to consider the example of the prostaglandins; a non-redundant class of 
eicosanoid compounds that find application in diverse aspects of therapy, e.g. 
Prostaglandin E2 (Dinoprostone) is used clinically to soften the cervix and induce 
uterine contraction and has vasodilator activity, whereas Prostaglandin E1 
(Alprostadil) is used to prevent the closure of the ductus arteriosus.  Particular 
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compounds within the SPM class might not be functionally redundant, and as such 
the particular SPM analogues currently in trial might not be those best suited to a 
CF application.  Therefore, further work is required to understand the differences 
between the various resolvins, protectins and maresins and distinguishing 
between functional redundancy, and tissue / cell type specific actions of each 
mediator. 
 
8.8.9 Biomarker applications 
A potential application of our findings might be to validate a combination of pro-
resolution mediators (including Resolvin D2, 15-d-PGJ2 and 13-HODE) measured 
in sputum at Day 6-8 of CFPE as a biomarker panel to predict the likelihood of 
successful recovery from CFPE. This could be used to aid treatment decisions e.g. 
for intensification or completion of therapy.   
 
8.8.10 Alternatives to direct SPM supplementation 
We have observed positive associations between PPARγ agonist concentrations 
measured in sputum during CFPE and full recovery of pre-morbid FEV1.  To that 
end our work lends weight to the body of opinion recommending the development 
of PPARγ agonists for CF application (362, 363).  Furthermore, the wider 
resolution field have proposed a range of alternative strategies to rectify resolution 
deficits and enhance SPM biosynthesis including; the use of aspirin to generate 
aspirin triggered isoforms of the SPMs; statins; glucocorticoids; supplementation of 
EPA and DHA; and the inhibition of Prostaglandin biosynthesis (486). 
 
8.8.11 Will there be a need for CF therapeutics in the post-corrector/modifier era? 
Whilst the field continues to celebrate the success of achieving therapeutic benefit 
via CFTR modulation strategies, for the majority of people with CF, these gains 
are not expected to be sufficient to completely prevent lung function decline, rather 
to slow the decline.  Restoration of airway hydration, muco-ciliary clearance, and 
strategies to reduce lung inflammation and heighten anti-microbial responses are 
likely to remain core goals of CF therapy for the majority.   
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8.9 Conclusion 
We have shown that in CF in vitro bronchial epithelial cell models, RvD1 restored 
ASL height, attenuated NFĸB mediated pro-inflammatory signalling and reduced 
the secretion of the neutrophil chemo-attractant IL8.  In primary CF alveolar 
macrophages, RvD1 promoted phagocytosis and intracellular killing of 
Pseudomonas aeruginosa (illustrated in Figure 8-5).   
 
 
Figure 8-5 Schematic illustrating the beneficial physiological effects of RvD1 
in CF models demonstrated in this thesis. 
In CF in vitro bronchial epithelial cell models RvD1 restored ASL height via 
ALX/FPR2 receptor stimulation, reduced the secretion of the neutrophil chemo-
attractant IL8 via preservation of IκB.  In primary CF alveolar macrophages, RvD1 
promoted phagocytosis and intracellular killing of Pseudomonas aeruginosa.   
 
We demonstrated that the synthesis of LXA4 is defective in CF.  In vivo evidence 
was presented of impoverished 15 Lipoxygenase-2 gene expression associated 
with a depressed LXA4 / LTB4 ratio in the lower airways of children with CF 
(illustrated in Figure 8-6).   
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Figure 8-6 Schematic illustrating the finding of impoverished 15 
Lipoxygenase-2 expression associated with a depressed LXA4 / LTB4 ratio in 
the lower airways of children with CF 
Airway epithelial cell expression of 15 LO-1&2 were not significantly different in CF 
cells. 
 
Moreover, favourable relationships between pro-resolution mediators RvD2 and 
15-d-PGJ2 concentrations in sputum and the full recovery of pre-exacerbation 
FEV1 following CFPE have been demonstrated (Figure 8-7).   
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Figure 8-7 A summary of the key findings of the PRINCE study relating pro-
resolution mediators in sputum to recovery of Baseline FEV1 post CFPE 
Higher concentrations of RvD2 and 15-d-PGJ2 measured in sputum during CFPE 
were found among children who fully recovered their pre-exacerbation baseline 
FEV1.  *Graph of FEV1 change over the course of time during CFPE adapted from 
Collaco et al (368) . 
 
SPM’s have the potential to counteract the release of free Neutrophil Elastase into 
the airway by reducing the neutrophil burden and removing dead and dying 
neutrophils from the airway.  We optimized methods to develop a better 
understanding of 15-LO regulation in CF alveolar macrophages and macrophage 
polarisation.  These studies advance novel strategies to tip the balance in favour 
of active resolution of prolonged frustrated neutrophilic inflammation.  Restoration 
of physiological concentrations of SPM’s, could potentially drive macrophages 
towards a resolution phenotype, and be attended by a cascade of de novo SPM 
biosynthesis and drive resolution of inflammation in the CF airway.  The most 
critical step in advancing this work will be in testing SPM’s in an animal model of 
CF faced by a bacterial challenge to mimic CF pulmonary exacerbations. 
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